












THE GLUTATHIONE S-TRANSFERASES: 
INHIBITION, ACTIVATION, BINDING AND KINETICS. 
by 
Alfred Ernst Adolf Thumser 
B.Sc.(Med. )(Hons.) 
A thesis submitted to the University of Cape Town Faculty of Medicine in partial 
fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
in the department of Medical Biochemistry. 
August, 1990 
i 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 











I would like to express my sincere appreciation to the following people: 
My supervisors, Associate Professor Kathryn M. Ivanetich and Dr. Paul A. Adams, 
for their guidance, constructive criticism and motivation. 
Dr. Richard Goold, a Ph.D. graduate from our laboratory at the time, for his help 
and assistance, especially with reference to computer analysis of data. 
The head, Professor G.G. Harrison, and staff of the Department of Anaesthetics, 
Grootte Schuur Hospital, for their assistance with work related to halothane. 
The staff of the Chemical Pathology laboratory, Red Cross War Memorial 
Children's Hospital for access to and assistance with the use of the Multistat 
Centrifugal Analyzer. 
For assistance related to various aspects of the thesis I would also like to thank Dr. 
Melanie Ziman, Dr. Cynthia Sikakana, Susan Phillips, Jo-Anne Harper, Sadia 
Titus, Henry Terblanche and all the other helping hands. 
I would like to gratefully acknowledge the financial assistance of the South African 










































































Micromolar (10- 6 M) 





High performance liquid chromatography 











Revolutions per minute 
Standard deviation 
n-Dodecylsulfate sodium salt 
SDS-Polyacrylamide gel electrophoresis 
Half-life of a reaction 
Trichloroacetic acid 





Maximum velocity of an enzyme r 1action Extinction coefficient (M- .cm-) 
iii 
List of Publications. 
1. Ivanetich, K.M. & Thumser, A.E.A.; Inhibition of the GSH S-Transferase 
Isoenzymes by Ethylene Dibromide.; Liver Update 2, 33-36, eds Kirsch, R.E., 
Kruskaly, J.B., Comos, G. & Terblanche, J., Balliere Trundall, London (1984). 
2. Ivanetich, K.M., Thumser, A.E.A., Ziman, M.R., Baruch, Y. & Kirsch, R.E.; in 
"The Liver Annual 5., Chapter 4: Liver Injury and Regeneration.", 71-115, eds 
Arias, I.M., Frenkel, M. & Wilson, J.H.P., Elsevier Science Publishers B.V. 
(1986). 
3. Ivanetich, K.M., Thumser, A.E.A., Ziman, M.R., & Kirsch, R.E.; in "The Liver 
Annual 6., Chapter 4: Liver Injury and Regeneration.", 91-162, eds Arias, I.M., 
Frenkel, M. & Wilson, J.H.P., Elsevier Science Publishers B.V. (1987). 
4. Ivanetich, K.M. & Thumser, A.E.A.; Reversible Inhibition and Activation of 
Hepatic GSH S-Transferases by Ethylene Dibromide.; Pharmacol. Ther. 33, 
85-88 (1987). 
5. Ivanetich, K.M., Thumser, A.E.A. & Harrison, G.G.; Halothane: Inhibition 
and Activation of Rat Hepatic Glutathione S-Transferases.; Biochem. 
Pharmacol. 37, 1903-1908 (1988). 
6. Adams, P.A., Byfield, M.P., Goold, R.D. & Thumser, A.E.; Kinetics of Heme 
Octapeptide (Microperoxidase-8 - MP-8) Formation Studied by High-Pressure 
Liqmd Chromatography (HPLC) Monitoring of the Peptic and Tryptic 
Hydrolysis of Horse Heart Cytochrome-c.; J. Inorg. Biochem. 37, 55-59 (1989). 
7. Adams, P.A., Goold, R.D. & Thumser, A.A.; Heme-Peptide Protein 
Interactions - The Binding of Heme Octa and Undecapeptides, and 
Microperoxidase-8 and Microperoxidase-11, to Human Serum Albumin.; J. 
Inorg. Biochem. 37, 91-103 (1989). 
8. Adams, P.A., Goold, R.D. & Thumser, A.E.; Haem Peptide-Protein 
Interactions. Part 2. - Kinetics and Mechanism of the Interaction of 
Microperoxidase-8 with Apomyoglobin.; J. Chem. Soc. Faraday Transact. 85, 
3845-3852 (1989). 
9. Ivanetich, K.M., Thumser, A.E.A., Phillips, S.E. & Sikakana, C.N.T.; Reversible 
Inhibition of Rat Hepatic GSH S-Transferase 1-2 by Bilirubin; Biochem. 
Pharmacol. (1990, in press). 
iv 
List of Presentations. 
1. Ivanetich, K.M. & Thumser, A.E.A.; Reversible Inhibition and Activation of 
GSH S-Transferases by 1,2-Dibromoethane; International Symposium on 
Clinical and Basic Aspects of Enzyme Induction and Inhibition, Essen, FRG 
(1985). 
2. Thumser, A.E.A., Ivanetich, K.M. & Harrison, G.G.; Halothane: Multiple 
Effects on Hepatic Glutathione S-Transferases; The First Joint Congress of the 
South African Biochemical Society, South African Genetics Society and the 
South African Society for Microbiology (1986). 
3. Ivanetich, K.M., Thumser, A.E. & Sikakana, C.N.T.; Reversible Inhibition of 
the GSH S-Transferases by Bilirubin; South African Biochemical Society, 
Ninth Congress (1988). 
4. Adams, P.A., Goold, R.D. & Thumser, A.E.A.; The Physical and Inorganic 
Biochemistry of Microperoxidase-8 (MP-8). (7) The Interaction of MP-8 with 
Apo Myoglobin; South African Biochemical Society, Ninth Congress (1988). 
5. Adams, P.A., Goold, R.D. & Thumser, A.E.A.; The Physical and Inorganic 
Biochemistry of Microperoxidase-8 (MP-8). ( 4) Interaction of MP-8 with 




The glutathione S-transferases are a group of xenobiotic detoxifying enzymes 
found in most plants and animals (Boyer & Kenney, 1985; Mannervik & 
Danielson, 1985). These proteins catalyze the conjugation of glutathione with a 
wide range of electrophilic compounds in the first step of their metabolism by the 
mercapturic acid pathway (Habig, 1983). In addition, these enzymes may act as 
hepatic transport proteins for endogenous compounds such as bilirubin. Aspects 
of the kinetics, inhibition, activation and ligand binding of the glutathione 
S-transferases are reported in this thesis; The focus was on the anesthetic 
halothane and an analogue, 1,2-dibromoethane, and subsequently on bilirubin and 
the heme peptides, microperoxidases 8, 9 and 11. 
The volatile anesthetic agent halothane has been shown to decrease hepatic 
bromosulfophthalein uptake after multiple exposures (Biebuyck et al, 1970). As 
bromosulfophthalein uptake is thought to be a function of the glutathione 
S-transferases (Boyer & Kenney, 1985; Boyer, 1989), we decided to study the effect 
of halothane on these enzymes. In vivo, a single exposure of rats to halothane did 
not significantly decrease hepatic glutathione S-transferase levels. In contrast, 
multiple exposures to halothane initially decreased, and subsequently increased, 
glutathione S-transferase activity. This effect was isoenzyme-specific with enzymes 
containing subunits 3 and 4 being affected, although the possible effect on 
subunits 1 and 2 is debatable. In vitro, inhibition of cytosolic glutathione 
S-transferases was apparently irreversible and concentration- and time-dependent, 
with apparent half-maximal inhibition at 15 mM halothane and a half-life of 
ca 5 min. Inhibition was isoenzyme-dependent as isoenzymes 3-3, 3-4 and 4-4, but 
not isoenzymes 1-1 and 1-2, were affected. Halothane did not inhibit glutathione 
S-transferase activity in cytosol and the protective factor could not be removed by 
dialysis or hepatic perfusion. 1,2-Dibromoethane, but not halothane, was 
metabolized by the cytosolic glutathione S-transferases. In vitro, isoenzyme 1-2 
was activated in a reversible process with a short half-life. 
The halothane analogue, 1,2-dibromoethane, is known to inhibit glutathione 
S-transferase activity in vivo (Botti et al, 1982) and in vitro (Ivanetich et al, 1984). 
In conjunction with the investigation of the reversible effect of halothane in vitro, 
the effect of 1,2-dibromoethane was also investigated. 1,2-Dibromoethane 
reversibly activated and inhibited rat hepatic glutathione S-transferases. 
Isoenzymes 3-3 and 4-4 were activated in an uncompetitive manner with respect to 
vi 
GSH. However, under conditions of CDNB variation these isoenzymes were 
inhibited at low, and activated at high, CDNB concentrations. These phenomena 
are explained in simplistic terms, but a comprehensive mechanistic scheme could 
not be formulated. 
The glutathione S-transferases may act as hepatic transport proteins for 
non-substrate ligands such as bilirubin which are also reversible inhibitors of the 
glutathione S-transferases (Boyer, 1989). In several publications by Vander Jagt 
et al (Simons & Vander Jagt, 1980; Vander Jagt et al, 1982, 1983) a system of 
"enzyme memory" has been proposed to explain the apparently complex inhibition 
kinetics of bilirubin and the protective effect of proteins. Our interpretation of the 
inhibition kinetics observed by Vander Jagt et al (Vander Jagt et al, 1982, 1983) 
differed from that of the authors. The process of bilirubin inhibition and 
protection by proteins was thus investigated. In our work, inhibition of isoenzyme 
1-2 by bilirubin was determined to be a pseudo first-order process with a 
calculated second-order rate constant of approximately 5.2 x 1o3 M-1.s-1. The 
addition of proteins to incubated mixtures of glutathione S-transferases and 
bilirubin prevented inhibition. Sephadex chromatography was used to 
demonstrate that the proteins bound high molar ratios of bilirubin and, in 
conjunction with inhibition experiments, the protective effect was shown to depend 
on protein identity and concentration. The hypothesis of "enzyme memory" 
(Simons & Vander Jagt, 1980; Vander Jagt et al, 1982, 1983) was consequently 
rejected and we postulate that the observed protective effects of proteins can be 
explained by the respective bilirubin-binding characteristics of the proteins. 
The glutathione S-transferase isoenzymes 7r and p similar or identical (Guthenberg 
& Mannervik, 1981). However, the kinetic mechanism of these isoenzymes has not 
been compared. The mechanism of action of isoenzyme 7r was being investigated 
in our laboratory (Ivanetich & Goold, 1989), and therefore an independent 
examination of isoenzyme p was undertaken. The kinetic mechanism of 
isoenzyme p was elucidated by a matrix of kinetic experiments which combined 
substrate concentration variation, product inhibition studies and computer 
modelling. Variation of the concentrations of the substrates CDNB and 
glutathione were consistent with either a random rapid equilibrium or ordered 
steady state mechanism. Product inhibition experiments confirmed a random BiBi 
rapid equilibrium mechanism with the formation of an enzyme-CDNB-product 
dead-end complex. This mechanism is identical to that of human placental 
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isoenzyme 71", with slightly different evaluated kinetic constants (Ivanetich & Goold, 
1989). 
The microperoxidases, heme-peptides used to investigate heme protein function 
(Adams, 1990), have been shown to bind and inhibit isoenzyme 7r (Adams & 
Goold, 1990). A similar procedure was utilized to investigate the interactions of 
microperoxidases with isoenzyme p. Initially the procedure used for the 
preparation of the microperoxidases was investigated and substantially improved 
by various modifications. Subsequently, microperoxidases 8, 9 and 11 were shown 
to bind to and inhibit isoenzyme p in a time-dependent manner. Inhibition 
followed pseudo first-order kinetics with a half-life of approximately 900 seconds. 
The inhibition process was dependent on the peptide concentration and the 
apparent inhibition constant (Ki) increased with microperoxidase size from 0.57 to 
1.62 and 3.15 µM for microperoxidases 8, 9 and 11, respectively. Binding to 
isoenzyme p was a monoexponential process with a calculated apparent 
dissociation constant (Ko) of 3.4 x 10-7 M. Glutathione did not affect MP-9 
binding to isoenzyme p, but CDNB abolished microperoxidase binding and 
bilirubin increased the rate of binding. The rate of binding was similar for all 
three microperoxidases. These findings differ from those obtained with 
isoenzyme 7r (Adams & Goold, 1990) and we propose that the glutathione 
S-transferase p and 7r probably show small differences at the tertiary or 
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1.1 Drug Metabolism. 
The diet of humans and animals consists not only of nutrients, but also contains 
foreign and non-nutritive compounds. The kidneys can excrete polar substances 
rapidly whereas lipid soluble materials, which includes many xenobiotics, are 
eliminated slowly and require prior metabolism to polar products. The pathways 
of drug metabolism catalyze various reactions, including oxidation, reduction, 
hydrolysis and conjugation. The enzymes involved in these pathway include the 
cytochromes P-450, monoamine oxidases, glucuronyl transferases, glutathione 
S-transferases * and enzymes of the mercapturic acid pathway, to name a few 
(Williams, 1959; Gillette, 1979). This thesis focuses on the glutathione 
S-transferases. 
1.2 The Mercapturic Acid Pathway. 
Although the significance of glutathione# (GSH; r-glutamylcysteinylglycine) 
(Meister, 1988) in the detoxication of xenobiotics was recognized as early as 1936 
(Boyland & Levi, 1936), the enzymes catalyzing GSH-dependent reactions were 
only discovered a quarter of a century later (Booth et al, 1960) when a hepatic 
soluble enzyme active in conjugating GSH with organic electrophiles to produce 
mercapturic acids (Booth et al, 1961), and an enzyme conjugating 
bromosulfophthalein (BSP) with GSH were discovered (Combes & Stakelum, 
1961). 
Subsequently, several proteins which bound ligands including bilirubin and bile 
acids (Levi et al, 1969), azocarcinogens (Ketterer et al, 1967) and cortisol 
metabolites (Morey & Litwack, 1969) were isolated. These proteins were later 
characterized as ligandin (Kaplowitz et al, 1973; Habig et al, 1974; Litwack et al, 
1971) and as rat isoenzymes 1-1 and 1-2 (Jakoby et al, 1984). The proteins 
discovered by Booth et al (1960) and Combes and Stakelum (1961) have now been 
identified as GSTs (Mannervik, 1985). 
* Footnote: In this thesis the glutathione S-transferases will also be referred to as 
the GSH S-transferases, transferases or GST. 
# Footnote: The terms GSH or glutathione apply to reduced glutathione; 
Oxidized glutathione is referred to as GSSG. 
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The GSH S-transferases catalyze the first step in the mercapturic acid pathway 
(Fig. 1.1 ), detoxifying potentially toxic electrophiles by converting them into 
hydrophilic compounds (Habig, 1983). Mercapturic acids are are end-products of 
the biosynthetic pathway proposed by Barnes et al (1959) and Bray et al (1959). 
The GSH thioethers produced by the GSTs are preferentially excreted into the 
bile and then the intestines and faeces, or reabsorbed into the intestines to 
undergo enterohepatic circulation (Nielsen & Rasmussen, 1977; Chasseaud, 1976). 
In the kidneys the conjugates are converted to L-cysteine derivatives by the 
1-glutamyltranspeptidase and glycyl peptidase enzymes (Kozak & Tate, 1982), 
and are modified either to mercapturic acids by conjugation with acetyl CoA 
(Chasseaud, 1976) or converted to thiol derivatives, pyruvate and ammonia 




























Fig. 1.1: The mercapturic acid pathway. 







RSH + NH3 + PYRUVATE 
3 
Bromobenzene, a potentially toxic xenobiotic, is metabolized by the enzymes of 
the mercapturic acid pathway (Habig, 1983). In the rat, bromobenzene is initially 
converted mainly to bromobenzene-3,4-epoxide by the cytochrome P-450 enzymes 
of the endoplasmic reticulum (Jollow et al, 1974). The epoxide is either 
enzymatically converted to a dihydrodiol by a microsomal epoxide hydrase enzyme 
(Daly et al, 1972), conjugated with GSH by cytosolic GSTs (Brodie et al, 1970; 
Habig, 1983) or non-enzymatically converted to 4-bromophenol (Daly et al, 1968; 
Gillette, 1979). Conjugation of the epoxide with GSH eventually produces 
bromophenylmercapturic acid as the end-product of the mercapturic acid pathway 
(Jerina et al, 1968; Boyland, 1971). 
Other xenobiotics such as paracetamol (acetaminophen) and naphthalene 
(Mitchell et al, 1974; Hayakawa et al, 1975) are also activated by cytochromes 
P-450 before being conjugated with GSH by the GSH S-transferases, while 
compounds such as chloronitrobenzenes, epoxides, a, ,8-unsaturated compounds, 
aflatoxin and aminoazo dye carcinogens are conjugated directly with GSH 
(Chasseaud, 1973; Boyland & Chasseaud, 1969; Ketterer et al, 1982). In animals, 
paracetamol dosage decreases hepatic GSH levels by more than 70% and cause 
liver necrosis (Mitchell et al, 1973; Potter et al, 1974). Toxic doses of 
bromobenzene decrease the mercapturic acid metabolite from 70% to 48% and 
increase the concentration of 4-bromophenol, which produces tissue necrosis 
(Zampaglione et al, 1973). 
1.3 The Glutathione S-Transferases. 
The glutathione S-transferases (EC 2.5.1.18) are a family of enzymes detoxifying a 
wide spectrum of xenobiotics by catalyzing their conjugation with GSH. This 
reaction is the first step of the mercapturic acid pathway (Habig, 1983), which is 
generally considered as a detoxication mechanism for the metabolism and 
excretion of mutagens, carcinogens and other toxic chemicals (Mannervik & 
Danielson, 1988). The GSTs are also active as GSH peroxidases and steroid 
isomerases, and thus catalyze a wide spectrum of reactions requiring GSH as 
co-substrate (Boyer & Kenney, 1985; Jakoby et al, 1976). 
The GSTs also bind non-electrophilic substrates such as bilirubin and bile salts, 
and appear to act as intracellular transport or storage proteins. The GSTs can act 
as scavengers of alkylating agents and strong electrophiles by covalently binding 
4 
them, concomitantly inactivating the enzyme (Boyer & Kenney, 1985; Jakoby, 
1978). 
1.4 Occurrence of the GSH S-Transferases. 
The GSTs are found in most aerobic organisms including mammals, insects, plants 
and bacteria (Table 1.1). With the exception of a membrane-bound microsomal 
form, the enzymes are cytosolic, water-soluble proteins (Morgenstern et al, 1984; 
Boyer, 1989). In mammalian tissues, concentrations are usually high (up to 10% of 
the total soluble protein), the GSTs being found in most organs and tissues 
(Table 1.1 ), although low levels of the enzyme are found in some non-mammalian 
species (Mannervik, 1985; Sugiyama et al, 1981). 
The cytosolic GSTs usually occur as functional homo- or hetero-dimers. A 
trimeric microsomal form has been found in rats and humans, and a monomeric 
isoenzyme isolated from cell extracts of Tetrahymena themwphila (Boyer et al, 
1986; Overbaugh et al, 1988). Numerous GST isoenzymes have been identified 
and isoenzyme expression is diverse as a result of variable or non-expression of 
isoenzymes (Suzuki et al, 1987), or multiple genes and hybridization of subunits 
(Mannervik, 1985). GST isoenzymes can be characterized by subunit composition, 
substrate specificity, binding affinity for non-substrate ligands, isoelectric point 
and inhibition characteristics (Boyer & Kenney, 1985; Mannervik & Danielson, 
1988). 
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1.5 Nomenclature and Classification. 
Early publications on the GSH S-transferases referred to them as aryl-, alkyl-, 
aralkyl-, alkene- or epoxide-transferases, depending on the structure of the 
electrophilic substrate (Boyland & Chasseud, 1969). However, several 
laboratories (Pabst et al, 1973; Askel6f et al, 1975) demonstrated the overlapping 
substrate specificities of the GSTs, thus necessitating an improved nomenclature 
(Jakoby et al, 1976). Various terminologies have been proposed for the rat GSTs 
and are briefly discussed below. 
Habig et al (1974) designated the rat hepatic GSTs according to the reverse order 
of elution from CM-cellulose, ie isoenzymes D & E, C, B, A and AA. These 
proteins were dimers with subunits of approximately 25 000 daltons and could be 
differentiated by catalytic and immunological properties, although they exhibited 
overlapping substrate specificities (Habig et al, 1974, 1976). Ligandin, a protein 
thought to be important in the hepatic transport and storage of bilirubin, drugs and 
carcinogens (Litwack et al, 1971; Arias et al, 1976) was identified as isoenzyme B, 
with two distinct related subunits of 22 000 and 24 000 daltons. These subunits, 
designated Ya and Y c (Bass et al, 1977; Beale et al, 1982) also formed 
homodimers, ie Ya Ya and Y c Y c (Hayes & Clarkson, 1982). However, some 
laboratories referred to the Ya Ya homodimer as ligandin (Jakoby et al, 1976). 
Isoenzymes A, C and D were subsequently shown to be composed of two different 
Yb subunits and were renamed isoenzymes Yb Yb, Yb Yb' and Yb,yb'• respectively 
(Beale et al, 1983; Hayes, 1983). 
As the nomenclature for the rat GSTs was clearly unacceptable and vague, a 
* terminology for the rat soluble GSTs denoting each distinct protein subunit by a 
Arabic numeral was recommended (Table 1.2) (Jakoby et al, 1984). This 
terminology reflects the subunit structure, heterogeneity and dimeric nature of the 
GSTs. 
* Footnote: In this thesis the new nomenclature shown in table 1.2 will be used 
for the rat GST isoenzymes. Human GSTs are identified by Greek letters 
(Mannervik & Danielson, 1988). Erythrocyte GST isoenzymes will also be 
referred to as the acidic (P, rho) or basic erythrocyte GSTs. 
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Table 1.2: Nomenclature for the rat cytosolic GSTs. 
(adapted from Jakoby et al, 1984, Mannervik & Danielson, 1988) 
New Previous Nomenclatures 
Nomenclature 
(1) (2) (3) (4) (5) (6) (7) 
Isoenzyme 1-1 Ligandin B Ligandin B1 YaYa L2 
Isoenzyme 1-2 Ligandin B B B2 YaYc BL 
Isoenzyme 2-2 AA AA YcYc B2 
Isoenzyme 3-3 A A ybyb A2 
Isoenzyme 3-4 C C ybyb' AC 
Isoenzyme 4-4 D D yb,yb' C2 
Isoenzyme 5-5 E E 
Isoenzyme 6-6 MT YaYa 
Isoenzyme 7-7 p Yp or Yf 
Isoenzyme 8-8 K YkYk 
(1) Jakoby et al, 1984; (2) Bass et al, 1977; (3) Habig et al, 1974; (4) Hayes et al, 
1981; (5) Ketterer et al, 1983; (6) Bass et al, 1977, Ketterer et al, 1983; 
(7) Mannervik & Jensson, 1982. 
GST isoenzymes containing subunits 1 and 2 display high isomerase and 
selenium-independent GSH peroxidase activity (Mannervik & Jensson, 1982), 
while isoenzymes with subunits 3 and 4 are reactive with DCNB and 
tran.s-4-phenyl-3-buten-2-one (Booth et al, 1961; Mannervik & Jensson, 1982). 
Epoxy propane is a good substrate for isoenzyme 5-5 (Fjellstedt et al, 1973) which 
does not bind S-hexyl GSH (Mannervik, 1985). (Table 1.3) 
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Table 1.3: Specific activities of rat and human GSTs towards various substrates. 
(adapted from Mannervik & Danielson, 1988) 
Specific activity (µmol/min/mg protein) 
Class Alpha Mu Pi 
lsoenzymea 1-1 2-2 8181 Cl-E 3-3 4-4 µ 7-7 7r 
Substrate: 
CDNBb 50 17 82 64 58 17 187 24 105 
DCNB <0.04 <0.04 0.25 0.05 5.3 0.18 0.032 0.048 0.11 
BSP <0.01 <0.01 N.D. 0.005 0.94 0.04 <0.002 0.01 <0.002 
T-4-P <0.04 <0.04 N.D. 0.0015 0.05 1.18 0.36 0.22 0.01 
Epoxy propane <0.1 <0.1 0 0 0.53 1.37 0.11 N.D. 0.37 
Cum. Hyd. 3.1 7.9 31 10.6 0.35 0.72 0.63 0.048 0.03 
H202 <0.01 <0.01 N.D. <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
And. Dione 4.2 0.36 N.D. 8.0 0.02 0.002 0.12 N.D. N.D. 
a lsoenzymes with numerical designations refer to rat isoenzymes, Greek letters 
refer to human GSTs. 
b Abbreviations: CDNB: 1-chloro-2,4-dinitrobenzene; 
DCNB: 1,2-dichloro-4-dinitrobenzene; BSP: Bromosulfophthalein; 
T-4-P: trans-4-phenyl-3-buten-2-one; 
Epoxypropane: 1,2-epoxy-3-(p-nitrophenoxy)-propane; 
Cum. Hydroperoxide: Cumene hydroperoxide; And. dione: Androstene dione. 
N.D.: Not determined 
The human GSTs are broadly classified into three groups according to their 
isoelectric points, namely the basic (pl = 7.8 - 8.9), near-neutral (pl = 6.0 - 6.5) 
and acidic (pl < 5) transferases (Kamisaka et al, 1981; Marcus et al, 1978; 
Guthenberg & Mannervik, 1981). 
The human basic GSTs being characterized by high GSH peroxidase and 
isomerase activity (Warholm et al, 1983). Although five very similar basic 
isoenzymes (a, f3, r, o , E) were isolated from human liver (Kamisaka et al, 
1975), some of these enzymes appear to be charged isomers of each other (Boyer 
& Kenney, 1985). These basic isoenzymes therefore cannot be rigorously 
identified and have collectively been specified as the "basic" transferases 
(Mannervik et al, 1983) or transferases "a-c" (Warholm et al, 1983). A further 
three basic human GSTs, including two homodimers and a corresponding 
heterodimer, have also recently been characterized (Soma et al, 1986; Stockman 
et al, 1985, 1987). 
The near-neutral isoenzymes are characterized by their relatively high activity with 
trans-4-phenyl-3-buten-2-one (Warholm et al, 1983) and are strongly inhibited by 
cibacron blue (Tahir et al, 1985). A near-neutral isoenzyrne, µ, has been found at 
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concentrations of 15% - 20% of the total GST protein in approximately 60% of 
humans investigated (Mannervik, 1985; Boyer & Kenney, 1985). 
Acidic GSTs have been found in the liver (l/J & w) (Awasthi et al, 1980), placenta 
(n, pi) (Guthenberg et al, 1979; Polidoro et al, 1980) and erythrocytes (P, rho) 
(Marcus et al, 1978) Isoenzymes 7£ and p are identical or closely related 
(Guthenberg & Mannervik, 1981). 
Physicochemical characteristics of rat and human cytosolic GSTs reflect their 
similarity in size in spite of the wide spectrum of isoelectric points and overlapping 
substrate specificities (Table 1.4). These isoenzymes can be identified by substrate 
specificity, subunit molecular weight, isoelectric point, inhibition characteristics 
and immunological properties (Mannervik & Danielson, 1988). 
Table 1.4: Physicochemical characteristics and specific activities with various 
substrates of rat and human cytosolic GSTs. 
(adapted from Mannervik & Danielson, 1988) 
Isoenzymes 
Rat Human 
1-1 1-2 2-2 3-3 3-4 4-4 7-7 B1B1 B2B2 µ 7£ 
Class Alpha Alpha Alpha Mu Mu Mu Pi Alpha Alpha Mu Pi 
Apparent subunit 25 25/28 28 26.5 26.5 26.5 24 25 25 26.5 23 
M.IJ.a (kD) 
Subunit M.IJ. b 25434 N.D.c 25209 25806 N.D. 25592 23307 25526 N.D. N.D. N.D. 
(kD) 
Amino acid 221 N.D. 220 217 N.D. 217 209 221 N.D. N.D. N.D. 
residues/subunit 
Isoelectric point 10 9.9 9.8 8.9 8.0 6.9 7.0 8.9 8.4 6.6 4.8 
a From SDS polyacrylamide gel electrophoresis. 
b From the amino acid analysis. 
C N.D.: Not Determined 
Mammalian cytosolic GSTs have been classified into three groups, viz alpha, mu 
and pi, according to their physicochemical properties, ie substrate specificity, 
sensitivity to inhibitors, amino acid sequence and immunological cross-reactivity 
(Mannervik et al, 1985). Within each class, the isoenzymes have similar 
N-terminal amino acid sequences. Polyclonal antisera responsive to isoenzymes of 
one class do not cross-react with isoenzymes of other classes. The classes also 
exhibit differences in subunit molecular weights ( on SDS-PAGE): Class pi 
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isoenzymes having the lowest apparent subunit molecular weights and class mu the 
highest (Table 1.5) (Mannervik et al, 1985). 
Table 1.5: Classification of GST isoenzymes. 
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A distinct microsomal GST has been isolated from rats, mice and humans 
(Morgenstern et al, 1980, 1984; Andersson et al, 1988). The protein is a 
membrane-bound trimer with subunits of 14 000 daltons (Morgenstern et al, 1979; 
Boyer et al, 1986) and an isoelectric point at pH 10.1 (Morgenstern & DePierre, 
1983). Unlike the cytosolic GSTs, the microsomal isoform is activated by 
sulfhydryl reagents such as N-ethylmaleimide (Morgenstern et al, 1979; 
Morgenstern & DePierre, 1983) or by washing the microsomes with liposomes 
(Boyer et al, 1986), although it is not induced by phenobarbital, 
3-methylcholanthrene or trans-stilbene oxide (Morgenstern et al, 1980). 
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1.6 Purification of GSH S-Transferases. 
GST purification is complicated by the multiplicity of isoenzymes. However, 
isolation has been greatly simplified by affinity chromatography, the most 
commonly used matrices containing S-hexyl GSH or GSH linked to 
epoxy-activated agarose. 
S-hexyl GSH is coupled to agarose by the a-amino group of its glutamic acid 
residue (Guthenberg & Mannervik, 1981); GSH is linked to agarose through the 
cysteine thiol (Simons & Vander Jagt, 1977). The binding capacity of both 
matrices is equivalent (Mannervik, 1985), but there are differences: The S-hexyl 
GSH resin can bind glyoxalase 1 (Aronsson & Mannervik, 1977), but does not bind 
isoenzyme 5-5 under standard conditions (Mannervik, 1985). S-hexyl GSH is a 
GST inhibitor, although low concentrations are required for enzyme elution 
(Boyer & Kenney, 1985). In contrast, high concentrations of GSH are required for 
elution from the GSH matrix (Boyer & Kenney, 1985), and this method has been 
reported to alter the apparent isoelectric point of some GSTs (Ramage & Nimmo, 
1983). 
A survey of purification methods reported in the literature indicates that the most 
popular methods of GST isoenzyme separation are chromatofocusing and 
ion-exchange chromatography. Isoelectric focusing has been used to separate GST 
isoenzymes (Clark et al, 1973; Askelof et al, 1975), but this method has limited 
capacity and is very slow (Mannervik, 1985). Chromatofocusing is a rapid method 
with higher capacity and has been used to purify rat and human GSTs (Mannervik 
& Jensson, 1982; Jensson et al, 1982; Vander Jagt et al, 1985). Fast protein liquid 
chromatography (FPLC) has also been used to purify rat and mouse liver 
isoenzymes by chromatofocusing (Nin et al, 1985; Warholm et al, 1986). 
Ion-exchange chromatography was originally used by Habig et al (1974) to separate 
rat hepatic isoenzymes. Cytosol was applied to DEAE-cellulose, which retained 
approximately 80% of the protein, and the GST isoenzymes were subsequently 
separated on CM-cellulose resin using a salt gradient, individual GSTs were 
further purified using hydroxylapatite (Habig et al, 1974). Other laboratories have 
used the same basic method with minor modifications, including affinity 
chromatography (Mannervik & Guthenberg, 1981; Pattinson, 1981), molecular 
sieving (Askelof et al, 1975), and ion-exchange chromatography on TEAE cellulose 
(Boyer et al, 1983). 
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Various HPLC methods have been used in conjunction with affinity 
chromatography to identify and separate GSTs. All rat isoenzyme subunits can be 
identified and quantified by reverse-phase HPLC chromatography (Ostlund 
Farrants et al, 1987; Vandenberghe et al, 1988; Meyer et al, 1989), while 
anion-exchange HPLC has been used to separate charge isomers of human 
placental (Radulovic & Kulkarni, 1985, 1986) and erythrocyte GSTs (Singh et al, 
1986). 
1.7 Substrates of the GSH S-Transferases. 
The GSTs catalyze a bimolecular reaction, usually between GSH and a 
electrophilic substrate. The enzymes display high affinity and specificity for GSH 
as nucleophilic substrate; In contrast, the binding of electrophilic compounds to 
the hydrophobic site is of low-affinity and broad-specificity (Keen et al, 1976). 
Catalysis appears to depend on: (a) the presence of a substrate sufficiently 
electrophilic to react with GSH; (b) the binding of both substrates ( electrophile 
and GSH) to the enzyme; ( c) the enhanced nucleophilicity of the GSH thiol group 
when bound to the enzyme (Kaplowitz, 1980). Among the electrophilic substrates 
of the GSTs are numerous xenobiotics, eg bromobenzene and paracetamol 
(Mitchell et al, 1974; Habig, 1983), but relatively few endogenous substrates. The 
latter include leukotrienes, prostaglandins, steroids and products of lipid 
peroxidation (Mannervik, 1985; Boyer, 1989). Several xenobiotic and endogenous 
GST substrates are discussed below: 
1.7.1 Xenobiotics. 
GST substrates include halo and nitro derivatives, epoxides, thio esters and 
a, .8-unsaturated compounds (Habig et al, 1974 ). In addition to the substrates 
commonly used for identification and characterization of GSH conjugating activity, 
eg CDNB and DCNB, compounds conjugated with GSH include 1-menaphthyl 
sulfate (Gillham, 1973), 1,4-dihalobutanes (Marchand & Abdel-Monem, 1985), 
chlorotrifluoroethylene (Dohn & Anders, 1982), fluoroacetimide and 
2,4-dinitrofluorobenzene (Kostyniak & Soiefer, 1984), propanolol (Sasame et al, 
1987), styrene oxide (DePierre & Moron, 1979), bromosulfophthalein (Kaplowitz 
et al, 1973) and bromobenzene metabolites (Habig, 1983). The GSTs are 
stereoselective in the conjugation of some substrates, eg benz(a)pyrene 
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(Morgenstern et al, 1982), arene and alkene oxides (Dostal et al, 1987), aralkyl 
halides (Mangold & Abdel-Monem, 1980), stilbene oxide (deSmidt et al, 1987), 
and vicinal-dihaloalkanes (Livesey et al, 1982). 
The GST isoenzymes display overlapping substrate specificities. CDNB is the 
most universal substrate and is often used to follow GST activity. Analysis of 
substrate specificity is frequently used for identification and characterization of 
GST isoenzymes (Boyer & Kenney, 1985). The substrate specificities of some rat 
isoenzymes are shown in Table 1.6. 
Table 1.6: Specific activities of rat cytosolic GSTs. 
(adapted from Mannervik & Danielson, 1988) 
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T-4-P <0.01 
Epoxypropane <0.1 
C. Hydroperoxide 3.1 






























































C. Hydroperoxide: cumene hydroperoxide; A. Dione: androstene dione. 
N.D.: Not determined 
1.7.2 Endogenous substrates. 
Few endogenous GST substrates have been identified. These include organic 
hydroperoxides, prostaglandin H2, leukotriene A4 and !J.5-3-ketosteroids. One 
possible role of the enzyme in endogenous metabolism is the protection of lipid 
membranes from peroxidation. The peroxidase activity of the GSTs is not 
selenium-dependent (Lawrence & Burk, 1976; Prohaska & Ganther, 1977) and is 
catalyzed mainly by GST subunits 1, 2 and 5 (Mannervik & Danielson, 1988). 
These isoenzymes only display activity with organic hydroperoxides including fatty 
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acid peroxides and hydroperoxides (Lawrence & Burk, 1976; Prohaska & Ganther, 
1977; Gibson et al, 1980; Tan et al, 1984; Rietjens et al, 1987; Williamson et al, 
1986), and products of lipid peroxidation such as methyl linoleate ozonides, 
cholesterol a-oxide and malondialdehyde (Vos et al, 1987; Meyer & Ketterer, 
1982; Burk et al, 1980). 
The selenium-independent GSH peroxidases, ie the GSTs, also catalyze the 
reduction of prostaglandin H2 to prostaglandin F20: by GSH (Fig. 1.2) (Burgess 
et al, 1987; Hong et al, 1989). The reaction is catalyzed in rats predominantly by 
isoenzymes containing subunits 1 and 2 (Chang et al, 1987) and in sheep lung by 
GSTs with subunits of the same size as rat subunit 1 (Hong et al, 1989). 
Selenium-dependent GSH peroxidases catalyze the formation of prostaglandin H2 
from prostaglandin Gz, the selenium-independent and selenium-dependent GSH 
peroxidases therefore interacting in the biosynthesis of prostaglandin F20: (Burgess 
et al, 1987; Hong et al, 1989). 
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Fig. 1.2: The reduction of prostaglandin Hz to prostaglandin Fzo: as catalyzed by 
the GSH S-transferases. 
(adapted from Hong et al, 1989) 
The metabolism of leukotriene A4 to leukotriene C4 (Fig. 1.3) is· catalyzed by both 
rat and human GSTs, with the rat 4-4 and human near-neutral(µ) isoenzymes 
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being the most active (Chang et al, 1987; Soderstrom et al, 1985; Mannervik et al, 
1984). However, a unique microsomal enzyme is primarily responsible for the 
reduction of leukotriene A4 to leukotriene C4 in vivo (Soderstrom et al, 1988; 
Yoshimoto et al, 1985). 
GSH 
Fig. 1.3: The reduction of leukotriene A4 methyl ester to leukotriene C4 
monomethyl ester by conjugation with GSH as catalyzed by cytosolic GST. 
(adapted from Mannervik et al, 1984). 
Principally associated with AS-3-ketosteroid isomerase activity is isoenzyme 1-1 
(Mannervik & Jensson, 1982), catalyzing the isomerization of AS-3-ketosteroids to 
the corresponding A4-3-ketosteroids (Fig. 1.4). These enzymes are activated by 
GSH, which decreases the Km for AS-androstene-3,17-dione, although GSH is not 
consumed in the reaction. This is a unique GST reaction as GSH is not expended 
(Benson & Talalay, 1976). 
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Fig. 1.4: The enzy.ratic conversion of 115-3-ketosteroids to the corresponding 
a,,8-unsaturated A -3-ketosteroids. 
R = 0 or a-H, ,B-CH3CO 
(adapted from Benson et al, 1977) 
Furthermore, products of lipid peroxidation comprising 4-hydroxynonenal, 
4-hydroxydecenal (Nin et al, 1985), cholesterol a-oxide (Meyer & Ketterer, 1982), 
methyl linoleate ozonides (Vos et al, 1987) are endogenous GST substrates. 
Isoenzyme 4-4 exhibits the highest activity with 4-hydroxynonenal and 
4-hydrox.ydecenal (Nin et al, 1985). 
Recently two fatty acid ethyl ester synthases, which metabolize alcohol in a 
non-oxidative process, have been proposed to be unidentified human neutral and 
acidic GSTs (Bora et al, 1989a, 1989b). 
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1.8 Glutathione: Properties and Reactions. 
Glutathione is the most prevalent cellular thiol and typically present at 
concentrations of 0.1 to 10 mM (Meister, 1988; Fahey, 1977). Characteristic 
features are a r-glutamyl linkage and sulfhydryl (-SH) group (Meister, 1988). 
NH o O 
I 2 II H II 
HOOC-C-C-C-C-N-C-C-N-C-COOH 
H H2 H2 H I H H 
CH 2 I 2 
SH 
Fig. 1.5: The structure of reduced glutathione. 
(adapted from Meister, 1988). 
The sulfhydryl group is a strong nucleophile, and can function_as a reducing agent 
for disulfides and peroxides; react with aldehydes to yield thio-hemiacetals; and 
form conjugates with electrophiles (Ketterer, 1982). GSH protects cells against 
radiation damage, oxygen toxicity and toxic compounds. GSH is required for 
leukotriene, prostaglandin and ketosteroid synthesis, and is a substrate for the 
GSH peroxidases, GSH transhydrogenases (thiol transferases) and GSTs (Meister, 
1988; Meister & Anderson, 1983). 
GSH can react with the electrophilic centers of substrates by a variety of reactions, 
ie Michael additions, reactions with electrophilic cations, or nucleophilic attack 
involving the opening of a strained ring system, as well as nucleophilic 
displacement at either a saturated or aromatic carbon atom (Ketterer, 1982). The 
reaction of GSH with electrophilic substrates depends on the chemical hardness or 
softness of the electrophile. Soft electrophiles (eg polarized double bonds) have a 
readily polarizable low positive charge density at the electrophilic centre whereas 
hard electrophiles have a large positive charge density. The chemical selectivity of 
nucleophiles reacting with electrophiles is based on the high potential energy 
barrier to reactions of hard electrophiles with soft nucleophiles, and vice versa, 
resulting from the high energy of the transition state (Coles et al, 1985). 
The large atomic volume and diffuse electron charge density of sulfur make thiol 
groups particularly soft nucleophiles (Pearson & Songstad, 1967). The reaction of 
hard electrophiles with soft nucleophiles is slow and GSH will therefore react 
more rapidly, and often non-enzymatically, with soft electrophiles, whereas the 
conjugation of hard electrophiles with GSH is unfavorable and requires a 
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enzymatic reaction to proceed at a reasonable rate (Ketterer, 1986; Ketterer et al, 
1983). 
Although the GSTs are relatively specific for GSH as the nucleophile (Jakoby, 
1978) other thiol compounds such as propylthiouracil (Yamada & Kaplowitz, 
1980), peptide analogues of GSH (Adang et al, 1988, 1989) and ,8-mercaptoethanol 
(Principato et al, 1988) can substitute for GSH in the enzymic conjugation 
reaction. Observations with GSH peptide analogues have shown that either the 
GSH-binding sites of different isoenzymes were not identical, or conformational 
states induced by binding of the analogues could affect catalytic ability (Adang 
et al, 1989). The requirement of S-methylglutathione for the conjugation of 
,8-mercaptoethanol with CDNB by isoenzyme 4-4 was thought to indicate a dual 
role for GSH in the catalytic reaction of GSTs, ie to induce a catalytically efficient 
conformation of the enzyme and to provide the sulfhydryl group required as a 
substrate for the reaction (Principato et al, 1988). 
1.9 The Chemical Mechanism of the GSH S-Transferases. 
The GSTs catalyze two types of reactions (Douglas, 1987): 
(1) The formation of a stable GSH conjugate by nucleophilic attack of GSH at an 
electrophilic centre in the second substrate (scheme 1.1). This reaction takes place 
with most of the commonly used GST substrates, including CDNB and DCNB. 
RX+ GSH -RSG + XH (scheme 1.1) 
(2) In the second class of reaction, as exemplified by the peroxidase activity of the 
GSTs (scheme 1.2), two reduced products and GSSG are produced. The enzymic 
reaction forms an unstable intermediate (R'SG), the latter is then 
non-enzymatically conjugated with a further molecule of GSH to generate a 
reduced product (R'H) and GSSG. Examples of R'X' are the organic nitrates and 
organic hydroperoxides. 
R'X' + GSH - R'SG + X'H 
R'SG + GSH - R'H + GSSG 
R'X' + 2 GSH -R'H + GSSG 
(scheme 1.2) 
Hammett plots of the enzyme-catalyzed conjugation of 4-substituted 
1-chloro-2-nitrobenzenes with GSH demonstrated the nucleophilic nature of the 
reaction and the strong dependence on the electrophilicity of the non-thiol 
19 
GSH + 
substrate (Keen et al, 1976). The rate enhancement observed with GST 3-4 for the 
conjugation of CDNB with GSH at pH 7.0 was approximately 500 M (Jencks, 
1969), denoting that the GSTs are not powerful catalysts (Jakoby, 1978). 
Investigation of the chemical mechanism of isoenzyme 4-4 with several GSH 
peptide analogs and 4-substituted 1-chloro-2-nitrobenzenes has shown that the 
GSTS reduce the pKA of enzyme-bound GSH by 2 to 2.5 pK units to a pKA of 
approximately 6.6 (Chen et al, 1988; Jung et al, 1972; Reuben & Bruice, 1976). 
With site occupancy data this was consistent with the presence of either a GSH 
thiolate (E.GS) or ion-paired thiolate (EH+ .GS-) at the active site (Graminski 
et al, 1989a). Using substrate analogues it was resolved that the formation of a 
a-complex was the rate-determining step for the GSH-conjugating reaction of the 
GSTs (Chen et al, 1988). The pH-dependence of the apparent a-complex 
formation constants implied a double-ionization mechanism 
(eg H+E.GSH = H+E.Gs- = E.Gs-) with pKA values of 5.7 and 7.6 for the 
thiol and a protonated base at the active site (Graminski et al, 1989b ). 
Cl GS 






Fig. 1.6: The conjugation reaction of GSH with CDNB sho\\ing a-complex 
formation. 
(adapted from Graminski et al, 1989, Boyer & Kenney, 1985). 
N02 
The steroid isomerase activity demonstrated by some of the GST isoenzymes 
(Benson & Talalay, 1976) catalyzing the conversion of AS-steroids to A4-steroids 
involves the rearrangement of a double bond coincident with a 1,3 proton shift 
· (Spector, 1982). Transfer of the hydrogen from atom C-4.B to C-6.B involves the 
partial exchange of the proton with the medium (Talalay & Wang, 1955; Smith 
et al, 1980) and is stereospecific and intramolecular (Malhotra & Ringold, 1965; 
Viger et al, 1981). The stereochemistry of the reaction provides evidence for a 
single basic group at the active site (Wang et al, 1963; Malhotra & Ringold, 1965; 
Viger et al, 1981; Hanson & Rose, 1975), with possibly an electrophilic or 
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+ H+ er 
proton-donating group at the active centre polarizing the C-3 carbonyl group 
(Spector, 1982). 
(ow 













Fig. 1.7: The proposed mechanism of ll-isomerase activity. 
(1). Protonation of carbonyl, loss of 4/3-proton. 
(2). Reprotonation at 6/3 carbon, deprotonation of carbonyl. 
A = proton donor, B = proton acceptor 
(adapted from Spector, 1982, Malhotra & Ringold, 1965) 
1.10 The Kinetic 1\1:echanism of the GSH S-Transferases. 
The detailed kinetic mechanism of the GSTs has been elucidated for only a small 
number of isoenzymes. A rapid equilibrium or steady state random sequential 
mechanism appears to be favored at present for all isoenzymes studied. 
The kinetic mechanism of GST 3-3 has been investigated most intensively and 
displays non-Michaelis-Menten kinetics. Initial rate, product inhibition and 
binding studies reflect a substrate-dependent biphasic kinetic mechanism (Pabst 
et al, 1974; Mannervik, 1985). The data were initially thought to reflect two 
different enzymic pathways as determined by the GSH concentration: At low 
GSH concentrations, the electrophilic substrate was proposed to bind first in a 
ping pong mechanism, and at high GSH concentrations the electrophile bound 
after GSH in an ordered sequential mechanism (Pabst et al, 1974). Analysis by 
non-linear regression suggested that the rate equation required a constant term in 
the denominator, thus excluding a ping pong pathway and providing evidence for a 
random sequential mechanism (Mannervik & Askelof, 1975). Evidence for a 
random sequential pathway has subsequently been provided by stereochemical 
studies with phenethyl halides (Mangold & Abdel-Monem, 1980, 1983), and 
experiments with a spin-labelled product (Schramm et al, 1984) and GSH 
analogues (Chen et al, 1988). 
Building upon the simple random steady state mechanism, Jakobson et al (1977) 
investigated possible contributions from enzyme-product complexes. They 
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concluded that a steady state random sequential mechanism with kinetically 
significant enzyme-product complexes was favored over simple mechanisms, even 
though the rate equation contained redundant parameters when analyzed by 
regression methods (Jakobson et al, 1977, 1979a). However, it has subsequently 
been argued that the simplest steady state mechanism without product inhibition is 
sufficient to explain the observed kinetics of isoenzyme 3-3. This conclusion was 
based on the observation that the random sequential BiBi steady state mechanism 
was the simplest mechanism consistent with the observed kinetics, and that more 
complex models were overdetermined (Ivanetich et al, 1990). 
The anomalous behavior of GST 3-3 cannot be explained by cooperativity between 
enzyme subunits or by the effects of ethanol, used as a solvent for the electrophilic 
substrate (Jakobson et al, 1977, 1979b). Possible conformational changes induced 
by the binding of GSH to the protein have been proposed as an explanation of the 
non-hyperbolic kinetics observed with some of the GSTs (Principato et al, 1988). 
The kinetic mechanism of GSTs appears to be isoenzyme-specific since the human 
placental isoenzyme n, the major bovine brain GST and GST 1-1 exhibit a rapid 
equilibrium random sequential mechanism, as characterized by initial rate and 
product inhibition experiments (Ivanetich & Goold, 1989; Young & Briedis, 1989; 
Schramm et al, 1984 ). 
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1.11 Reversible Binding and Inhibition. 
The GSTs reversibly bind ligands such as heme, bilirubin, steroids, bile acids and 
other amphipathic and hydrophobic molecules. Association constants for ligandin 
range from 2 x 1oS to 108 M-1. These ligands are in general not metabolized by 
the enzyme, hence the term "non-substrate" ligands (Jakoby, 1978). Although all 
the GSTs bind-non-substrate ligands, the affinity for these ligands is variable, as 
shown in Table 1.7. 
Table 1.7: Dissociation constants for non-substrate ligands binding to rat soluble 
GSTs. 
(adapted from Boyer & Kenney, 1985? 
Ko (µM) 
Ligand 
Bilirubin Hematin Indocyanine green 
Isoenzyme: 
1-1 0.34 0.55 
1-2 0.68 (2) (0.1) 0.94 ( 3) 
2-2 4.1 ( 100) (4) 3.69 (100) 
3-3 (15) (2) (3) 
3-4 (3) (7) ( 1) 
a Dissociation constants were obtained from Boyer et al, 1983, values in 
parenthesis are from Ketley et al, 1975, and Arias et al, 1976. 
One of the primary in vivo ligands for the GSTs is bilirubin, which usually binds to 
rat GSTs at both high and low affinity sites, the latter acting to decrease enzyme 
activity. 
Human hepatic ligandin has no high-affinity bilirubin-binding sites, whereas rat 
isoenzymes 1-2 and 3-3 contain primary and secondary bilirubin binding sites 
(Simons & Vander Jagt, 1980; Vander Jagt et al, 1982). Although bilirubin binding 
does not affect the catalytic activity of human placental GST ,r (Vander Jagt et al, 
1981), activity of human hepatic ligandin and rat GSTs 1-2 and 3-3 is decreased by 
bilirubin (Simons & Vander Jagt, 1980; Vander Jagt et al, 1982, 1983). 
Isoenzymes containing subunits 1 and 2 (1-1, 1-2, 2-2) appear to bind bilirubin at a 
single site (Maruyama et al, 1984; Ketley et al, 1975). Covalent labelling of 
GST 1-1 and 2-2 with a bilirubin enol ester derivative showed that equimolar ratios 
of ester and enzyme blocked ligand binding, but did not affect enzyme activity. It 
was also suggested that a single high-affinity bilirubin binding site is formed on 
23 
interaction of the subunits and does not reside on a particular subunit (Boyer, 
1986). 
In some instances, inhibition of GST catalytic activity by non-substrate ligands is 
pH-dependent, although binding is not. Indocyanine green, biliverdin and 
chenodeoxycholate inhibit isoenzymes 1-2 and 2-2 at pH 6.0, but not at pH 8.0, 
although indocyanine green and biliverdin bind to the enzymes at both pH 6 and 
pH 8. The proteins were therefore presumed to form catalytically active 
enzyme-inhibitor-substrate complexes at the high pH and behave as both enzymes 
and binding proteins (Boyer et al, 1984). 
The formation of kinetically stable conformational isomers, which are dependent 
on the order of addition of reactants and pH, has been postulated to take place on 
binding of bilirubin to GST (Simons & Vander Jagt, 1980; Vander Jagt et al, 1982). 
The addition of GST to incubation mixtures containing foreign proteins and 
bilirubin suggested that the protein allowed the retention of GST activity. 
However, the concentrations of foreign proteins required for this effect was 
variable (Vander Jagt et al, 1983). It was proposed that bilirubin has two roles: It 
must first bind to the enzyme to initiate conformational changes, subsequent to 
which bilirubin competes with the foreign protein to establish the GST 
conformations formed. It was concluded that weak protein-protein interactions 
take place between the foreign protein and the bilirubin-GST complex. The ability 
of foreign proteins to regulate the conformational states of the GSTs was proposed 
to represent a type of enzyme memory, since the different conformational states 
were apparently stable (Vander Jagt et al, 1983). 
The main driving force for the binding of non-substrate ligands to GSTs is 
hydrophobic in nature (Tipping et al, 1976). For example, the tendency of 
porphyrins to aggregate is paralleled by increased binding affinities of porphyrins 
for the GSTs (Tipping et al, 1976) Also, conjugation of non-polar ligands with 
sulfate or GSH only increased binding affinity to a small extent, illustrating that 
apolar binding dominated in the binding process (Tipping et al, 1976). The 
secondary binding site is possibly charged to facilitate binding, as indicated by the 
inhibitory effect of different porphyrins and bile acids (Smith et al, 1985; Boyer 
et al, 1984). Comparison of inhibition by chenodeoxycholate, lithocholate and 
cholate showed that the binding site was relatively hydrophobic with a significant 
ionic interaction at the binding domain (Hayes & Mantle, 1986). 
24 
The role of the GSTs in the intracellular transport and/or storage of ligands has 
been difficult to determine, and it has been suggested that these enzymes act as 
intracellular binding proteins, thereby increasing cytosolic ligand concentrations 
(Boyer, 1989; Tipping & Ketterer, 1981; Jakoby 1978). 
Evidence for the role of the GSTs in the hepatic uptake of organic anions is 
provided by the following observations: 
(1.) Several species of amphibia have no GST (ligandin) before metamorphisis 
and show delayed plasma disappearance of injected BSP and/ or bilirubin; After 
metamorphisis these animals have abundant GST and show selective hepatic 
uptake of BSP and bilirubin (Levine et al, 1971). 
(2.) Newborn guinea pig, rat, monkey and humans exhibit slow plasma clearance 
of, and/ or low hepatic content of organic anions. This process matures in the first 
10 days after birth, in parallel with increased hepatic GST (ligandin) content (Levi 
et al, 1970; Arias, 1970). 
(3.) Induction of ligandin is associated with increased disappearance of organic 
anions from the plasma (Reyes et al, 1971). 
( 4.) PB-induction of dogs reduced the efflux of bilirubin from the liver, but did not 
change hepatic bilirubin influx (Arias et al, 1976). 
(5.) Administration of bilirubin to normal rats decreased the transfer of 
triiodothyronine, a high-affinity GST ligand, from the plasma into the liver 
(Lichter et al, 1976). 
( 6.) Decreased BSP excretion and GST levels were determined after partial 
hepatectomy (Oleaga et al, 1987); Increased induced intracellular ligandin 
concentrations enhanced the net hepatic uptake of bilirubin (Wolkoff et al, 1979). 
(7.) A case of Rotor's syndrome, a condition of familial hyperbilirubinemia with 
prolonged plasma BSP retention has been reported in which normal GST activity 
was significantly decreased (Adachi & Yamamoto, 1987). 
1.12 Irreversible Inhibition of the GSTs and Covalent Binding. 
A wide range of compounds covalently bind to the GSTs and inhibit enzyme 
activity. As with reversible binding, covalent inhibition of the GSTs is also 
isoenzyme-dependent. It has been predicted that strong electrophiles will react 
with the nucleophilic groups of proteins with which they come into contact to form 
covalent bonds. Thus, considering the high concentrations of the GST enzymes, 
this type of interaction is expected. This process usually leads to the loss of GST 
activity (Jakoby, 1978). 
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Several GST substrates are inhibitors of GSH conjugating activity. CDNB was 
first reported to inhibit GST activity by Pabst et al (1974). The human lung acidic 
isoenzyme is inhibited in a pseudo first-order process by CDNB, which bound to 
all human lung isoenzymes (Corrigal et al, 1989). Inactivation of GST 7r by CDNB, 
MP-8 and buffer has been proposed to result from solvation of the hydrophobic 
active centre (Adams et al, 1989); A second mechanism of inhibition appeared to 
involve the possible covalent binding of CDNB to a sulfhydryl group near the 
catalytic site (Adams & Sikakana, 1990). Ethacrynic acid also inhibits GST activity 
(Ahokas et al, 1984), covalently binding to isoenzyme 3-4 (Yamada & Kaplowitz, 
1980). 
Several conjugates and analogs of GSH are inhibitors of GST activity. The GSH 
analogs -y-L-Glu-SerGly and -y-L-Glu-AlaGly are dead-end inhibitors of 
isoenzymes 3-3 and 4-4 (Chen et al, 1985). S-hexyl, S-benzyl and 
S-(2,4-dinitrophenyl) GSH conjugates are strong, moderate and weak inhibitors, 
respectively, of isoenzymes 1-1, 2-2, 3-3 and 3-4, but have no effect on isoenzymes 
4-4 and 5-5 (Ong & Clark, 1986). 
Other covalent inhibitors of GST activity include carcinogens, drugs as well as 
spectrum of other widely used chemicals. In this respect binding to the GSTs is 
important in the detoxification of carcinogenic aminoazo dyes, polycyclic aromatic 
hydrocarbons and aromatic amines (Smith et al, 1977). Industrial solvents and 
chemicals such as chloroform, carbon tetrachloride, bromobenzene and 
1,2-dibromoethane also preferentially inhibit certain GST isoenzymes (Aniya & 
Anders, 1985a; Aniya & Anders, 1985b; Ivanetich et al, 1984; Botti et al, 1982). 
Other GST inhibitors include cuprous complexes, mercury and cadmium 
(Dierickx, 1982, 1986), penicillin and cephalosporins (Polidoro et al, 1984) and 
paracetamol metabolites (Wendel & Cikryt, 1981). 
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1.13 The Conjugation of 1,2-Dibromoethane to GSH and Subsequent Toxicity 
of the Conjugate. 
1,2-Dibromoethane (ethylene dibromide; DBE) is a colorless, dense, 
non-flammable liquid with a distinctive chloroform-like odor. DBE is used to 
fumigate vegetables, fruits and grains, and a lead scavenger in petrol (Rannug, 
1980; USEP A, 1977). Approximately 2.5 million kg were used in the U.S.A. in 
1975 and low concentrations of DBE have been detected in fumigated foods and 
ambient air (Fishbein, 1979). 
Exposure of animals to DBE causes early mortality, weight loss, tumor formation 
and influences reproduction; DBE is a strong mutagen in microorganisms 
(Bogdan & Grey, 1984; Weisburger, 1985; Rannug, 1980; Wong et al, 1982). 
Although the effect of industrial exposure to DBE on reproduction and fertility is 
contentious (Weisburger, 1985; Ratcliffe et al, 1987), acute exposure has caused 
death (Weisburger, 1985). In monkeys the location of tissue binding corresponds 
to tissue lesions observed in DBE-poisoned humans (Brandt et al, 1987). In mice, 
renal and hepatic non-protein sulfhydryl concentrations were decreased by DBE 
(Kluwe et al, 1981), while DNA synthesis, mitotic activity (Ledda-Columbano et al, 
1987) and DNA damage were increased (Kitchin & Brown, 1986). DBE adducts 
bound to DNA, RNA and proteins in all major types of rat tissue (Nachtomi & 
Sarma, 1977; Hill et al, 1978). 
DBE t9xicity is probably mediated by two separate mechanisms, viz oxidative 
metabolism and conjugation with GSH (van Bladeren et al, 1980). Treatment of 
hepatocytes with DBE decreases GSH levels and increases covalent binding to 
cellular macromolecules (Albano et al, 1984 ). Thirty to forty percent of a single 
dose of DBE administered to was excreted as the mercapturic acid (van Bladeren 
et al, 1980). Isolated metabolites include N-acetyl-S-(,8-hydroxyethyl) cysteine, 
S-(,8-hydroxyethyl) cysteine, S-(,8-hydroxyethyl) GSH and S-(,8-hydroxyethyl) 
mercapturic acid (Nachtomi et al, 1966; Nachtomi, 1970; Edwards et al, 1970). 
DBE reacts efficiently with sulfhydryl groups in vitro (Edwards et al, 1970) and 
GSH conjugation may be important in the mutagenicity of DBE through the 
formation of reactive half-mustards covalently binding to DNA (Fig. 1.8) 
(van Bladeren et al, 1980, 1981). Mutagenicity towards Salmonella is enhanced by 
the addition of a 100 000g hepatic supernatant fraction (van Bladeren et al, 1980) 
and is considerably decreased in GSH-deficient Salmonella strains (Zoetemelk 
et al, 1987). Rat cytosolic components and GSTS catalyze the covalent binding of 
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DBE to DNA in the presence of GSH with rat isoenzyme 1-2 displaying the 
highest activity in vitro (White et al, 1984; Inskeep & Guengerich, 1984; Ozawa & 
Guengerich, 1983; Wiersma et al, 1986; Sundheimer et al, 1982). 
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Fig. 1.8: DBE activation and excretion pathways. 






A single major DNA adduct, identified as S-[2-(N 7-guanyl)ethyl]GSH, was isolated 
from incubations of DBE, DNA, GSH and .GST (Koga et al, 1986; Ozawa & 
Guengerich, 1983). This adduct has been postulated to result from the attack of 
the DNA guanine N 7 nitrogen on the episulfonium ion formed by the 
non-enzymatic dehydrohalogenation of the half-mustard produced following the 
conjugation of DBE with GSH (Koga et al, 1986). 
The oxidative metabolism of DBE by microsomal proteins also initiates binding of 
DBE metabolites to cellular RNA, DNA and protein (DiRenzo et al, 1982; Hill 
et al, 1978; Wiersma et al, 1986). 2-Bromoacetaldehyde and 2-bromoethanol are 
important intermediates in this process (Banerjee et al, 1979; Hill et al, 1978). 
However, the rate of microsomal DBE metabolism to DNA-binding adducts is 
much lower than the process mediated by the GSTs (Sundheimer et al, 1982; 
Wiersma et al, 1986) and the mixed-function oxidase pathway has been suggested 
to be the primary route of DBE clearance (Working et al, 1986). 
1.14 The Characteristics of Bilirubin. 
Bilirubin is produced from the catabolism of heme-proteins, of which hemoglobin 
is the largest component. Bilirubin IXa (Fig. 1.9), formed in mammals by the 
reduction of biliverdin IXa, is a yellow, toxic compound. This compound exhibits 
poor solubility in water as a result of internal hydrogen bonding (Fig. 1.9) and 
requires biotransformation or isomerization before it can be excreted (Brodersen, 






Fig. 1.9: The structure of bilirubin IX-a sho\\ing the hydrogen bonding between 
the relevant atoms. 
(adapted from Brodersen, 1980) 
Bilirubin is tightly bound to albumin in the blood and conjugated with glucuronic 
acid in the hepatocytes before excretion in the bile. The hepatic clearance of 
bilirubin is divided into three distinct, interdependent processes, viz the initial 
uptake of bilirubin into the hepatocytes from the sinusoids, conjugation in the 
hepatocytes to water-soluble derivatives, and secretion of conjugated bilirubin into 
the intestinal lumen through the biliary tract (Brodersen, 1980; Gourley & Odell, 
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1989). The hepatocyte plasma membrane contains receptor-carrier molecules that 
bind bilirubin and facilitate its transport into hepatocytes (Stremmel et al, 1983; 
Odell & Gourley, 1989) Once in the hepatocytes, bilirubin is bound to the GSTs 
(Levi et al, 1969), one of three distinct groups of bile acid binding proteins which 
have been identified (Stolz et al, 1989). 
1.15 Halothane: Historical Aspects. 
Halothane (CF3CHC1Br), an inhalational anesthetic, was introduced into clinical 
practice in England and the U.S.A. in 1956 and 1958, respectively (Becker & 
Lamont, 1988). Halothane rapidly achieved general acceptance since it could be 
administered readily and accurately, was non-explosive, non-flammable, and 
thought to have minimal side effects (Touloukian & Kaplowitz, 1981). No toxic 
effects were initially encountered (Raventos, 1956; Stephen et al, 1957), but by 
1964 over 100 cases implicating halothane in postoperative hepatic injury or 
hepatitis had been recorded (Blackburn et al, 1964; Touloukian & Kaplowitz, 
1981). Originally the relationship between halothane and hepatitis was 
contentious and proponents of halothane thought that unexplained hepatitis 
following halothane anesthesia was incidental with viral hepatitis or ischemic liver 
"shock" (Touloukian & Kaplowitz, 1981). However, hepatitis viruses A and B were 
* not be associated with halothane hepatitis and the lower age distribution and low 
mortality (less than 1 % ) of viral hepatis differentiated it from the higher age 
disposition and elevated mortality (greater than 50% of recognized cases) of 
halothane hepatitis (Dienstag, 1980). 
In the National Halothane Study (1969) an incidence of one fatality per 36 000 
halothane administrations within six weeks of anesthesia was detected. However, 
later studies found an incidence of between one in 6000 and one in 20 000 deaths 
as a result of severe hepatic dysfunction after halothane anesthesia (Inman & 
Mushin, 1974; Hottinger et al, 1976). Partiality in the National Halothane Study 
may have decreased the importance of halothane hepatitis (Touloukian & 
Kaplowitz, 1981; Mccaughey, 1972; Becker & Lamont, 1988). Further analysis of 
the National Halothane Study exposed the increased incidence of hepatitis 
following multiple halothane anesthesia (Mccaughey, 1972). Subsequent studies 
* Footnote: The term "halothane hepatitis" refers to the form of hepatitis found 
in some patients after anesthesia with halothane and cannot be explained by 
other forms of hepatitis. This form of hepatitis has also been referred to as 
"unexplained hepatitis following halothane" or "halothane-associated hepatitis". 
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showed that more than 80% of patients with halothane hepatitis had been exposed 
to halothane more than once (Walton et al, 1976; Touloukian & Kaplowitz, 1981). 
An increased incidence of halothane hepatitis was also found in middle-aged 
women and the obese (Walton et al, 1976; Bottinger et al, 1976; Neuberger & 
Williams, 1984 ). 
Two distinct forms of halothane hepatotoxicity have now been identified: The 
minor form occurs in approximately 20% of patients after halothane anesthesia 
with coincident small increases in serum aminotransferase levels (Wright et al, 
1975; Trowell et al, 1975); The more severe form induces hepatic damage and 
necrosis, ie halothane hepatitis (Neuberger & Kenna, 1987). 
1.16 Halothane Metabolism. 
Halothane is metabolized primarily by the hepatic microsomal cytochrome P-450 
enzyme system in two pathways, ie a reductive and oxidative pathway. Fluoride, 
2-chloro-1, 1-difluoroethylene ( CD F) and 2-chloro-1, 1, 1-trifluoroethane ( CTF) are 
products of the reductive pathway, whereas trifluoroacetic acid (TF A) and 
bromide are oxidative metabolites. These compounds are excreted in the urine 
(TFA, fluoride, bromide) or exhaled in the breath (CDF, CTF). However, 
metabolic intermediates can also bind to liver macromolecules and ultimately 
cause hepatotoxicity and necrosis, although the mechanism of toxicity is 
controversial and both metabolic pathways have been implicated in this process 























F O H H 

























RE-EXPOSURE - - - - - - - 1 
I 
V 
FULMINANT HEPATIC FAILURE 
Fig. 1.10: The oxidative metabolism of halo thane. 
I I I I 
F H H H 







~ 0 CtJ 
a: - w J: J: m :I_. 0 
I J: I :I CtJ :::, ~ w w<o 
c3-u. cc c3-U-J: :I ..J w a.;; ~ \ u. a. ..J w I \"' I I- cOO --->-::C :s 
U.-()-U. + U..-()-U. 
() w t- :I C < 
I 0: I a: ~ 0 ..J C u. u. :::, a: :s !c C ~ z z < :I ,J~ w C 
J: w I z z 
c3-u-a5 < 0 
I ::c tc t-
U..-()-U.. 0 .... 










:c ~ +I 
N w 
if J: c3 J: tc I I J: (/) C, I 'ul :::, u-U-:C Cl) ,u-u u. (!) .., 
I \ .. I II C \ .. z 
U..-()-U.. U..-()-U. I u, () 
0 
u. 0 I I u! u. ::c u. u. Cl) 
C, 
Fig. 1.11: The reductive metabolism of halothane. 
(adapted from Cohen et al, 1975, Owen & Van der Veen, 1986, Horsch & Schmidt, 
1987) 
33 
Reports of increased urinary bromide and TF A levels appeared in the literature a 
few years after halothane was introduced into clinical practice (Stier et al, 1964; 
Rehder et al, 1967). N-trifluoroacetyl-2-aminoethanol and N-acetyl-S-
(2-bromo-2-chloro-1, 1-difluoroethyl)-L-cysteine were also identified as halothane 
metabolites in urine and thought to indicate binding of halothane metabolites to 
cellular macromolecules such as GSH and phospholipids (Cohen et al, 1975). In 
the presence of oxygen, TF A formation was associated with microsomal 
cytochrome P-450 levels (Karashima et al, 1977). Under anaerobic conditions, 
halothane adducts covalently bound to microsomal proteins in a cytochrome P-450 
dependent process on incubation of microsomes from PB-pretreated rats (Uehleke 
et al, 1973), suggesting halothane metabolism by the hepatic microsomal 
mixed-function oxidase pathway. The anaerobic dehalogenation of halothane is 
cytochrome P-450 isoenzyme-specific, as is the formation of the reductive 
metabolites CTF and CDF (Fujii et al, 1981; Ahr et al, 1982; Van Dyke et al, 1988). 
Rat hepatic cytochrome P-450 isoenzymes induced by PB or polychlorinated 
biphenyls (but not 3-methylcholanthrene) catalyzed the reductive defluorination of 
halothane under low oxygen tensions, while TF A was formed at high oxygen 
concentrations (Van Dyke & Gandolfi, 1976). Levels of CTF, CDF and lipid 
peroxidation were increased by halothane anesthesia in PB-induced rats under 
hypoxic (02 ~ 14%) conditions (Gourley et al, 1980), although lipid peroxidation 
has been proposed to result from cell death rather than inducing necrosis (Knights 
et al, 1988; Younes et al, 1988). Halothane metabolites bound mainly to 
microsomal phospholipids after perfusion of rat livers, but protein binding was 
prevalent after in vivo administration of halothane to rats (Van Dyke & Gandolfi, 
1974 ). Incubation of hepatocytes and microsomes with halothane indicated that 
halothane metabolites bound to both cellular lipids and proteins (McLain et al, 
1979; Baker & Bates, 1988; Smith et al, 1988). 
The administration of halothane to PB-induced rats under hypoxic conditions 
(02 ~ 14%) initiated hepatic damage and liver necrosis in male, but not female, 
rats (Stenger & Johnson, 1972; McLain et al, 1979; Ross et al, 1979; Jee et al, 1980; 
Ross et al, 1984; Hatano et al, 1985). Under these conditions halothane 
hepatotoxicity was associated with hepatic cytochrome P-450 levels and halothane 
concentration (Ross et al, 1984; Jee et al, 1980). In the male rat model of 
halothane hepatotoxicity both PB-induction and hypoxia were required for toxicity 
(Jee et al, 1980; McLain et al, 1979; Ross et al, 1979). 
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Under mildly hypoxic conditions the administration of deuterated halothane to 
PB-induced rats did not alter levels of reductive metabolites (fluoride, CDF, CTF) 
or affect the degree of hepatotoxicity, while substantially decreasing levels of 
oxidative metabolites (TF A, bromide). It was therefore proposed that oxidative 
metabolism of halothane involved the insertion of an oxygen atom at the C-H 
bond, this is prevented by the stability of the C-D bond. In contrast, reductive 
metabolism does not involve splitting of the C-H bond, but is implicated in 
hepatotoxicity (Sipes et al, 1980). 
In guinea pigs the administration of deuterated halothane reduced plasma TFA 
and bromide levels and hepatotoxicity, associating oxidative metabolism with 
halothane hepatotoxicity in the guinea pig (Lind et al, 1989). Other studies with 
rats and guinea pigs have shown that the administration of halothane under 
normoxic conditions (Oz = 21 % ) caused hepatic damage subsequent to oxidative 
metabolism (Rice et al, 1987; Lind et al, 1989). Studies with monolayers of rat 
hepatocytes disclosed that hypoxia, PB-induction and halothane exposure were 
important factors in cell death (Schieble et al, 1988). 
1.17 Halothane Hepatotoxicity. 
The mechanism of halothane hepatitis remains controversial and has been 
proposed to be the result of either a direct toxicity or a hypersensitive response. 
Direct toxicity was implicated by the presence of centrilobular necrosis, the short 
intervals required between exposures, 10% - 20% occurrence of anicteric hepatitis 
with multiple exposures, and the presence of necrosis in animal models. 
Hypersensitivity was indicated by the low incidence of halothane hepatitis, the 
requirement of multiple exposures or rechallenges, the presence of autoantibodies, 
rash or eosinophilia in some patients, and the presence of antibodies to the plasma 
membranes of halothane-exposed hepatocytes (Touloukian & Kaplowitz, 1981). 
Recent findings have indicated that the fulminant form of halothane hepatotoxicity 
may have an immunological explanation (Satoh et al, 1986) since patients with this 
form of hepatitis displayed increased occurrence of a liver kidney microsomal and 
thyroid antibodies and autoimmune complement fixation (Walton et al, 1976). 
Sensitization to halothane-modified hepatocyte constituents was also found in 
some patients with halothane hepatitis, with antibodies apparently specific for this 
form of hepatitis and not complementary to liver damage (Mieli-Vergani et al, 
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1980; Vergani et al, 1978; Kenna et al, 1985). However, patients with halothane 
hepatitis differed in their patterns of antigen recognition, which was presumed to 
reflect a idiosyncratic variability in drug metabolism and/or immune response 
(Kenna et al, 1985). Four distinct polypeptides from halothane-treated rabbits 
were labelled by antibodies in sera from 11 of 14 patients with halothane hepatitis 
(Kenna et al, 1985), while a rat cytochrome P-450 isoenzyme found in the 
microsomal and plasma membranes was labelled by an antibody to TF A adducts 
(Satoh et al, 1985; Satoh et al, 1986). In guinea pigs multiple halothane anesthesia 
induced the formation of an antibody recognizing a trifluoroacetylated guinea pig 
serum albumin (Siadat-Pajouh et al, 1987). 
The immunological determinants of halothane hepatotoxicity have been proposed 
to include unidentified bound reductive metabolites of halothane or altered 
autoantigens, the immunological explanation of halothane hepatotoxicity appears 
to be complicated (Satoh et al, 1986). 
1.18 Additional Effects of Halothane. 
Cytochrome P-450 activity is decreased by halothane, possibly as a consequence of 
the involvement of this group of enzymes in the metabolism of halothane (Ross 
et al, 1979; Stenger & Johnson, 1972; McLain et al, 1979). The reaction of 
halothane with reduced microsomal cytochrome P-450 shows a unusual difference 
spectrum effected by a trifluoromethyl carbene complex with the reduced 
hemoprotein. The partial destruction of cytochrome P-450 implicated a highly 
reactive carbenoid species probably formed by a two-electron reduction of 
halothane under anaerobic conditions (Mansuy et al, 1974; Nastainczyk et al, 1978; 
Loew & Ooldblum, 1980). The spectral intermediate was assigned to a ferric 
cytochrome P-450 and CF3CHCr carbanion complex (Monig et al, 1983; Ruf et al, 
1984). 
Halothane and its metabolites are not mutagenic or carcinogenic (Baden et al, 
1976; Edmunds et al, 1979; Sachdev et al, 1980). However, halothane does inhibit 
lipogenesis (Mapes, 1977), glycolysis (Biebuyck et al, 1972) and drug metabolism 
(Reilly et al, 1985), while activating the adenylate cyclase (Rosenberg & Pohl, 
1975; Bernstein et al, 1985) and protein kinase c enzymes (Tsuchiya et al, 1988). 
Halothane anesthesia caused mild hepatic damage in humans (Johnstone et al, 
1976) and rats (Oiler et al, 1976), and increased serum OST levels (Allan et al, 
1987). Multiple, but not single, exposures of halothane to rats has been found to 
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increase BSP retention in liver perfusates one to three weeks after exposure to 
halothane (Biebuyck et al, 1970). 
1.19 The Microperoxidases as Models of Heme Protein Function. 
Most organisms require transducing electron-transport chains for adenosine 
triphosphate production (Salemme, 1977). The proteins comprising such chains 
utilize iron porphyrins to mediate the electron transport reaction and are part of a 
group of proteins, the heme-proteins, which catalyze a variety of reactions 
including oxygen transport (hemoglobin, myoglobin), H202 metabolism 
(peroxidases, catalases ), oxygen activation and regio-specific insertion 
(cytochromes P-450), reduction of dioxygen to water (terminal oxidases) and 
electron transport (cytochrome b5, cytochromes c) (Adams, 1990). 
The most intensely investigated electron transporting heme proteins are the highly 
conserved cytochromes c (Salemme, 1977). The greatest homology between the 
cytochromes c from different species is found in the surface structure and charge 
topography on the side of the protein facing the heme crevice. The mechanism of 
oxidoreduction has been proposed to involve the direct electron addition to, and 
withdrawal from, the heme moiety (Salemme et al, 1973; Salemme, 1977). The 
reaction diversity of different heme proteins implies that the apo-protein controls 
reactivity of the heme by varying the number, nature and strength of axial ligands 
of the heme or by the diversity of the apo-protein amino acids surrounding the 
heme moiety (Adams, 1990). 
Hemin (ferriprotoporphyrin IX) and related porphyrins were considered as the 
most relevant model systems for the peroxidases in early studies (Dunford & 
Stillman, 1976). However, autoxidation and aggregation of these compounds in 
aqueous solution, the latter requiring detergents or organic solvents for prevention, 
has required the development of simple hemoprotein analogues (Shack & Clark, 
1947; Simplicio & Schwenzer, 1973; Davies, 1973; Adams, 1990). For this purpose 
specifically designed iron porphyrins or heme peptides, the so-called 
microperoxidases, have been used (Adams, 1990). 
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1.20 Properties of the Microperoxidases. 
* The microperoxidases are a group of heme peptides prepared by the proteolytic 
digestion of cytochrome c (Adams, 1990). The peptide fragment confers aqueous 
phase solubility on the heme group and the amino acid composition and chain 
length can be varied by the use of several proteolytic enzymes and cytochrome c 
from diverse species. The heme moiety is linked to cysteine amino acids by 
covalent thioether bonds and the Fe11I + of the ferriheme-c is axially ligated to the 
imidazole of a histidine (His-18#) (Baldwin et al, 1987). Although these peptides 
were first isolated some 40 years ago (Tsou, 1951), interest in them as models for 







Fig. 1.12: The amino acid sequence of the various microperoxidases obtained by 
the enzymatic digestion of cytochrome c. The amino acids are numbered 
according to their positions in the cytochrome c primary sequence. 
(adapted from Baba et al, 1969) 
The microperoxidases dimerize in aqueous solutions, the Ko for MP-8 at pH 7.0 
(25 °C) being 1.17 x 1a5 M-1. However, the concentration of monomers is 
enhanced with increasing hydrophobicity of the solution (Aron et al, 1986; Baldwin 
et al, 1987). Dimerization of MP-8 takes place by the stacking or oblique 
orientation of the 7Hr system of the tetrapyrrole ring (Urry & Pettegrew, 1967; 
Adams, 1990). MP-9 and MP-11 aggregate by the intermolecular coordination of 
amino groups to the iron atom in a nearly head-to-tail alignment of the heme 
planes (Urry, 1967; Peterson et al, 1980, 1983; Wilson et al, 1977). At 
concentrations required for catalytic studies ( < 10-6 M) MP-8 is water-soluble and 
* Footnote: The microperoxidases will be referred to by the abbreviated format 
MP, ie MP-8 refers to microperoxidase-8. The numeral in the nomenclature 
refers to the number of amino acids _present in the peptide. 
# Footnote: The amino acids of the m1croperoxidases are generally numbered 
according to their position in cytochrome c. 
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essentially monomeric in aqueous and aqueous/methanol solutions (Aron et al, 
1986). MP-8 has been used as a model for the cytochromes (Harbury & Loach, 
1960), hemoprotein anion-binding (Blumenthal & Kassner, 1980) and the 
peroxidase enzymes (Baldwin et al, 1985). 
Three reversible, concentration-independent pK values have been determined for 
MP-8 and attributed to the deprotonation of His-18 (and its coordination to Fe1n), 
bound H20, and bound His-18 to form a imidazolate complex (Baldwin et al, 
1986). The coordination sphere of Fein consists of His-18 and H20 as axial 
ligands in MP-8 and MP-9 (Aron et al, 1986; Baldwin et al, 1987). MP-11 also 
undergoes at least three pH-dependent transitions ascribed to the binding of a 
deprotonated imidazole group to the ferric iron and the binding of the two 
available amino groups (a-NH2 ofvaline and c-NH2 of lysine) (Wilson et al, 1977). 
1.21 Microperoxidase Purification. 
The microperoxidases are prepared by the digestion of cytochrome c with a range 
of proteolytic enzymes. MP-11 and MP-9 are prepared by pepsin and trypsin 
digestion of cytochrome c, respectively. MP-8 is obtained by the tryptic digestion 
of MP-11, and MP-6 by nagarse (a non-specific protease) digestion of either MP-8 
or cytochrome c. Most methods require long incubation times(~ 12 hours), 
although a trypsin-Sepharose column has been used requiring approximately 5 
hours. Several purification procedures, including protein precipitation, molecular 
sieving, ion-exchange chromatography and dialysis, are usually required, most 
methods appearing to require at least two days to purify the microperoxidases 
(Baba et al, 1969; Plattner et al, 1977; Peterson et al, 1980, 1983). However, the 
use of reverse-phase HPLC as a purification step has substantially decreased the 
preparation time for MP-8 from cytochrome c (~ 30 h), at the same time increasing 
yield (> 98%) and purity (> 90%) of the sample (Adams et al, 1988). 
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1.22 Motivation for Study. 
In this thesis a number of topics relating to the GSH S-transferases were covered. 
The reasons for this diversity were two-fold. In the first instance our laboratory 
started working on the GSTs one year before my arrival and therefore were still in 
the process of setting up the laboratory with respect to work related to the GSTs. 
Secondly, my initial supervisor, Associate Professor K.M. Ivanetich, emigrated 
from South Africa during 1988. It was therefore necessary to find a second, 
resident supervisor, Dr. P.A. Adams. The work with Dr. Adams concentrated on 
heme protein and peptide chemistry. 
Initial studies related to the interactions of the anesthetic halothane with the 
GSTs. The prime motive for this was a report of halothane decreasing the hepatic 
uptake of BSP (Biebuyck et al, 1970). It was hypothesized by us that this finding 
possibly reflected a decrease in hepatic GST levels as BSP is known to bind to 
certain GST subunits (Jakoby et al, 1976; Mannervik & Jensson, 1982). In 
addition, other halocarbons such as carbon tetrachloride (Younes et al, 1980) and 
1,2-dibromoethane (Ivanetich et al, 1984; Botti et al, 1982) had been demonstrated 
to inactivate GSTs in an isoenzyme-dependent manner. (Chapter 3) 
Incubations of GSTs with halothane (this study) and 1,2-dibromoethane (Ivanetich 
et al, 1984) appeared to have similar effects on rat hepatic GST activity. 
Therefore, following on the studies of the reversible effects of halothane on GST 
activity, the reversible effects of DBE were also analyzed. (Chapter 4) 
The binding of bilirubin to the GSTs and the resultant inhibition of GST activity 
has been widely reported (Simons & Vander Jagt, 1980; Vander Jagt et al, 1982, 
1983; Ketley et al, 1975; Arias et al, 1976). However, GST inhibition by bilirubin 
was prevented by the addition of proteins to incubations and it was proposed that a 
form of "enzyme memory" resulted in the observed protective effect (Simons & 
Vander Jagt, 1980; Vander Jagt et al, 1982, 1983). Our analysis of the relevant 
data appeared to indicate that the results had possibly been incorrectly analyzed 
and that a simpler explanation could explain the observed phenomenon. Thus our 
investigation of bilirubin inhibition and protein protection. (Chapter 5) 
The kinetic mechanism of only a few GSTs have been elucidated (Mannervik, 
1985; Boyer & Kenney, 1985). Since GSTs p and 1r had been proposed to be 
similar or identical (Guthenberg & Mannervik, 1981) and the kinetic mechanism 
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of isoenzyme 1r was in the process of being elucidated in our laboratory (Ivanetich 
& Goold, 1989), the mechanism of GST p was investigated. The kinetic 
mechanism of GST 7r and GST p was found to be virtually identical. (Chapter 6) 
The heme peptides (microperoxidases) are known to bind to human serum 
albumin and GST 1r (Adams et al, 1989; Adams & Goold, 1990). An additional 
discriminatory mechanistic tool, in the form of microperoxidase binding and 
inhibition, was therefore used to investigate the similarity of these two isoenzymes 
at the structural level and to further investigate mechanisms and binding of 
non-substrate ligands to the GSTs. (Chapter 7) 
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Materials and Methods. 
Materials. 
Chemicals. 
Isoflurane, enflurane, methoxyflurane: Abbott Laboratories, Kent, U.K.; 
trans-4-phenyl-3-buten-2-one: Aldrich Chemicals, Gillingham, Dorset, U.K.; 
Diaflo ultrafiltration membranes: Amicon Corporation, Lexington, Mass., USA; 
Ammonium persulfate, DTI, DBE (1,2-dibromoethane), bis-acrylamide, 
,B-mercaptoethanol: BDH Chemicals, Poole, England; Acetonitrile; Beckman; 
Bio-rad protein determination kit (including r-globulin protein standard), Bio-rad 
silver staining kit: Bio-rad Laboratories, Miinchen, West Germany; DCNB: 
EGA-CHEMIE, Steinheim/ Albuch, West Germany; Cumene hydroperoxide 
(70% in cumene): Fluka AG, Buchs, Switzerland; Halothane: Maybaker, South 
Africa; CDNB, hydrogen iodide, DTNB, SDS, acrylamide, TF A, TEMED, 
DMSO, Folin-Ciocalteu's phenol reagent: Merck, Darmstadt, West Germany; 
BSA: Miles Research Products, Cape Town, South Africa; 
1-Chloro-2,2-difluoroethylene: PCR Research Chemicals, Gainsville, Florida, 
USA; Sephadex G-25, PBE 118 & PBE 94 chromatofocusing resins, Pharmalyte 
pH 10-8.5 chromatofocusing buffer, Polybuffer 96, Polybuffer 74, epoxy-activated 
Sepharose 6B: Pharmacia Fine Chemicals, Uppsala, Sweden; Acetonitrile: 
Rathbum Chemicals Ltd., Walkerbum, Scotland; Blood transfusion bags: 
SABAX, Johannesburg, RSA; GSH, GSH Sepharose, BSP GSH Sepharose, 
trypsin, pepsin, cytochrome c, HSA, TEAE cellulose ion-exchange chromatography 
resin, DTE, bilirubin, human hemoglobin, bovine pancreatic ribonuclease A, 
aldolase, DTE, GSH reductase, MP-11, GSH reductase, NADPH, dialysis tubing: 
Sigma Chemical Company, St. Louis, MO, USA; DEAE ion-exchange 
chromatography resin (DE 52), CM-cellulose ion-exchange chromatography resin 
(CM 52): Whatman, Maidstone, Kent, U.K.: 
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HPLC Columns: 
Synchropak AX-300 HPLC column: 25 cm x 4.6 mm, weak anion exchange 
column; Synchrom Incorporated, Linden, IN, USA. 
Microbondpak Cm HPLC column : 10 cm x 8.0 mm, reverse phase column; 
Waters Associates, Milford, MA, USA. 
Methods. 
All reagents used were analytical reagent (AR) grade, aqueous solutions were 
made up using de-ionized, pyrogen-free water, unless otherwise stated. 
Concentrations given as percentages indicate either weight/volume or 
volume/volume. 
2.1 Assays for GST Activity. 
2.1.1 Standard Assay Conditions. 
All spectrophotometric assays were performed at 25 ° C in 0.1 M potassium 
phosphate buffer of the indicated pH (Table 2.1). Substrates with limited water 
solubility were prepared weekly as stock solutions in ethanol (3.33% ethanol final 
concentration in assay medium) and protected from light. GSH solutions were 
made fresh daily in degassed water or phosphate buffer and neutralized with KOH. 
The electrophilic substrates were equilibrated with buffer (in cuvettes), and GSH 
was added immediately before assays were initiated by the addition of enzyme. 
Absorbance measurements were routinely performed using a Beckman UV 5230 
or Unicam SP1800 spectrophotometer (Habig & Jakoby, 1981; Askelof et al, 1975). 
The electrophilic substrates were made up in ethanol and added to phosphate 
buffer at 25 °C. GSH (150 µ1) was added prior to the addition of diluted enzyme 
(50 µI) used to start the assay. 
For kinetic studies, experiments were performed on a centrifugal analyzer (see 
Section 2.1.3). 
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The CDNB, DCNB and trans-4-phenyl-3-buten-2-one assays have been reported as 
apparently linear for at least three min at absorbance changes of less than 
0.05 per min (Habig et al, 1974). The CDNB assay was linear in our system for 
only up to one min. Enzymic rates were generally measured over one min. 
Reactions in the absence of enzyme were significant and linear for at least five min 
under the conditions used. 
2.1.2 Cumene Hydroperoxide Assay. 
The cumene hydroperoxide assay differs from the above in that it is a coupled 
GSH peroxidase in which NADPH oxidation is measured as a function of 
peroxidase activity. 
The enzyme was preincubated in a cuvette with 100 µl EDTA (3.0 mM), GSH 
(1.0 mM), NADPH (0.11 mM) and GSH reductase (13 ng protein/100 µl) and 
buffer (100 µl) at room temperature for 10 min prior to starting the assay by 
addition of cumene hydroperoxide (0.1 mM in 1 % EtOH) (Wendel, 1981). All 
solutions were made up fresh daily. The reaction was linear for one min at 
absorbance changes of less than 0.05 absorbance units per min ( own observation). 
Table 2.1: Conditions for spectrophotometric GST assays. 
Substrate 
CDNB DCNB trans-4-phenyl- Cumene 
3-buten-2-one hydroperoxidea 
Conditions 
[Substrate] (rrM) 1.0 1.0 0.05 
[GSH] (rrM) 1.0 5.0 0.25 1.0 
IJavelength (nm) 340 345 290 340 
Extinction coefficient 9.6 8.5 -24.8 -6.0 
CrrM- 1.cm- 1) 
Phosphate buffer (pH) 6.5 7.5 6.5 7.ob 
a A further description of the cumene hydroperoxide assay is given below. 
b The phosphate buffer used in the cumene hydroperoxide assay also contains 
0.1 M KCI. 
(adapted from Habig et al, 1974, Wendel, 1981) 
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2.1.3 Centrifugal Analyzer. 
For detailed kinetic studies of erythrocyte GST p, a MultistatR Plus centrifugal 
analyzer was used (Instrumentation Laboratory, Lexington, MA, USA). The 
MultistatR Plus System is an automated centrifugal absorbance detector used to 
measure simultaneously absorbance changes of multiple samples. Reactants were 
loaded into disposable plastic rotors; These contain 20 separate cuvettes, divided 
by a slight ridge. This division allows for separation of reagents to be maintained 
until the start of the assay. After loading the cuvettes were placed in the 
instrument and the rotor allowed to temperature equilibrate (30 ° C). Reaction 
was initiated automatically in the instrument using a rapid spin/stop procedure. 
Enzyme activity towards CDNB was measured in triplicate at 340 nm at 
30 ± 0.2 °Cat 6 second intervals for 1 min. Non-enzymic absorbances were 
measured at 30 second intervals over 5 min. Absorbance measurements were 
started 10 seconds after mixing of the reagents. 
CDNB (0.2 - 2.0 mM) was dissolved in DMSO (2% v/v in assay; protected from 
light) and mixed into 0.1 M phosphate buffer (pH 6.5). GSH was dissolved in 
degassed phosphate buffer and the solution neutralized with KOH. The enzyme 
was diluted in buffer to the correct concentration before use. Assay volumes were 
as follows: premixed buffer and CDNB (180 µl), GSH (10 µl) and diluted enzyme 
(10 µl). All solutions, with the exception of buffer, were made fresh daily. 
The CDNB solution was added to the outer chamber of the rotor with the enzyme 
added to the inner compartment (see diagram of Multistat rotor below). GSH was 
added to the CDNB solution immediately before loading the rotor into the 
instrument. The enzyme was kept separate from the other constituents until the 
samples were mixed by the instrument. 
Results were fitted to a straight line by linear regression (using Lotus 1-2-3R). 
Enzyme rates were corrected for the non-enzymic reaction. 
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Fig. 2.1: Diagrammatic representation of the MultistatR centrifugal analyzer 
rotor. 
(obtained from the instruction manual) 
2.2 Protein Concentration Assays. 
2.2.1 Lowry Protein Assay. 
The Lowry procedure was used for all protein assays, except for GST p studies and 
unless otherwise stated, were carried out using the Lowry method (Lowry et al, 
1951; Chaykin, 1966). 
A 2.0% sodium carbonate solution in 0.1 M NaOH (solution A) was combined 
with a 1.0% copper sulfate solution (solution B) and a 2.0% sodium tartrate 
solution (solution C) in the ratio 50:1:1 (A:B:C) to give solution D, made fresh 
daily. Solution E consisted of 1 part Folin-Ciocalteu's reagent diluted with 2 parts 
water. 
The diluted protein sample (0.5 ml) was mixed with solution D (5 ml), and 10 min 
later solution E (0.5 ml) was added with mixing. The absorbance of the sample 
was measured after 10 min at 600 nm and the data corrected for the relevant 
control, which did not contain protein. 
BSA (in water) was used as a protein standard (0 - 100 µg/ml). The concentration 
of BSA standards was measured at 280 nm (1 mg/ml = 0.667 absorbance units). 
2.2.2 Bio-rad Protein Assay. 
The Bio-rad protein assay was performed according to the suppliers instructions. 
In the standard assay (20 - 140 µg protein, 200 - 1400 mg/ml) samples (0.1 ml) 
were mixed with 5.0 ml dye reagent (5-fold dilution). In the microassay (1 - 20 µg 
protein; <25 µg/ml) samples (0.8 ml)were mixed with 0.2 ml concentrated dye 
reagent (The absorbance measured between 5 and 60 min later at 595 nm). 
Since the dye adsorbs on glass and plastic, absorbances were measured in a cuvette 
pre-equilibrated with the dye concentrate. 
2.2.3 Spectrophotometric Assays. 
The following equation was used to estimate protein concentrations in samples 
prior to quantification by the above methods: 
[protein] (mg/ml) = 1.45 x A230 nm - 0.74 x A260 nm 
(Thorne, 1978) 
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2.3 Protein Gel Electrophoresis. 
2.3.1 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE). 
SDS-PAGE gels were generally run using a discontinuous buffer system in a 
modification of the method by Laemmli (1970), as described by Hames (1981), 
with the stacking and separating gels, containing 5% and 12.5% acrylamide, 
respectively, prepared from a stock solution containing 30% acrylamide, 
0.8% bis-acrylamide and 0.1 % SDS. The stacking gel buffer consisted of 
125 mM Tris.HCl and 0.1 % SDS, pH 6.8, and the separating gel buffer 
375 mM Tris.HCl, 0.1 % SDS and 20% glycerol (pH 8.8). The electrode buffer 
contained 25 mM Tris.HCl (pH 8.3), 192 mM glycine and 0.1 % SDS. 
In order to facilitate polymerization the acrylamide solutions were mixed with 
ammonium persulfate (0.1 % stock solution, final concentration between 0.0005% 
and 0.001 % ) and degassed on an aspirator for one min. Solutions were filtered 
through 0.2 µm filters before TEMED (10 µl) was added and the gels poured 
immediately. The resolving gel was usually covered with a 0.1 % SDS solution and 
allowed to polymerize overnight. The stacking gel was prepared in the same way 
and poured onto the polymerized separating gel. Samples were loaded onto the 
stacking gel, electrophoresis buffer was added to the system and electrophoresis 
started. 
Protein samples (approximately 10 µg per protein band in less than 25 µl) were 
diluted 2-fold in 125 mM Tris.HCl buffer containing 4% SDS and 24% glycerol 
(pH 6.8). ,8-Mercaptoethanol (5%), used as a reductant, and bromophenol blue, a 
marker dye, were added to samples before boiling for 3 min and loading. Samples 
with low protein concentrations were lyophilized and redissolved in approximately 
20 µl water and treated in the same way. 
Initially a constant current of 25 mA was applied to the gels; This was increased to 
30 mA when the protein entered the resolving gel. Samples were electrophoresed 
until the bromophenol blue reached the lower border of the gel. Subsequently gels 
were stained for protein detection as described below. 
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2.3.2 Protein Staining. 
2.3.2.1 Coomassie Blue Stain. 
Polyacrylamide gels were stained with a solution of 50% methanol, 20% acetic 
acid and 0.12% Coomassie Blue in water for at least 2 hours before non-specific 
stain was removed with a solution of 10% methanol and 10% acetic acid and the 
gel stored in water (Hames, 1981). 
2.3.2.2 Bio-rad Silver Stain. 
In samples containing too little protein for detection by the Coomassie Blue stain 
the more sensitive Bio-rad silver stain method was used. 
The Bio-rad silver stain (Bio-rad bulletin 1089) was used in kit form containing the 
following solutions: Fix I (40% methanol and 10% acetic acid in water); Fix II 
(10% ethanol and 5% acetic acid in water); Oxidizer (this solution was supplied as 
a 10-fold concentrate, composition unknown); Silver reagent (supplied as a 
10-fold concentrate, composition unknown); Developer (supplied in powder form 
and dissolved in water); Stopping solution (5% acetic acid in water). 
The gels were soaked in fix I for 30 min, followed by fix II (twice for 15 min), which 
could be left with the gel overnight. Subsequently the gel was gently shaken in 
oxidizer for 5 min, followed by silver solution for 20 min and developer (twice for 
5 min). The second treatment with developer was continued until protein bands 
became visible and the reaction was then stopped by addition of the stopping 
solution (15 min). Gels were stored in water. 
2.4 Glutathione Assays. 
Two methods were used to measure GSH in the millimolar and micromolar 
concentrations ranges. The first method (see below) was used to gauge the effect 
of dialysis and chromatography on GSH levels. Halothane metabolism, 
ie conjugation with GSH, was determined by the second method. 
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2.4.1 Glutathione Concentrations in the Millimolar Range. 
Protein was removed from GSH samples (1.5 ml) by precipitation with 0.1 ml TCA 
(33%) and centrifugation at 2000 rpm for 5 min. A 0.1 ml aliquot of the 
supernatant was mixed with 1.5 ml of a 0.05 mM DTNB solution in 0.1 M 
phosphate buffer, pH 6.5, and the absorbance measured at 412 nm after 30 min 
(Ellman, 1959; van Bladeren et al, 1980). 
2.4.2 Glutathione Concentrations in the Micromolar Range. 
Lyophilized samples were dissolved in 10 mM HCl to a GSH concentration of 0.3 
to 1.5 µM and aliquots (300 µl) added to test tubes at 25 ° C. Reagents 1 and 2 
(300 µleach) (see below) were added to the sample simultaneously and the 
absorbance at 412 nm measured after 15 min. 
Reagent 1 contained sodium phosphate buffer (110 mM Na2HP04/40 mM 
NaH2P04) at pH 7.2 with 15 mM EDTA, 0.04% BSA and 0.3 mM DTNB 
(Ellman's reagent), whereas reagent 2 comprised 15 mM imidazole.HCl, 1 mM 
EDTA, 0.02% BSA, GSSG reductase (1.2 IU/ml) and 0.6 mM NADPH (pH 7.2). 
NADPH and GSH reductase were added to reagent 2 daily (Tietze, 1969; Brehe & 
Burch, 1976). 
Incubation mixtures containing GSH were diluted with 10 mM HCl and an aliquot 
lyophilized. The samples were redissolved in 10 mM HCI and the GSH 
concentration determined as described. 
2.5 Anesthesia of Rats with Halothane. 
Male Long-Evans rats (200 ± 10 grams) were starved for 24 hours before being 
anesthetized with halothane (1 % in medical air, 1.25 MAC) in standard anesthetic 
tanks. Halothane/air was delivered at a flow rate of 61/min under controlled 
conditions of temperature and humidity. 
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2.6 Purification of Rat Hepatic GST Isoenzymes. 
2.6.1 Cytosolic Preparation. 
Rat hepatic cytosol was prepared from livers of male Long-Evans rats (200 ± 10 
grams). The livers were washed with 10 mM Tris.HCl buffer, pH 7.8, 
homogenized in the same buffer (20% homogenate) and centrifuged at 18 OOOg 
(Beckman 12-21 centrifuge; JA-20 rotor) for 15 min. The supernatant was 
centrifuged at 100 OOOg (Beckman L8-70M ultracentrifuge; Type 65 rotor) for 1 
hour to remove the microsomes. The supernatant from the 100 OOOg 
centrifugation was used as cytosol for further experiments or purification of the 
transferase isoenzymes (Ernster et al, 1962). 
2.6.2 Purification of the Mixture of Rat GST Isoenzymes *. 
2.6.2.1 Method 1. 
Approximately 20 ml cytosol was applied to a Sephadex G-25 column 
(1.6 cm x 100 cm) equilibrated with 10 mM Tris.HCl, pH 7.8, to remove low 
molecular weight contaminants. Protein eluting in the void volume was collected 
and loaded onto a S-hexyl GSH affinity column equilibrated with 10 mM Tris.HCl, 
pH 7.8, and washed (usually overnight) with 10 mM Tris.HCl containing 0.2 M 
NaCl, pH 7.8, to remove non-specifically bound proteins. The GSH S-transferases 
were eluted with the Tris/NaCl buffer containing 5 mM S-hexyl GSH (pH 7.8). 
The eluted enzyme was chromatographed on a second Sephadex G-25 column to 
remove S-hexyl GSH, which is an inhibitor of the transferases. The latter column 
was equilibrated with 10 mM Tris.HCl buffer, pH 7.8, for subsequent storage of 
the GST mixture, or equilibrated with the relevant buffers for further purification 
by chromatofocusing (Guthenberg & Mannervik, 1979; Jensson et al, 1982). 
* The family of rat GSTs which have been partially purified by affinity 
chromatography are referred to as the GST mixture. The purified isoenzymes 
are referred to as GST isoenzymes, while cytosolic GSTs are the GST enzymes 
present in cytosol. 
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2.6.2.2 Method 2. 
Cytosol was prepared in 10 mM Tris.HCl, pH 8.0, and filtered through 
cheese-cloth to remove free floating lipids. The cytosol was applied to a 
DEAE-cellulose column (5 cm x 20 cm) equilibrated with 10 mM Tris.HCl, pH 8.0, 
and the void volume collected (Habig et al, 1974). 
The collected protein was concentrated on an Arn.icon PM-10 ultrafiltration 
membrane and dialyzed against 25 mM sodium phosphate buffer, pH 9.4, before 
purification of the GST mixture on a GSH affinity column (1 cm x 13 cm) 
equilibrated with the same buffer. The affinity column was washed overnight with 
25 mM sodium phosphate containing 150 mM NaCl, pH 9.4, and the enzyme 
eluted with the latter buffer containing 100 mM GSH. Before storage the enzyme 
was dialyzed against 10 mM potassium phosphate buffer, pH 6.7, containing 
30% glycerol (w/v) and 1 mM EDTA (Simons & Vander Jagt, 1977). 
2.6.3 Preparation of Affinity Matrices. 
2.6.3.2 Preparation of S-Hexyl GSH. 
GSH was dissolved in water to a concentration of 1.0 Mand 4.0 mmoles NaOH 
added to 2 ml of this solution with stirring at room temperature. Ethanol was 
added dropwise with stirring to form a cloudy precipitate, following which an 
equimolar amount of 1-iodohexane was added over 30 min with stirring. The 
pH of the solution was reduced to 3.5 with 47% hydriodic acid, and the solution 
left overnight at 4 ° C. The resulting precipitate was removed by filtration and 
washed with water prior to recrystallization from water/ ethanol. The crystals were 
dried and stored in a dessicator at -20 °C (Vince et al, 1971). 
2.6.3.2 S-hexyl GSH Sepharose Affinity Matrix. 
The S-hexyl GSH affinity matrix was prepared according to the instructions of the 
manufacturer. S-hexyl GSH (0.011 mM) was dissolved in 0.1 M sodium 
carbonate.NaOH, pH 10.6, and added to washed epoxy-activated Sepharose 6B. 
Thirty ml of ligand, was added to 15 g Sepharose. The reaction was left to proceed 
at 30 °C for 30 hours with gentle shaking. The resin was washed with 
approximately 400 ml each of 0.1 M sodium carbonate (pH 10.6), 0.1 M sodium 
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borate containing 0.5 M NaCl (pH 8.0), 0.1 M sodium acetate containing 
0.5 M NaCl (pH 4.0), and water. 
2.6.3.3 GSH-Sepharose Affinity Matrix. 
Epoxy-activated Sepharose 6B ( 4 g) was washed on a Buchner funnel with 500 ml 
water and 40 ml 44 mM phosphate buffer (pH 7.0). The gel was transferred to a 
50 ml flask and the volume adjusted to 20 ml with the latter buffer, and nitrogen 
bubbled through the suspension for 5 min. A 4 ml solution of GSH (400 mg/4 ml), 
pH 7.0, was added to the gel suspension and coupled for 24 hours at 37 ·c with 
shaking. The coupled gel was washed with 100 ml water and the active groups 
blocked by treatment with 1.0 M ethanolamine (4 hours) before washing (100 ml 
each) with 0.1 M sodium acetate/0.5 M KCl (pH 4.0) and 0.1 M sodium 
borate/0.5 M KCl (pH 8.0), with storage at 4 °C in water (Simons & Vander Jagt, 
1977). 
2.6.4 Separation of the Rat GST Isoenzymes by Chromatofocusing. 
The GST isoenzymes were separated on chromatofocusing resin PBE 118 
(1 cm x 30 cm) with a pH 11 - 8 gradient, according to the specifications of the 
supplier. The resin was equilibrated with 25 mM triethylamine.HCl (pH 11.0). 
The proteins were eluted with Pharmalyte pH 10 - 8.5 buffer which had been 
adjusted to pH 8.0 and diluted 80-fold with water (Jensson et al, 1982; Mannervik 
& Jensson, 1982). 
Alternatively, PBE 94 resin (1 cm x 30 cm) was equilibrated with 25 mM 
ethanolamine.HCI, pH 10.0, and the isoenzymes eluted with a 10% solution of 
Polybuffer 96 and Polybuffer 74 (6:4 v/v, pH 5.5) (lvanetich et al, 1984). 
In both chromatofocusing methods, eluate was monitored for protein (A2so nm) 
and GST activity (CDNB assay). 
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2.6.5 Separation of GST Isoenzymes by Ion-Exchange Chromatography. 
Cytosol was prepared in water and chromatographed on a DEAE-cellulose column 
(9 cm x 23 cm) equilibrated with 10 mM Tris.HCl (pH 8.0). Proteins eluting in the 
void volume were collected (this fraction contained approximately 70% of the 
loaded GST activity) and concentrated on a hollow fibre concentrator. (Although 
this concentration method resulted in the loss of enzyme activity, the Amicon 
ultrafiltration system used later in the separation procedure was too slow for the 
volumes which were concentrated at this initial stage). 
The concentrate was dialyzed against 10 mM Tris.HCI, pH 9.4, before 
chromatography on TEAE-cellulose (2 cm x 23 cm). Isoenzymes with subunits 1 
and 2 were eluted in the buffer wash; Isoenzymes comprising subunits 3 and/ or 4 
were eluted with 40 mM Tris.HCI (pH 8.0). 
Both enzyme fractions (ie isoenzymes 1-1, 1-2 and 2-2 in one fraction, and 
isoenzymes 3-3, 3-4 and 4-4 in the other fraction) were loaded onto GSH affinity 
columns (2 cm x 4.7 cm). The matrix was equilibrated with 25 mM sodium 
phosphate, pH 9.4, and washed with 25 mM sodium phosphate containing 
150 mM NaCl (pH 9.4). Both GST fractions were eluted with the phosphate/NaCl 
buffer containing 100 mM GSH, pH 9.4, concentrated on Amicon PM-10 
ultrafiltration membranes and dialyzed against 10 mM potassium phosphate, 
pH 6.7 (36 hours). 
The isoenzymes were separated on two CM-cellulose columns (2.5 x 36 cm) 
equilibrated with 10 mM potassium phosphate, pH 6.7, and washed with 
equilibration buffer (500 ml) before application of a linear O - 75 mM KCl gradient 
in equilibration buffer (1000 ml). Protein peaks (280 nm) were pooled before 
concentration and dialysis against 10 mM potassium phosphate buffer (pH 6.7) 
containing 30% (w/v) glycerol and 1 mM EDTA (36 hours). 
(Boyer et al, 1983; Boyer & Kenney, 1985; Habig et al, 1974) 
GST isoenzymes purified by chromatofocusing and ion-exchange chromatography 
were characterized by their elution profiles, subunit size on SDS-PAGE, and 
substrate specificities for CDNB, DCNB, trans-4-phenyl-3-buten-2-one and 
cumene hydroperoxide (Jensson et al, 1982; Mannervik & Jensson, 1982). 
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2.7 Purification of Human Erythrocyte GST s. 
Blood was collected from healthy individuals into 500 ml blood bags containing a 
dextrose/phosphate solution as the anticoagulant (70 ml per unit of blood). Blood 
was centrifuged at 500g for 10 min (Beckman 12-21 centrifuge; lA-10 rotor) and 
plasma and buffy coats removed, followed by filtration through cotton wool to 
remove leukocytes. The erythrocytes were washed four times with six volumes of 
10 mM potassium phosphate containing 140 mM NaCl (pH 7.0) by centrifugation 
at 500g for 10 min (Beckman 12-21 centrifuge; lA-10 rotor). 
The washed erythrocytes were hemolyzed using six volumes of 5 mM potassium 
phosphate containing 1.4 mM ,8-mercaptoethanol, pH 7.0, and dialyzed against 
22 mM potassium phosphate containing 1.4 mM ,8-mercaptoethanol (pH 7.0). 
The dialyzed hemolyzate was centrifuged at 10 OOOg for one hour (Beckman 12-21 
centrifuge; lA-10 rotor) and the supernatant fraction chromatographed on a GSH 
affinity column ( 4 cm x 4 cm). The affinity column was washed overnight with 
dialysis buffer and the enzyme eluted with 10 mM GSH in 50 mM Tris-KOH 
(pH 9.6). The enzyme was subsequently dialyzed against 10 mM potassium 
phosphate buffer, pH 7.4, before chromatography on a BSP-GSH agarose affinity 
column ( 4 cm x 4 cm) equilibrated with the same buffer. GST p eluted as a sharp 
peak immediately after the void volume. The column was washed thoroughly with 
the equilibration buffer and the basic erythrocyte GST eluted with 10 mM 
potassium phosphate containing 10 mM GSH, pH 7.4 (Clark et al, 1977; Awasthi & 
Singh, 1984). Both enzyme fractions were concentrated on Amicon PM-10 
ultrafiltration membranes before dialysis against 5 mM potassium phosphate 
containing 1.4 mM ,8-mercaptoethanol, pH 7.0 (Awasthi & Singh, 1984). 
An aliquot of GST p was dialyzed against 5.5 mM citrate-phosphate buffer 
containing 1 mM DTT and 5 mM GSH (pH 5.85). A Synchropak AX-300 
anion-exchange HPLC column ( 4.6 mm x 250 mm) was equilibrated with the same 
buffer (at least 6 hours) and an aliquot of the enzyme (100 - 200 µg protein) loaded 
onto the column. The column was washed for 5 min with the equilibration buffer, 
followed by a linear gradient of O - 0.4 M potassium chloride for 20 min and a 
20 min wash with 0.4 M potassium chloride (in equilibration buffer). The flow-rate 
was 1 ml/min and 0.5 ml fractions were collected and assayed for GST activity 
(Singh et al, 1986). 
Purity of erythrocyte GST p was determined by SDS-PAGE (Laemmli, 1970). 
Protein concentrations were determined by the Bio-rad method since both 
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,B-mercaptoethanol and GSH were compatible with this assay (Bradford, 1976; 
Bio-rad instruction manual). 
All buffers containing DTI and GSH were made up in degassed water 
immediately before use. Buffers required for the HPLC were degassed and passed 
through 0.22 µm filters. ,8-mercaptoethanol at the required concentrations did not 
affect the pH of the relevant buffers ( own observation) and was only added to 
these buffers before use. 
2.8 Enzyme Incubations. 
2.8.1 Incubations with Inhibitors. 
The enzyme was usually incubated with halocarbons in 500 µl volumes containing 
enzyme (variable volume), inhibitor ( 40 µl) and 35 mM Tris.HCl, pH 8.2, for 
15 min at 25 °C. When present, GSH (40 µl) and EDTA (20 µl) were added to the 
incubations at final concentrations of 10 mM and 4.2 mM, respectively. Incubation 
mixtures were kept on ice until the enzyme was added. Enzyme activity was 
measured at O min incubation and after a 15 min incubation at 25 • C. The 
reaction was then terminated by placing the incubation mixtures on ice at 4 • C 
prior to assay. 
The enzyme was added to the incubations at a sufficient concentration to give an 
absorbance change of 0.05 per min in the standard CDNB assay (50 µl diluted 
enzyme in a total assay volume of 3 ml). 
2.8.2 Inhibitor Solutions. 
Inhibitors (halothane, isoflurane, methoxyflurane, enflurane, ethylene dibrornide) 
were dissolved in ethanol to a concentration of 0.5 M, with a final concentration of 
40 mM in the incubations ( 40 µ1/500 µl incubation; 8% ethanol). 
2-Chloro-1, 1-difluoroethylene ( a gas) was dissolved in 10 ml cold ethanol ( 4 • C) in 
a gas-tight stoppered test tube. Solutions were weighed and concentrations 
calculated (by the mass difference). 
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2.8.3 Bilirubin Incubations. 
GST isoenzymes were incubated with bilirubin or NaOH and, as indicated, other 
components, in 20 mM potassium phosphate buffer containing 0.1 M NaCl, pH 6.5, 
at 25 • C in cuvettes without shaking. Incubation times and order of addition of 
components are shown with the relevant results. Enzyme activity was measured in 
cuvettes following consecutive addition of 1.0 mM CDNB and 2.5 mM GSH. 
GSH (50 mM) and bilirubin (2.1 mM in 10 mM NaOH; protected from light) were 
prepared daily, and CDNB (30 mM; protected from light) was prepared weekly. 
2.8.4 Incubations with Microperoxidases. 
GST p was incubated with microperoxidases in 0.1 M phosphate buffer (pH 6.5) 
for 15 min at room temperature (24 ± 2 • C) before assay of enzyme activity in a 
Multistat centrifugal analyzer. 
2.9 Reversible Activation/Inhibition by Halothane and DBE. 
The reversible activation and/or inhibition by halothane and DBE was measured 
using the standard CDNB assay previously referred to. Either halothane or DBE 
was mixed with 0.1 M phosphate buffer, pH 6.5, in a stoppered test tube. The 
buffer (2.75 ml) was added to a cuvette and CDNB (20 µl) added. The cuvettes 
were equilibrated at 25 ·c, and GSH (150 µI) was added before initiation of the 
reaction with enzyme (50 µI). 
In experiments with varied CDNB concentrations (0.028 - 0.27 mM) the GSH 
concentration was kept constant at 1.0 mM; In experiments with varied GSH 
concentrations (0.132 - 1.43 mM), the concentration of CDNB was maintained at 
0.27mM. 
Halothane and DBE (0.5 M stock solution in ethanol), CDNB and GSH solutions 
were prepared daily. The enzyme was diluted in buffer to give an absorbance 
change of approximately 0.07 per min at 340 nm at the highest concentration of 
substrates. 
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2.9.1 Reversibility of Activation/Inhibition by Dilution. 
Halothane was added to the buffer to give a final concentration of 22.4 mM and 
the solution equilibrated to 25 ° C. In order to determine enzymic activation, 
CDNB and GSH were added to cuvettes containing the halothane mixture and the 
enzyme added immediately before the kinetics were started. To evaluate 
reversibility the enzyme was added to smaller volumes of halothane/buffer and 
diluted immediately with a solution of buffer containing CDNB and GSH. 
2.10 Synthesis of S-(2,4-Dinitrophenyl)GSH. 
CDNB (30 mM) was dissolved in 50% aqueous ethanol and a stoichiometric 
equivalent of GSH added over a period of 40 min with continuous stirring. The 
pH was maintained between 7 and 8 during the reaction by addition of NaOH. 
The reaction was monitored spectrophotometrically at 340 nm. On completion of 
the conjugation reaction the volume was reduced(± 50%) under vacuum and 
unconjugated CDNB removed by 3 extractions with diethyl ether. Ethanol was 
added to the solution to faint turbidity before storage at 4 ·c for 48 hours. An oily 
precipitate was dissolved in water and chromatographed on a Sephadex G-15 
column (2.5 cm x 30 cm) equilibrated with H20. GSH-free fractions containing 
S-(2,4-dinitrophenyl)GSH were lyophilized and stored (Schramm et al, 1984). 
2.11 Preparation of Microperoxidases. 
The conditions for the preparation of MP-6, MP-8, MP-9, and MP-11 are detailed 
below (Table 2.2). Samples were usually incubated for 24 hours at 40 ° C and 
lyophilized before being redissolved in 0.1 % TF A for purification by HPLC. 
58 






















a The substrates and enzyme were dissolved in 0.1 M ammonium phosphate 
buffer, pH 8.5 (20 ml). 
b Pepsin was added in 2 batches: 32 mg at O min and 32 mg 15 min later. 
(Peterson et al, 1980, 1983; Baba et al, 1969; Plattner et al, 1977). 
2.11.1 Purification of Microperoxidases by HPLC. 
Microperoxidases were purified on a MicroBondpak C-18 reverse phase HPLC 
column using 30% acetonitrile/0.1 % TFA as the aqueous phase with a flow rate 
of 2 ml/min. Elution was monitored at 398 nm (heme moieties) or 220 nm 
(peptides). Heme peptides were collected and purity confirmed by 
rechromatography on the HPLC column. Retention times were determined by the 
use of microperoxidases obtained commercially. Purified samples were lyophilized 
and stored at 4 ° C. 
2.11.2 Extinction Coefficients. 
The microperoxidases are known to aggregate, with a concomitant decrease in the 
extinction coefficient. The extinction coefficients for MP-8 and MP-9 are 
1.57 x 1a5 (monomer) and 1.21 x 1a5 (dimer) M-1.cm-1 in 0.1 M phosphate buffer, 
pH 7.0 (Baldwin et al, 1987). Microperoxidase concentrations were therefore 
measured at absorbances below 0.15 (ie ~ 1 µM) at the Soret peak ( approximately 
396 nm). The dimer concentration in this region was assumed to be 10% and an 
extinction coefficient of 1.53 x 105 M-1.cm-1 was used for MP-8 and MP-9. 
MP-11 was dissolved in 0.1 M phosphate (pH 7.0) and a small aliquot 
(~ 100 µ1/ 3 ml) diluted in 10 mM HCl (pH 2 - 2.5) and the absorbance measured 
at the Soret peak (c394 nm= 178 mM-1.cm-1) (Peterson et al, 1983). 
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2.11.3 Binding of the Microperoxidases to GST p. 
Microperoxidase binding was measured spectrally at 396 nm (25 ± 0.2 ° C) using a 
Varian Techtron 635 spectrophotometer. Data was transferred to a Hewlett 
Packard 85 computer through a Hewlett Packard 3438A digital multiplier and a 
print-out obtained for analysis. 
2.12 Statistics and Calculations. 
In general, results are expressed as the mean ± standard deviation. 
Student's t-test was used to determine a significant difference between means; 
P < 0.01 was assumed to be significant, while P < 0.001 was highly significant. 
Student's t-test was performed on Epistat (Gustafson, 1985). 
In the chapter relating to inhibition by halothane (Chapter 3) the data were also 
analyzed according to the following method as proposed by the Institute of 
Biostatistics of the South African Medical Research Council: The mean and 
standard deviation were computed for O min samples separately for controls and 
control + inhibitor. For each datum value the O min mean ( of the corresponding 
experiment) was subtracted and this value divided by the relevant O min standard 
deviation. The same process was repeated for the control + inhibitor experiments. 
A two-way analysis of variance was then carried out on this data with O min and 
15 min as the levels of one factor, and control and control + inhibitor as the levels 
of the other factor. The comparison between control and control + inhibitor was 
therefore tested. 
No difference in statistical parameters was found between the latter method and 
Student's t-test, although the analysis of variance was more complicated to 
perform. 
All model fitting to relatively simple equations (Michaelis-Menten equation; first 
and second order decay curves) was performed on a non-linear least squares 
regression program with no weighting of the data (Enzfitter, Elsevier-Biosoft, 
Cambridge, U.K.). Fitting of complex kinetic mechanisms was accomplished on a 
statistical non-linear regression program, BMDP AR, using the inverse of the 
variance as a weighting factor (BMDP Statistical Software, University of 
California, USA). The relevant equations are shown in the results section. 
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Halothane: Inhibition and Activation of Rat 
Hepatic GST. 
3.1 The Effect of Halothane Anesthesia on Rat Hepatic GST Activity in vivo. 
A single anesthesia of rats with halothane (1.25 MAC for 3 h) had no significant 
inhibitory effects on rat cytosolic GST activity (Table 3.1). In contrast, multiple 
halothane anesthesia (1.25 MAC for 1 hon three alternative days) initially 
decreased and subsequently increased GST activity, reaching a minimum at 
10 days after the first anesthesia and a maximum after 25 days (Table 3.2). The 
effect appeared to be isoenzyme specific with DCNB activity (specific for 
subunit 3) markedly affected, while the effect on trans-4-phenyl-3-buten-2-one 
activity (specific for subunit 4) was not as dramatic. GSH peroxidase activity, as 
measured with cumene hydroperoxide, showed the same trend as GST with CDNB 
as substrate. However, although this substrate is relatively specific for GST 
subunits 3, 4 and 5, it is also a substrate for the selenium-dependent GSH 
peroxidases. 
Table 3.1: Effect of a single halothane anesthesia on rat hepatic GST activity 
in vivo. 
Time after anesthesia (days) 
4 10 15 25 32 
Activity 106 ± 9 98 ± 6 116 ± 88 84 ± 6 97 ± 6 121 ± 9 
Rats were treated with 1.25 MAC halothane for 3 hours on day 1. Specific activity 
of cytosolic GSTwas measured with CDNB. Activity(%) is relative controls 
exposed to air under identical conditions (N = 3 - 4 for each determination). 
a Significantly different from controls (P < 0.01). 
No significant differences were detected at P < 0.001. 
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Table 3.2: Effect of multiple halothane anesthesias on rat hepatic GSH 
S-transferase and GSH peroxidase activity. 
9,-
0 Activity relative to controls 
Time after first halothane anesthesia (days) 
Assay Activity per 5 10 16 20 25 30 
CDNB mg protein 94 ± 3 64 ± 2a 93 ± 3 108 :t 4 153 :t 2a 111 :t 2a 
g liver 94 :t 3 70 :t 2a 89 :t 3b 92 :t 3 114 :t 2a 125 ± 2a 
(N) (6) (4) (6) (6) (6) (6) 
DCNB mg protein 89 :t 2a 66 ± 1a 90 ± 1a 103 :t 2 133 ± 1a 102 :t 2 
g liver 90 ± 2b 72 ± 1a 85 :t 1a 87 :t 2a 99 :t 1 115 :t 3a 
(N) (4) (6) (6) (6) (6) (6) 
trans-4-phenyl- mg protein 95 :t 7 90 :t 1a 115 :t 6a 104 :t 2 109 :1: 2b 95 :t 3a 
3-buten-2-one g liver 95 :t 7 98 ± 2 110 ± 6 88 :t 1a 82 :t 4a 107 ± 3b 
(N) (6) (6) (6) (8) (7) (8) 
Cumene mg protein 101 :t 3 84 :t 2a 99 :t 1 122 ± 3a 185 :t 7a 107 ± 1a 
hydroperoxide g liver 102 ± 3 92 ± 3b 95 ± 1b 103 :t 3 138 :t 5a 121 :t 1 a 
CN) (6) (6) (6) (6) (6) (6) 
Groups of 9-15 rats were exposed to 1.25 MAC halothane or medical air for 1 hour 
on days 1, 3 and 5. Results are from one experiment, with each time point 
representing Ndeterminations on the pooled hepatic cytosol from 3 control or 3 
anesthetized rats. Similar results for days 5, 10 and 16 were obtained in a separate 
experiment. 
Specific activities (µmol/min/mg protein) for control rats were as follows: 
CDNB, 1.0; DCNB, 0.055; trans-4-phenyl-3-buten-2-one, 0.013; 
Cumene hydroperoxide, 0.17. 
a Differs significantly from corresponding control values, P < 0.001 
b Differs significantly from corresponding control values, P < 0.01 
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3.2 Inhibition of GST Activity in vitro. 
Incubation of the mixture of GST isoenzymes with four volatile anesthetics 
(Table 3.3) significantly inhibited enzyme activity in a time-dependent manner in 
the absence of GSH. A metabolite of halothane, 1-chloro-2,2-difluoroethylene 
(16 - 57 mM) did not show significant concentration-dependent inhibition of the 
enzyme, with activities varying from 80% - 104% relative to controls. 
Purification of the mixture of GST isoenzymes in the presence of DTE, a thiol 
reagent, did not have any effect on inhibition (Table 3.3). 
Table 3.3: Time-dependent inhibition of the mixture of rat GSTs by volatile 
anesthetics and DBE in vitro. 
9,-
0 CDNB activity after 15 min incubation (N) 
Anesthetic (mM) Control + Anesthetic 
Halothane ( 4 0) a 91 ± 5 (18) 70 ± 1 (18)C 
Isoflurane ( 40) a 93 ± 7 (12) 76 ± 4 (12)C 
Enflurane ( 40) a 93 ± 7 (12) 70 ± 10 (12)C 
Methoxyflurane ( 40)8 93 ± 7 (12) 65 ± 5 (12)C 
Halothane ( 40) b 92 ± 5 (6) 78 ± 2 (8)C 
Isoflurane ( 4 0) b 92 ± 5 (6) 74 ± 2 (8)C 
DBE ( 40) b 92 ± 5 (6) 45 ± 4 ( 8) C 
a Incubations contained the mixture of rat liver GSTs (ca 0.3 units/ml), and a 
solution of ethanol or anesthetic in ethanol in 35 mM Tris.HCl, pH 8.2, at 
25 ·c. 
b The enzyme was purified in buff er containing 0.2 mM DTE. 
c Differs significantly from value for control, P < 0.001. 
Activity ( % ) is relative to identical zero time samples. 
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Inhibition of the GST mixture by halothane followed pseudo first-order kinetics 
(Fig. 3.1) in the absence of GSH. The inhibition was essentially complete after 
30 min. The observed first-order rate constant for inhibition was 
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Fig. 3.1: Time-dependent inhibition of GST activity by halothane. The GST 
mixture (ca 0.44 units/ml) was incubated \\ith 4 mM EDTA and 35 mM Tris.HCl, 
pH 8.2, in the absence (o) and presence(+) of 40 mM halothane at 25 °C. 
Activity(%) is relative to a zero time sample in the absence of halothane. 
Inset: ln(Aco-At) vs time. 
a Differs significantly from zero time sample, P < 0.05 
b Differs significantly from zero time sample, P < 0.01 
Halothane inhibition of the mixture of GST isoenzymes was 
concentration-dependent with apparent half-maximal inhibition at concentrations 
of greater than 15 mM halothane (Fig. 3.2). However, assays were not carried out 
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Fig. 3.2: Concentration-dependence of halothane inhibition. The GST mixture 
(ca 2.0 units/ml) was incubated with 10 mM GSH, 4 ml\1 EDTA, and halothane in 
35 mM Tris.HCI, pH 8.2, for 15 min at 25 °C. Activity(%) is relative to a zero 
time sample in the absence of halo thane. 
a Differs significantly from zero time control, P < 0.01 
Halothane inhibition of rat GST activity was found to be isoenzyme specific 
(Table 3.4 ). Isoenzymes containing subunits 1 and 2 were not inhibited by 
halothane, while isoenzymes containing subunits 3 and 4 were significantly 
inhibited. 
In contrast to the rat isoenzymes, human placental isoenzyme 7r was not inhibited 
by either anesthetic agents or DBE (Table 3.5). 
65 
Table 3.4: Time-dependent inhibition of rat GST isoenzymes by halothane. 
9--0 CDNB activity after 15 min incubation 
Isoenzyme control + Anesthetic 
1-1 N. D. 8 94 ± 3 
1-2 95 ± 3 89 ± 6 
3-3 109 ± 3 43 ± 3b 
3-4 85 ± 4 62 ± 4b 
4-4 80 ± 1 45 ± 12b 
Incubation mixtures contained pure rat GST isoenzymes (ca 0.3 units/ml), ethanol 
or halothane in ethanol ( 40 mM), and 10 mM GSH in 35 mM Tris.HCl, pH 8.2, at 
25 °C (N = 3 - 4 for each analysis). 
Activity(%) is relative to identical zero time samples. 
8 N.D. Not determined. 
b Differs significantly from value for control, P < 0.01. 
Table 3.5: Time-dependent inhibition of human placental GST 7f in vitro. 
9,-
0 CDNB activity after 15 min incubation 
Anesthetic (mM) Control + Anesthetic 
Halothane ( 40) 95 ± 4 (8) 95 ± 6 (8)8 
Isoflurane ( 4 0) 95 ± 4 (8) 90 ± 3 (8)8 
Enflurane ( 40) 95 ± 4 (8) 92 ± 4 (8)8 
DBE ( 40) 95 ± 4 (8) 92 ± 3 (8)8 
(N) 
Incubation mixtures contained the mixture of human placental GST (ca 0.3 
units/ml enzyme stored in 50 mM Tris.HCl containing 10 mM GSH, pH 9.6), and 
a solution of ethanol/anesthetic in ethanol in 35 mM Tris.HCl, pH 8.2, at 25 °C. 
Activity ( % ) is relative to identical zero time samples. 
The placental enzyme was purified in our laboratory by R.D. Goold. 
8 No significant differences were detected. 
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3.3 Prevention of Halothane Inhibition by Cytosol in vitro. 
* The addition of diluted cytosol (0.02 mg protein) or albumin (200 mg) to 
incubations of the GST mixture prevented inhibition by halothane, although 
albumin significantly activated the enzymic activity (data not shown). 
Incubations of cytosol with inhibitors of GST activity showed that only CDNB 
significantly affected enzyme activity in the cytosol (Table 3.6). Neither the in situ 
perfusion of rat livers nor the dialysis of cytosol resulted in inhibition of cytosolic 
GST activity by h~lothane (Table 3.7). 
Table 3.6: Incubations of cytosol with GST inhibitors. 
Addition (mM) Percentage activity (N) 
Control + Halocarbon 
Halothane ( 40) 98 ± 5 (12) 102 ± 4 (12) 
DBE (37) 98 ± 5 (12) 105 ± 4 (4) 
CDNB ( 1. 2) 98 ± 5 (12) 75 ± 4 ( 8) a 
Cytosolic GST (ca 0.4 units/ml) was incubated with the above inhibitors in 35 mM 
Tris.HCl (pH 8.2) for 15 min at 25 °C. Inhibitors were dissolved in ethanol to give 
a concentration of 8% ethanol in the incubation. CDNB activity(%) is relative to 
identical zero time samples. 
a Significantly different from controls containing ethanol only, P < 0.001. 
* Footnote: Cytosol contributed less than 10% of the total GST activity in the 
incubations. 
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Table 3. 7: Effect of perfusion and dialysis on the time-dependent inhibition of 
cytosolic GST activity by halothane. 
CDNB activity (%) 
Treatment Additions to Time of dialysis (h) 
of rat incubation 0 1 24 
None Ethanol 95.8 :t: 5.0 (8) 94.7 :t: 2.6 (8) 94.4 :t: 3.4 (8) 
Halothane 96.6 :t: 3.4 (8) 92. 7 :t: 1.9 (8) 98.9 :t: 1.9 (8) 
Liver Ethanol 94. 7 :t: 3 .6 (8) 97.5 :t: 1.8 (8) 97.9 :t: 4.4 (8) 
perfusion Halothane 88.0 :t: 4.3 (12) 97.6 :t: 6.1 (7) 99.7 :t: 3.3 (8) 
Reaction mixtures containing cytosolic GST (ca 0.5 units/ml), 4 mM EDTA, and 
ethanol (8%) or halothane ( 40 mM in ethanol) in 35 mM Tris.HCl, pH 8.2, were 
incubated at 25 °C for 15 min. Samples were dialyzed at 4 °C versus 10 mM 
Tris.HCI, pH 7.8, for 22 hours. Rat livers were perfused in situ with 10 mM 
Tris.HCl, pH 7.8, at 4 °C. Activity(%) is relative to identical zero time samples. 
3.4 Reversal of Halothane Inhibition in vitro. 
As a result of the volatility of halothane, we attempted to reverse inhibition by 
removing the anesthetic from incubations by bubbling with nitrogen. The GST 
mixture was incubated with ethanol or halothane in the presence of 10 mM GSH 
for 15 min, and the samples were then divided, one aliquot exposed to air for 5 min 
while the second aliquot was bubbled with nitrogen. Bubbling with nitrogen 
resulted in an approximately 25% loss in activity. Reversal of halothane inhibition 
was not indicated as the difference between control and halothane samples was 
still approximately 13%. These results are, however, inconclusive in view of the 
loss of activity incurred by the nitrogen bubbling procedure. 
3.5 Metabolism of Halothane and DBE in vitro. 
Halothane was not metabolized measurably by cytosolic GST (~ 0.2 nmol), as 
determined by glutathione metabolism (Fig. 3.3). In contrast, DBE was 
significantly conjugated with GSH under identical conditions (3.8 nmol.min-1.mg 
protein-1 during the first 30 min of incubation). 
Metabolism was measured with cytosol since GST activity was not inhibited by 
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Fig. 3.3: Metabolism of halo thane and DBE by cytosolic GST in the presence of 
GSH. Halothane + GSH (o); Halothane + GSH + GST (+); DBE+ GSH (O); 
DBE + GSH + GST (6). 
Halothane and DBE (20 mM) were incubated with 0.2 mM GSH in the presence 
and absence of cytosol (± 0.04 mg protein) in 35 mM Tris.HCI, pH 8.2, at 25 ° C. 
Aliquots of the incubations were removed at the specified time points and 
Iyophilized. GSH concentrations were determined after dilution '\\ith 10 mM HCI 
using the GSH assay effective in the micromolar concentration range. 
Attempts to measure halothane metabolism by bromide release were not 
successful as bromide levels in incubations of the GST mixture were lower than the 
detection limit (5 µM Br-) of the bromide-selective electrode used. The enzyme 
was incubated with 20 mM halothane, 4 mM EDTA and 5 mM GSH in 35 mM 
Tris.HCl, pH 8.2, at 25 °C for 15 min (data not shown). 
3.6 Reversible Activation by Halothane in vitro. 
The reversible effect of halo thane on GST activity was measured at various 
concentrations of the substrates CDNB and GSH in the presence of halothane 
using a modification of the standard CDNB assay: Phosphate buffer (pH 6.5) was 
pre-equilibrated with halothane and CDNB at 25 ·c in cuvettes before the 
addition of GSH and enzyme immediately before spectral tracings were begun. 
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Activation of the GSTs was rapid and complete before spectral tracings were 
begun (ie ti;2 ~ 5 sec) and was readily reversible upon dilution of halothane in 
reaction mixtures (Table 3.8). 
Activation was related to halothane, CDNB and GSH concentrations. Cytosolic 
transferases were consistently activated by halothane (Fig. 3.4). Of the purified 
isoenzymes, only isoenzyme 1-2 was significantly activated by halothane in vitro 
(Fig. 3.5). Isoenzymes 1-1 and 3-3 were not significantly affected by halothane 
over a range of CDNB concentrations* (Fig. 3.6). 
Dilution of halothane from 22.4 to 11.2 and 7.8 mM in the presence of cytosolic 
GST decreased halothane-dependent activation from 117 ± 1 % to 113 ± 1 % and 
104 ± 1 %, respectively (relative to samples containing ethanol treated in an 
identical manner). 
* Footnote: Although the lines fitted by linear regression are different in the 
presence and absence of halothane, the values obtained at the different CDNB 
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Fig. 3.4: Reversible activation of cytosolic GST activity by halothane \\ith respect 
to CDNB (A) and GSH (B) variation. Ethanol (D); 11.2 mM halothane (+); 
22.4 mM halothane (0), 
Insets show the double-reciprocal plots of the relevant data. Curves were fitted to 
Michaelis-Menten equation. Activity is sho\\n as M 340 nm/min. 
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Fig. 3.5: Reversible activation of GST 1-2 by halothane as a function of CD
NB 
concentration. Ethanol ( D) and 22.4 mM halothane ( 0). 
Insets show the double-reciprocal plots of the relevant data. Curves were f
itted to 
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Fig. 3.6: Reversible activation of GST 1-1 (A) and 3-3 (B) by halothane as a 
function of CDNB concentration. Ethanol ( D) and 22.4 ml\1 halothane ( 0), 
Insets show the double-reciprocal plots of the relevant data. Curves were fitted to 
Michaelis-Menten equation. Activity is shown as M340 nm/min. 
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Miscellaneous Results: 
3.7 Purification of Rat GSH S-Transferases. 
The mixture of rat GSH S-transferases was purified by affinity chromatography on 
either S-hexyl GSH- or GSH-Sepharose with two chromatographic steps on 
Sephadex G-25. The specific activity of the final material was consistently found to 
be within the range of 15 - 25 µmol.rnin- 1.mg protein-1. It was found that the two 
steps on Sephadex G-25 consistently decreased enzyme activity by approximately 
30% per chromatographic run, consequently the effect of dialysis on GST activity 
was assessed. 
Chromatography on Sephadex G-25 (3.9 cm x 17 cm) was found to decrease 
cytosolic GST activity to 68 ± 5% of the total activity loaded, whereas dialysis 
(22 hours) did not significantly decrease activity (96 ± 6%). The time course of 
GSH dialysis indicated that more than 95% of the GSH was removed after 
24 hours (Fig. 3.7). GSH concentrations were decreased to 10.2% and 5.7% upon 
chromatography and dialysis, respectively. 
3.7.1 Effect of DTI on GST Activity. 
The addition of dithiothreitol (1 mM final concentration) to the enzyme before 
incubation at 4 ° C slightly increased enzyme activity after 22 hours: At 2, 4 and 
22 hours after dilution of enzyme activity into 1 mM DTT, GST activity was 92%, 
97% and 107% of the activity at zero time. 
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Fig. 3.7: Time course of GSH dialysis. GSH (SO ml in H20) was dialyzed against 
one change of H20 (4000 ml) after 5 hours. Aliquots were removed and diluted 
with H20 before GSH concentrations were determined with an assay effective in 
the millimolar range (see Section 3.12). 
3.8 Effect of Solvents on Enzyme Activity. 
The electrophilic substrates generally used to assay for GST activity (eg CDNB) 
are relatively insoluble in water and must therefore be dissolved in organic 
solvents before addition to the GST assay buffer. Since various solvents have been 
reported to inhibit enzyme activity (Aitio & Bend, 1979), the effect of solvents on 
GST activity in the assay system and upon incubation was investigated. Acetone 
caused the smallest apparent initial decrease in activity (Table 3.8), but had a 
greater inhibitory effect than ethanol when incubated with the enzyme for 15 min 
at pH 8.2 (Table 3.9). 
Previous studies have shown that the conjugation of DCNB with GSH in rat liver 
cytosol is markedly inhibited(> 35%) by solvents such as acetonitrile, dioxane, 
ethanol and methanol (3.3%, v/v). However, DMSO, dimethylformamide, 
dioxolane and tetrahydrofuran were among the solvents which were less inhibitory 
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(~ 20% inhibition relative to controls containing 0.33% DMSO) (Aitio & Bend, 
1979). 
Table 3.8: Effect of different solvents on GST activity. 
Solvent 9-,, 0 (v/v) Activity (%) 
None 100 
Ethanol 5 77 
10 68 
Methanol 5 68 
10 47 
DMSO 5 84 
10 77 
Acetone 5 89 
10 85 
20 73 
Acrylonitrile 5 22 
The solvents were added to the standard CDNB assay (3.3% ethanol) and enzyme 
activity assayed followin~ addition of GST. 
The partially purified IlllXture of rat GST was used in these studies. 
Table 3.9: Effect of incubation with acetone and ethanol on GST activity. 
Addition Time (min) Activity (%) 
Ethanol ( 8%) 15 89 
Acetone ( 8%) 2 96 
5 83 
15 53 
The enzyme was incubated with the above solvents ( 40 µl per 500 µl incubation) 
for 15 min at 25 ° C and activity measured using the CDNB assay (3.3% ethanol) 
for comparison with identical zero-time samples. 
The partially purified mixture of rat GST was used in these studies. 
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3.9 Linearity of GST Assays on Beckman Spectrophotometer. 
The initial rate CDNB assay is linearly-dependent on enzyme concentration for 
absorbance changes below 0.05 A340 nm/min (Fig. 3.8). Spectral traces deviate 
from straight line behavior after 1 min (data not shown), requiring initial rates to 
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Fig. 3.8: Linearity of the CDNB assay on a Beckman UV 5230 spectrophotometer. 
The assay was performed in 3 ml glass cuvettes (1 cm pathlength) at 25 ° C in 
0.1 M phosphate buffef, pH 6.5, wit~ 50 µl diluted enzyme (rat liver cytosol, 
1.12 ± 0.18 µmol.min· .mg protein· ), 1.0 mM GSH and 1.0 ml\1 CDNB 
(3.3% ethanol). Activity is shown as M340 nm/min. 
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3.10 Linearity of the Cumene Hydroperoxide Assay. 
The peroxidase assay utilizing cumene hydroperoxide as substrate was shown to 
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Fig. 3.9: Linearity of the cumene hydro peroxide peroxidase assay on a Beckman 
UV 5230 spectrophotometer. The assay was performed in 1 ml cuvettes (1 cm path 
length) at room temperature and 10 µl diluted enzyme added before activity 
measured at 340 nm for one min. 
The partially purified mixture of rat GST (0.275 ± 0.025 µmol.min-1) was used in 
this experiment. 
3.10 Bromide Electrode. 
A standard curve for the bromide electrode used as a reference in the 
determination of the extent of halothane metabolism is shown in Fig. 3.10. The 
electrode exhibited a linear millivolt response to Br· concentration between 5 µM 
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Fig. 3.10: Linearity of the bromide-specific ion-electrode used to determine 
halothane metabolism (see Section 3.5). 
A stock solution of sodium bromide (1 ml\1 initial concentration in H20, 
60 
5 µ1\1 - 50 µM final solution) was diluted into 10 mM Tris.HCl, pH 8.2, (total 
volume = 980 µl) and 0.1 M sodium nitrate (20 µl) added 1 min later. The voltage 
(mV) was then measured using the bromide-specific electrode. 
3.12 Standard Curves for GSH Assays. 
Two GSH assays were used. The first GSH concentrations in the O - 1 mM range 
and the second for GSH concentrations up to 1.4 µM. The first assay was linear at 
concentrations up to 1 mM GSH (Fig. 3.11). 
The alternative assay for micromolar GSH concentrations (used to determine 
possible GSH conjugation with halothane and DBE) was linear at concentrations 
of less than 1.4 µM (Fig. 3.12). 
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Fig. 3.11: Concentration dependence of the GSH assay at (A) 0 - 1.0 mM and 
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Fig. 3.12: Concentration-dependence of the assay used to determine micromolar 
concentrations of GSH. 
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The Reversible Inhibition and Activation of Rat 
Hepatic GST by 1,2-Dibromoethane in vitro. 
The ability of 1,2-dibromoethane to reversibly affect rat hepatic GST activity was 
measured at various concentrations of both substrates (CDNB & GSH) in a 
modification of the standard assay. Phosphate buffer containing DBE and CDNB 
was equilibrated at 25 ·c in cuvettes before the addition of GSH and initiation of 
the assay immediately afterwards with enzyme. This modification was required in 
view of the low solubility of DBE, which necessitated vigorous vortexing into 
buffer before addition of the enzyme. 
Rat cytosolic GST activity was inhibited at low and activated at high CDNB 
concentrations (Fig. 4.1). Double reciprocal plots of the data intersected in the 
first quadrant, indicating mixed-type inhibition/activation with respect to CDNB. 
The mixture of GST isoenzymes was apparently uncompetitively activated with 
respect to GSH (Fig. 4.1). An identical pattern of inhibition/activation was 
obtained with GST 3-3 and 4-4 (Fig. 4.2 & Fig. 4.3). 
GST isoenzymes 1-1 and 1-2 were either slightly inhibited or not significantly 
affected by DBE (Fig. 4.3). 
Dilution of EDB, in the presence of cytosolic GST, from 10.4 mM to 5.2 mM and 
3.5 mM, by the addition of buffer immediately before assay, decreased enzyme 
activation from 115 ± 5% to 103 ± 8% and 97 ± 7% (relevant to controls 
containing ethanol), clearly demonstrating the reversibility of the activation of 
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Fig. 4.1: The reversible inhibition and activation of rat cytosolic GST by DBE as a 
function of CDNB (A) and GSH (B) concentrations. Ethanol (D); 
5.85 mM DBE(+); 10.4 ml\f DBE (O). 
Insets show the relative double-reciprocal plots. Activity is shown as 
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Fig. 4.1: The reversible inhibition and activation of rat cytosolic GST by DBE as a 
function of CDNB (A) and GSH (B) concentrations. Ethanol (o); 
5.85 mM DBE(+); 10.4 ml\1 DBE (0), 
Insets show the relative double-reciprocal plots. Activity is shown as 
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Fig. 4.2: Double-reciprocal plots of reversible inhibition and activation of GST 3-3 
by DBE as a function of CD1'1B (A) and GSH (B) concentrations. Ethanol (o); 
5.85 mM DBE(+); 10.4 mM DBE (0), 
Insets display the relative double-reciprocal plots. Activity is shown as 


































o 10 ao 30 
1/[CDKB] (1/mM) 
Fig. 4.3: Double-reciprocal plots of reversible inhibition and activation of 
isoenzymes 1-2 (A) and 4-4 (B) by DBE as a function of CDNB concentration. 
Ethanol (o); 5.85 mM DBE(+); 10.4 mM DBE (0), 
Activity is shown as AA340 nm/min. Curves were fitted to the J\,1ichaelis-l\1enten equation by non-linear regression. 
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Bilirubin: Inhibition of GST 1-2 
5.1 Time-Dependent Inhibition of GST 1-2 by Bilirubin. 
The time-dependent inhibition of GST 1-2 by bilirubin exhibited pseudo-first order 
kinetics with observed rate constants of 0.0214 ± 0.0005 s·1 and 0.040 ± 0.008 s·1 at 
4 and 8 µM bilirubin, respectively (Fig. 5.1). These values correspond to calculated 
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Fig. 5.1: Time-dependent inhibition of GST 1-2 in the presence of 4 µM ( +) and 
8 µM (0) bilirubin. GST 1-2 (4 nl\1) was incubated with bilirubin in 20 mM 
potassium phosphate containing 0.11\1 NaCl, pH 6.5, at 25 ·c. Enzyme rates are 
s~~wn ~s M340 nm/min and were corrected for loss of activity in the absence of 
b1hrubm. 
Curves were fitted to a three parametf{ f ecay equation: 
At = A - (~ - ~)e- 1 • Insert displays a plot ofln(At - ~) vs time. 
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The extent of inhibition of GST 1-2 was dependent on bilirubin concentration with 
half-maximal inhibition at approximately 4 µM bilirubin (Table 5.1). 
Table 5.1: Concentration dependence ofbilirubin inhibition of GST 1-2. 
Bilirubin (µM) Activity (%) 
0 88.2 ± 0.3 
0.5 84.1 ± 2.4 
1. 0 73.5 ± 2. 4a 
2.0 62.3 ± 0. 4a 
4.0 43.5 ± 6. 7a 
8.0 6.2 ± 2. 3a 
GST 1-2 (4 nM) activity was measured after incubation with bilirubin in 20 mM 
potassium phosphate and 100 mM NaCl, pH 6.5, for 20 min at 25 °C. Activity(%) 
1s relative to identical zero time samples in the absence of bilirubin. 
a Differs from samples in the absence of bilirubin, P < 0.001. 
5.2 Reversal of Bilirubin Inhibition. 
Inhibition of GST 1-2 by bilirubin was reversed by dilution: The enzyme (4 nM) 
was incubated with bilirubin (8 µM) at room temperature for 3 min, diluted 10-fold 
into buffer containing bilirubin (8 µM) or NaOH (0 - 50 µl), incubated for a further 
5 min and assayed for enzyme activity. Dilution of enzyme 10-fold into 8 µM 
bilirubin resulted in a complete loss of enzyme activity, while 10-fold dilution of 
both the enzyme and bilirubin concentrations (viz 0.8 µM bilirubin final 
concentration), caused only a 26% decrease in activity. Percentage activities are 
relative to enzyme samples treated exactly as above, but in the absence of 8 µM 
bilirubin in the first step. 
Bilirubin inhibition was pH-dependent and reversed by increasing the pH. 
Incubation of GST 1-2 with 8 µM bilirubin for 3 min reduced enzyme activity to 
0% and 55 ± 1 % at pH 6.0 and 7.4, respectively, compared to identical zero time 
samples. Following incubation of the enzyme at pH 6.0 with 8 µM bilirubin for 
3 min, the pH was adjusted to 7.4 and enzyme activity measured at 0, 2 and 4 min 
after the pH increase. Under these conditions enzyme activity returned to 
69 ± 2%, 92 ± 18% and 118 ± 33% relative to enzyme incubated at pH 7.4. in the 
absence of bilirubin. 
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5.3 Effect of Albumin on GST 1-2 Inhibition. 
Incubation of GST 1-2 in buffer in the presence or absence of CDNB resulted in 
approximately a 10% loss in activity, with albumin appearing to minimize the loss 
of activity (Table 5.2). Bilirubin significantly inhibited the enzyme. Pre-mixing 
bilirubin with albumin, before the addition of GST, effectively prevented or greatly 
reduced inhibition by bilirubin. In contrast, the enzyme was more strikingly 
inhibited when GST and albumin were mixed before the addition of bilirubin, 
although the extent of inhibition was not as large as in the absence of albumin. 
Table 5.2: Effect of bilirubin and albumin on GST 1-2 activity. 
Additions 
GST 
CDNB + GST 
HSA + GST 
(CDNB + HSA) + GST 
(8 µM BR+ CDNB) + GST 
(8 µM BR+ CDNB + HSA) + GST 
(CDNB + HSA + GST) + 8 µM BR 
(35 µM BR+ CDNB + HSA) + GST 
(CDNB + HSA + GST) + 35 µM BR 
Activity(%) 
89.0 ± 0.3 
88.4 ± 1.3 
98.4 ± 1.8 
100.4 ± 0.3 
0. oa 
93.3 ± O.lb 
75.2 ± 2.oa,b,c 
69.6 ± 1.9a,b 
26.5 ± 1.3a,b,c 
GST 1-2 ( 4 nM) activity was measured after incubation for 15 min at 25 ° C in the 
presence or absence of bilirubin (BR), albumin (HSA; 2 µM) and CDNB (1 mM). 
Components were added to the incubations in the order indicated, with 
components in parenthesis well mixed prior to subsequent additions. The enzyme 
assay was initiated with GSH (2.5 mM). Activity(%) is relative to identical zero 
time samples. 
a Differs significantly from activity for GST or CDNB and GST, P < 0.001 
b Differs significantly from activity for (BR + CDNB) and GST, P < 0.001 
c Differs significantly from activity for (BR + HSA) and GST, P < 0.001 
5.4 Bilirubin Binding by Proteins. 
The binding of bilirubin by various proteins was assessed by a number of methods, 
of these gel filtration on Sephadex G-25 proved to be the method of choice (see 
below for other methods examined). Protein and protein-bound bilirubin was 
eluted from Sephadex columns with buffer, whereas free bilirubin, which bound to 
the Sephadex, was recovered by washing the columns with 10 mM NaOH. In the 
absence of bilirubin, protein recovery in the buffer wash was between 84% and 
108% (assessed spectrophotometrically at 280 nm). Bilirubin recovery, in the 
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absence of protein, was between 93% and 136% in the NaOH wash (determined at 
468 nm). 
The ability of albumin, aldolase, hemoglobin and ribonuclease to bind bilirubin 
was determined by Sephadex chromatography (Fig 5.2). Protein-bound bilirubin 
was assumed to not bind to the Sephadex resin (see above) whereas free bilirubin 
bound to the resin and was eluted separately with 10 mM NaOH. Free bilirubin 
concentrations (ie that not bound to protein) decreased, and protein-bound 
bilirubin levels increased, with rising concentrations of albumin, hemoglobin and 
aldolase. These proteins decreased free bilirubin concentrations by greater than 
75% at protein concentrations greater than 0.05 µM (molar ratios of 
[bound bilirubin]/[protein] of up to 100 at approximately 0.04 µM protein) 
(Fig. 5.2). Under identical conditions, ribonuclease (~ 16 µM) appeared to bind 
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Fig. 5.2: Concentrations of free (D) and protein-bound(+) bilirubin in eluates 
from Sephadex G-25 columns as a function of protein concentration: 
(A) Albumin; (B) Aldolase; (C) Hemoglobin; (D) Ribonuclease. 
Proteins were mixed with bilirubin (4 µM) before application (1.0 ml) onto 
Sephadex G-25 columns (1.0 x 0.8 cm); Protein-bound bilirubin was eluted with 
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5.5 Protection against Bilirubin Inhibition by Proteins. 
Concentrations of albumin, hemoglobin and aldolase (0.001 - 0.01 µM), which did 
not significantly reduce concentrations of free bilirubin (Fig. 5.2), had no effect on 
bilirubin inhibition of GST 1-2 (Table 5.3). In contrast, higher concentrations of 
these proteins (0.2 - 0.4 µM) prevented inhibition by bilirubin, in direct proportion 
to their ability to bind free bilirubin (Table 5.3, Fig. 5.2). Ribonuclease, which did 
not appear to bind bilirubin (Fig. 5.2), also prevented inhibition at a concentration 
of greater than 0.5 µM, although low concentrations (0.004 µM) were not effective 
in preventing inhibition (Table 5.3). 
Table 5.3: Protection against bilirubin inhibition of GST 1-2 by proteins. 
Additions 
None 
Albumin (0.01 µ.M) 
Albumin (0.4 µ.M) 
Bilirubin 
Bilirubin + 
albumin (0.01 µM) 
Bilirubin + 
albumin (0.4 µM) 
Activity(%) 
84.1 ± 0.2 
83.4 ± 2.4 
90.9 ± 1.9 
54.2 ± 0.5a 
54.0 ± 0.1a 
78.4 ± 0.4b 
None 98.3 ± 0.4 
Aldolase (0.001 µM) 80.3 ± 5.9 
Aldolase (0.3 µM) 93.3 ± 0.4 
Bilirubin 53.6 ± 3.7a 
Bilirubin + 55.8 ± 1.oa 
aldolase (0.001 µM) 
Bilirubin + 89.4 ± 0.5b 
aldolase (0.3 µM) 
Additions Activity(%) 
None 88.2 ± 3.7 
Hemoglobin (0.001 µ.M) 94.3 ± 3.5 
Hemoglobin (0.2 µ.M) 97.9 ± 3.0 
Bilirubin 48.7 ± 0.9a 
Bilirubin + 51.0 ± 5.2a 
hemoglobin (0.001 µM) 
Bili rubin + 
hemoglobin (0.2 µM) 
95.2 ± 1.2b 
None 94.3 ± 2.7 
Ribonuclease (0.004 µM) 76.6 ± 2.7 
Ribonuclease (0.5 µ.M) 91.2 ± 3.1 
Bilirubin 55.2 ± 0.7a 
Bilirubin + 55.2 ± 0.7a 
ribonuclease (0.004 µ.M) 
Bilirubin + 97.1 ± 1.2b 
ribonuclease (0.5 µM) 
The relevant proteins were mixed with 4 µM bilirubin in 20 mM potassium 
phosphate/100 mM NaCl, pH 6.5, before addition of GST 1-2 (4 nM) and 
mcubation for 20 min at 25 • C. 
a Differs significantly from activity with no additions, P < 0.001 
b Differs significantly from activity with bilirubin, P < 0.001 
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5.6 Effect of Different Phosphate Buffers on Inhibition. 
Incubation of GST 1-2 with bilirubin (8 µM) in 0.1 M potassium phosphate 
(pH 6.5) decreased the activity to 31 ± 2% after a 5 min incubation. Incubation in 
20 mM phosphate containing 0.1 M NaCl (pH 6.5) decreased activity to 35 ± 4%. 
The ionic strength therefore did not significantly affect bilirubin inhibition of 
GST 1-2. 
5.7 Alternative Methods used to Measure Free Bilirubin Concentrations. 
Although bilirubin has a low solubility in water, it is soluble in basic aqueous 
solution and in organic solvents (Brodersen, 1980) The accurate determination of 
protein-bound bilirubin concentrations is therefore not a simple process and 
various approaches were therefore tested, Sephadex chromatography was found to 
be the best of these although still not an ideal method. The following methods 
were also attempted: 
5.7.1 The Use of Ultrafiltration Membranes to Separate Albumin and 
Bilirubin. 
Albumin (8 µM) and bilirubin (35 µM) were separately added to an Amicon 
PM-10 ultrafiltration membrane (MW cutoff= 20 kdaltons), and the relevant 
concentrations measured spectrophotometrically in the filtrate. Albumin 
(MW z 60 kdaltons) was virtually completely retained in the concentrate(~ 95%). 
However, contrary to expectations, bilirubin (MW = 584.7 daltons) was also 
retained(~ 97%). It appeared that bilirubin was bound to the membrane (as 
determined by the membrane being a dark red color), probably as a result of its 
high hydrophobicity, and could only be removed by washing the membrane with 
lOmMNaOH. 
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5.7.2 Use of Cation-Exchangers to Separate Protein and Bilirubin. 
Attempts were made to separate proteins from bilirubin by ion-exchange 
chromatography (Table 5.4). Only one resin, Amberlite CG50, bound 
ribonuclease significantly (75% binding), but this resin also bound bilirubin (60%). 
Attempts to saturate ion-exchange resins in columns with bilirubin were not 
successful as bilirubin only bound to the top of the resin. The resin was also not be 
saturated by mixing with bilirubin in a beaker. 
5.7.3 Precipitation of Proteins with Organic Solvents and TCA. 
Neither acetone (50% final volume) nor TCA (70% final concentration) 
significantly precipitated albumin, ribonuclease or hemoglobin (8 µM). 
Ammonium sulfate (60 - 70%) did not precipitate any of the proteins, but did 
precipitate albumin at 80% concentration. The latter process required filtration as 
the solution appeared to be saturated and the ammonium sulfate was not 
completely dissolved. Bilirubin was retained by the filter paper and this method 
could therefore not be used. 
Table 5.4: Binding of bilirubin and proteins to ion-exchange resins. 
9.,-
0 absorbance of supernatant 
Resin 
Dowex AG50 Amberlite CG120 Amberlite CG50 CM-cellulose 
Ligand (/LM) 
Bili rubin (35) 55 61 40 15 
Hemoglobin (0.1) 100 583 122 N.D. 8 
Ribonuclease (5.0) 111 145 25 118 
Samples were mixed with the relevant ion-exchange resin (1 g) and the amount of 
ligand bound to the resin determined by absorbance measurements of the 
supernatant. Binding was allowed to take place for 5 min with intermittent 
stirring. Bilirubin concentration was measured at 468 nm and protein at 280 nm 
(bilirubin and protein were analyzed separately). 
The cation-exchangers were equilibrated with 0.1 M potassium phosphate (pH 6.5) 
before use. All the resins were effective at pH 6.5, according to the manufacturers 
instructions. 
a N.D.: Not determined. 
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5.7.4 Bilirubin Extraction by Organic Solvents. 
Bilirubin (35 µM) in 0.1 M phosphate, pH 6.5, was extracted with equal volumes of 
organic solvents ( chloroform, benzene, toluene, carbon tetrachloride). The 
solvents extracted more than 95% bilirubin from the buffer. 
Extraction of protein solutions with these solvents caused the formation of a 
protein interface between the aqueous and organic phases, although these were 
less intense with chloroform and carbon tetrachloride. Extraction with carbon 
tetrachloride resulted in the loss of 15% - 20% of the protein sample from the 
aqueous phase, while less than 10% protein was apparently lost with chloroform, 
although hemoglobin could not be assayed by this method since the aqueous phase 
was cloudy. Chloroform extracted all of the bilirubin from samples containing 
protein, and therefore was not suitable for assessing bilirubin binding by proteins. 
5.7.5 Centrifugation of Bilirubin and Proteins. 
Hemoglobin, albumin and bilirubin were centrifuged at 280 OOOg for eight hours to 
pellet the protein and separate it from bilirubin in the supernatant. However, 
although hemoglobin (0.008 - 8.0 µM) and albumin (0.0125 - 2.0 µM) did 
precipitate, bilirubin (2 - 32 µM) appeared to aggregate and bind to the sides of 
the centrifugation tubes. 
5.7.6 Precipitation with Sulfuric Acid and Sodium Tungstate. 
Proteins can be precipitated by the addition of sulfuric acid ( 40 mM) and sodium 
tungstate (12 mM) and subsequent centrifugation at 2000 rpm for 5 min (Costa & 
lvanetich, 1984). Proteins were precipitated by this method, but bilirubin was also 
significantly precipitated (data not shown). 
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Kinetic Mechanism of Erythrocyte GST p (rho). 
6.1 Kinetic Studies of GST p. 
The kinetic mechanism of GST p was investigated by measuring initial conjugation 
rates at eight concentrations of the substrates CDNB and GSH. The range of 
concentrations were 0.25 - 2.00 mM for CDNB and 0.05 - 1.00 mM for GSH. Thus, 
a total of 64 different GSH/CDNB combinations (8 x 8 matrix) were used and all 
rate determinations were performed in one experiment ( experiments were 
repeated). 
The data were fitted to the Michaelis-Menten equation by non-linear regression. 
Double reciprocal plots of the data showed that the fitted lines intersected below 
the x-axis (Fig. 6.1), indicating a random rapid equilibrium type mechanism with 
a > 1 (Segel, 1975). 
93 
I l"'·1 





















. i° !;; 













1 o.oo o.,J :i.,o o.so o.sJ 1.00 1.20 1,40 uo uo 
'< 'tJJ :0:: 0.00......_ _______________ __, 








[ CDNB J (rnM) [GSHJ (mM) 
13 , 
I 








I . -I 
71 
I a 
e i a 
:, i 
C 





'-i a I 









-e -z z 10 1, II zz -z 
1/[CSH) (1/mll) 1/[CDU) (Vm.11) 
II I 1, ' 
aJ F 10 _j E I 
8 ~ 13 i IZ j 
I 
'1 !I -i 10 ~ 
:1 
I 
K 8-• ,J e I 
~ 
7.; 






'~ J 31 z, 
1..l 
o I 
-e -z z e 10 14 II Z2 -I I 
!/[en) (1/mll) k1CD1,J) (1/nul) 
Fig 6.1: Plots of initial rate data "ith cunres fitted to the Michaelis-Men ten 
equation (A, B) and replots of the obtained kinetic parameters (C, D, E, F). 
The GSH concentrations used in plot A were 0.05 mM (e), 0.10 mM (•), 
0.15 mM (v), 0.20 mM (X), 0.30 mM (6), 0.40 mM (o), 0.60 mM (+), and 
1.00 mM (o). 
The CDNB concentrations used in plot B were 0.25 mM ( e), 0.50 mM (•), 
0.75 mM (v), 1.00 mM (X), 1.25 mM (6), 1.50 mM (o), 1.75 mM (+), and 
2.00 mM (o). 
Subsequently the data were fitted to various kinetic mechanisms (Table 6.1) using 
non-linear regression to obtain kinetic parameters and appropriate statistical limits 
(Table 6.2). Discrimination between kinetic models was made using the following 
criteria: (a) parameter values, (b) convergence, (c) randomness of distribution of 
residuals, and (d) residual sum of squares (Mannervik, 1981). 
Ordered bireactant and ping pong mechanisms were eliminated because of lack of 
convergence, large residual sums squared (Table 6.2) or non-random distribution 
of residuals (not shown). 
A random BiBi steady state mechanism provided the lowest residual sum of 
squares with the analyzed data (Table 6.2). However, two parameters were either 
equal to zero (V2, K7), and a third did not differ significantly from zero (l<.4) 
(Table 6.2); Furthermore, the residuals at lower CDNB concentrations were not 
randomly distributed (Fig. 6.2). It was therefore therefore hypothesized that the 
random steady state mechanism could be overfitting the data and experiments 
were performed at higher GSH concentrations (0.25 - 8 mM) to assess possible 
adherence to simple Michaelis-Menten kinetics at high substrate concentrations. 
The results of these experiments were consistent with Michaelis-Menten kinetics 
(Fig. 6.3), and the random steady state mechanism was accordingly rejected in 
favor of the random rapid equilibrium mechanism. 
Replots of the data (Fig. 6.1) were consistent with a random rapid equilibrium 
mechanism, whereas non-linear regression analysis (Table 6.2) indicated either a 
random rapid equilibrium or an ordered steady state mechanism. In the absence 
of product the steady-state rate equations for these mechanisms are identical 
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Fig. 6.2: Double-reciprocal plots of initial rates as a function of GSH 
concentrations in the absence of product. The CDNB concentrations were 
0.25 mM (o), 0.50 mM (+), 0.75 mM (0), 1.00 mM (6), and 2.00 mM (v). 
The data were fitted to (A) a random rapid equilibrium mechanism and (B) a 
































































Fig. 6.3: Initial rates at different GSH and constant CDNB concentrations. 
CDNB concentrations were 0.25 mM (D), 0.50 mM (+), 0.75 mM (0), 
1.00 mM (6), and 1.50 ml\1 (X). 
(A) Substrate/velocity and (B) double-reciprocal plots. The curves show the 
relevant data fitted to the Michaelis-Menten equation. Activity is shown as 
M340 nm/min. 
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Random rapid equilibrium mechanism: 
[AJ [BJ 
= 
Ordered rapid equilibrium mechanism: 





Ordered steady state mechanism: 
(A binds before B) 
[AJ [BJ 
Ping pong mechanism: 
[AJ [BJ 
!SnA[BJ + ~B[AJ + [AJ [BJ 
Random steady state mechanism:a 
In the above equations v refers to the initial rate of the conjugation reaction, with 
V max the maximum attainanble rate. A and B are arbitrary references to the 
substrates CDNB and GSH, respectively. Michaelis constants (K) are 
combinations of microscopic rate constants (Segel, 1975). 
a VrJ-3) are constants related to Er; K(l-7) are combinations of rate constants (Mannervik & Askelof, 1975). 
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Table 6.2: Kinetic parameters obtained by fitting the initial rate data to different 
kinetic mechanisms. 
Random Rapid Equilibrium Mechanism 
a= 2.0 ± o.4 
KCDNB = 0.70 ± 0.11 
Kinetic parameters: 
vmax = 0.45 ± .0.02 
KGSff = 0.12 ± 0.02 
Statistical parameters: 
RSSa = 0.0052 R2 = 0.99 Variance= 0.0026 
DFa = 188 MSEa = 0. 000028 DFa = 185 
Random steady state Mechanism 
Kinetic parameters: 
v 1 = 0.45 ± 0.12 v 2 = 
K1 = 0.20 ± 0.03 K2 = 
K3 = 1.72 ± 0.59 K4 = 
K5 = 0.70 ± 0.39 K6 = 
Statistical parameters: 
RSS = 0.0041 R2 = 0.99 
0 v 3 = 0.18 ± 
0.20 ± 0.11 
0.0.003 ± 0.028b 
0.22 ± 0.14 K7 
0.07 
= 0 
DF = 188 MSE = 0.000023 
Variance= 0.0026 
DF = 181 
Ordered Rapid Equilibrium Mechanismc 
Kinetic parameters: 
KGSH = 0.63 ± 0.05 Vmax = 0.30 ± 0.01 
KcDNB = 0.51 ± 0.05 
Statistical parameters: 
RSS = 0.013 R2 = 0.97 Variance= 0.0026 
DF = 188 MSE = 0.000071 DF = 186 
ordered steady state Mechanismc,d 
Kinetic parameters: 
KGStt = 0.24 ± 0.02 
Ki(GSH) = 0.12 ± 0.02 
Vmax = 0.45 ± 0.02 
KcDNB = 1.41 ± 0.10 
Statistical parameters: 
RSS = 0.0052 R2 = 0.99 Variance= 0.0026 
DF = 188 MSE = 0.000028 DF = 185 
Ping Pong Mechanism 
Kinetic parameters: 
vmax = 0.66 ± 0.03 KGSH = 0.53 ± 0.03 
KCDNB = 2.70 ± 0.18 
Statistical parameters: 
RSS = 0.0085 R2 = 0.98 Variance= 0.0026 
DF = 188 MSE = 0.000046 DF = 186 
Initial rates (189 values) were fitted to the kinetic mechanisms by non-linear 
regression using the BMDP statistical analysis program. Data were weighted 
according to the inverse of the variance of the calculated rates obtained by linear 
regression. 
En_zyme rates are sJ10wn as AA34o nm/min; Michaelis constants (K) are given in umts of concentrations (mM). 
a RSS = Residual sums squared; MSE = Estimated mean square error; 
DF = Degrees of freedom for the variance and estimated mean squared error, 
respectively. 
b This parameter is not significantly different from zero. 
c Ordered addition of substrates refers to GSH as the first substrate. 
d In the case of CDNB binding first, the value of Ki(CDNB) is calculated to be 













6.2 Product Inhibition Studies. 
Inhibition of GST p by S-(2,4-dinitrophenyl)GSH, the product of the reaction 
between CDNB and GSH, was measured at a number of concentrations of the first 
substrate, with the second substrate fixed at non-saturating concentrations and 
vise versa (Segel, 1975). The conjugate demonstrated competitive and mixed-type 
inhibition with respect to GSH and CDNB (Fig. 6.4) indicating either an ordered 
bibi or a random rapid equilibrium mechanism with an enzyme-CDNB-conjugate 
dead-end inhibition complex. Replots of the inhibition data (Fig. 6.5) showed that 
Ki(slope) was dependent on the concentration of CDNB, indicating a random 
system (Segel, 1975). 
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Fig. 6.4: Double-reciprocal plots of GST p inhibition by S-(2,4-dinitrophenyl)GSH 
as a function of (A) CDNB (GSH = 0.3 mM) and (B) GSH (CDNB = 1.0 mM) 
variation. Concentrations of the fixed inhibitor are: no inhibitor ( o), 
15 µM inhibitor (+), 30 µ1\1 inhibitor ( O), 45 µM inhibitor (6), and 
60 µ1\1 inhibitor (X), 
Straight lines are calculated from the fit of the data points to the 
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Fig. 6.5: Replots of kinetic parameters obtained with the data in fig. 6.4. (A) 
Slope1/GSH vs [conjugate] at different concentrations of CDNB and (B) 
Ki(sloBe) vs [CDNB]. 
The C NB concentrations used were 0.30 mM (o), 0.60 mM (+), 1.00 ml\1 (0), 
1.25 mM (6), and 2.00 mM (v), 
This finding was substantiated by fitting the data to the relevant rate equations 
(Table 6.3). The random rapid equilibrium mechanism containing an 
u 
enzyme-CD NB-product dead-end complex was found to fit the data better than a 
random rapid equilibrium mechanism without a dead-end complex, as indicated by 
better R2 and residual sums squared values (Table 6.3). An ordered BiBi random 
system with product inhibition parameters .could not be fitted due to the 
complexity of the rate equation (Segel, 1975). 
The inhibition constant (Ki) determined for S-(2,4-dinitrophenyl)GSH was 
calculated to be 1.7 ± 0.4 x 10-5 M from the replots (Fig. 6.5) and 
1.55 ± 0.44 x 10-5 M by non-linear regression (Table 6.3). The alternative product 
of the reaction, chloride, was devoid of inhibitory action at concentrations up to 
100 µM (Fig. 6.6). 
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Fig. 6.6: Effect of chloride on GST p activity at different substrate concentrations: 
0.25 mM CDNB, 0.05 mM GSH (D); 0.25 mM CDNB, 1.00 mM GSH (+); 
2.00 mM CDNB, 0.05 mM GSH ( O); 2.00 mM CDNB, 1.00 mM GSH (6). 
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Table 6.3: Kinetic parameters obtained by fitting rate equations to initial rates in 
the presence of product inhibition (Segel, 1975). 
Rapid equilibrium random bibi mechanism with no dead-end inhibition 
V [A] [B]/aKAKB 
= 
vrnax 1 + [A]/KA + [BJ/KB + [P]/Kp + [A] [BJ/aKAKB 
Fitted values: 
Vrnax= 0.44 ± 0.03 
a= 2.35 ± 1. 37 
KCDNB= 0.44 ± 0.19 
KGsH= 0.15 ± 0.06 
Kp= 7.6 ± 2.5 X 10-3 
RSS= 6.42 X 10-3 
R2= 0.9815 






Vrnax= 0.48 ± 0.038 
a= 2.03 ± 0.99 
KCDNB= 0.62 ± 0.22 
KGsH= 0.17 ± 0.05 
Kp= 1.55 ± 0.44 X 10-3 
1= 3. 09 ± 1. 49 
RSS= 5.11 X 10-3 
R2= 0.9853 
Initial rates were fitted to the above equations by non-linear regression using the 
BMDP statistical analysis program. 
Enzyme ra~es are shown as AA34o nm/min; Michaelis constants (K) are given as 
concentrat10ns (mM). 
A = GSH; B = CDNB; P = Conjugate of CDNB/GSH reaction (mM); 
RSS = Residual sums squared. 
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It is concluded that GST p has a random sequential rapid equilibrium mechanism 
with a dead-end enzyme-CDNB-conjugate inhibition complex. The Michaelis 
constants for the substrates CDNB and GSH were 0.70 ± 0.11 and 0.12 ± 0.02 mM, 
respectively, with a value of 2.0 ± 0.4. The latter value for a indicates that the 
binding of one substrate decreases the affinity of the enzyme for the second 
substrate. The enzyme is inhibited by the conjugated product but not by chloride, 
the second product of the reaction. 
Miscellaneous Results: 
6.3 Purification of Human Erythrocyte GST p (rho). 
GST p was purified from the blood of apparently healthy individuals in a 
multi-step process. The enzyme preparations used for binding and kinetic studies 
were purified to specific activities of 30.6 and 42.7 µmol.min- 1.mg protein-1 (2.88 
and 9.9 x 10-6 M enzyme), respectively, in two separate purifications. 
The elution profile of erythrocyte GST p on a weak anion-exchange HPLC column 
is shown in Fig. 6.7. Both enzyme activity (Fig. 6.7) and absorbance analysis (not 
shown) indicated one major elution peak with other potential enzyme peaks at less 
than 5% of the total enzyme activity. 
Since more than 50% of the loaded enzyme activity was lost on HPLC and purity 
of the sample was not significantly increased, this step was only used as analytical 
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Fig. 6.7: Chromatography of GST p on a weak anion-exchange Synchropak AX 
300 HPLC column. Enzyme activity was measured \\ith CDNB. 
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6.4 Linearity of the Multistat Centrifugal Analyzer. 
The CDNB assay has previously been shown to be linear at least up to 0.200 
A340 run/min for one min on the centrifugal analyzer (R.D. Goold, personal 
communication) and this has been confirmed (Fig. 6.8). This instrument was only 
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Fig. 6.8: Linearity of the CDNB assay on a Multistat centrifugal analyzer. The 
total assay volume was 200 µl: 0.1 M phosphate buffer containing CDNB 
(2% DMSO; 180 µl), 1.0 ml\1 GSH (10 µl) and diluted GST p (10 µl). 
Measurements were started 10 sec after mixing of the sample with a total of 12 
measurements at 5 second intervals at 340 nm in 0.5 cm pathlength cuvettes. 
Data points were fitted to a straight line by linear regression. 
Activity is sho\\n as M340 nm/min and corrected for a 1 cm patylength cuvette. 
Enzyme activity of the undiluted sample was 2.0. ± 0.4 µmo I.min· . 
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Microperoxidases: Binding and Inhibition of 
GST p (rho). 
7.1 Purification of Microperoxidases. 
The preparation of microperoxidases by the enzymatic digestion of cytochrome c 
has in the past utilized various column purification and concentration procedures, 
with the resultant disadvantage that long time periods of up to 8 days were 
required (Peterson et al, 1983). We have used reverse phase HPLC 
chromatography as an analytical and preparative technique to purify MP-6, MP-8, 
MP-9 and MP-11 within 2 days. 
The tryptic digestion of MP-11 to MP-8 was efficient with respect to heme peptide 
(~ 95%) and the product was essentially free of non MP-8 heme by-products 
(Fig. 7.1). The digestion was temperature-dependent and complete within 30 min 
at 40 °C (Fig. 7.2) at the concentrations of MP-11 and trypsin used (see 
Section 2.11). MP-8 formation obeyed pseudo-first order kinetics (Fig. 7.2) which, 
assuming a Michaelis-Menten mechanism, indicated that the MP-11 concentration 
used was much lower than the Michaelis constant (Km) for this peptide with 
trypsin. Arrhenius behavior was observed for the temperature variation of kobs, 
with an apparent activation energy (Ea) of 16.2 kcal.mar 1 (Fig. 7.3). The further 
purification of MP-8 by HPLC or affinity chromatography on BSA- or 
HSA-Sepharose (Wilchek, 1972) to remove trypsin and non-heme contaminants 
could be completed within one day and the entire process could thus be concluded 
in two days (including lyophilization). 
All subsequent microperoxidase digestions were performed at 40 ° C. MP-9 
samples could not be purified completely in terms of non-heme peptide 










Fig. 7.1: HPLC elution profiles of microperoxidases: (A) MP-8, (B) MP-9, 
(C) MP-11, and (D) Nagarse digestion of cytochrome c (including the amino acid 
composition of the second peak). Absorbances were measured at (i) 398 nm and 
(ii) 210 nm. Samples were chromatographed on a Microbondpak C1s HPLC 






















































Fig. 7.2: Time-dependent trypsin digestion of MP-11 at 40 °C (D), 30 °C (+), 
20 °C (0), and 10 °C (6). 
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Digestion of horse heart cytochrome c by the non-specific protease nagarse 
resulted in the formation of three heme peptides which were separated cleanly on 
reverse phase HPLC (Fig. 7.1) but not by gel filtration chromatography on 
Sephadex (Fig. 7.4) (Peterson et al, 1983). Small quantities of the heme-peptides 
were collected on elution from the HPLC, lyophilized and subjected to amino acid 
analysis. The results of a typical digest and amino analysis of MP-6 are shown in 
figure 7.1 (d). 
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Fig 7.4: Elution profile on a Sephadex G-15 column (1.7 cm x 100 cm) of a 
cytochrome c nagarse digestion. The column was eluted with 2% acetic acid. 
7.2 Inhibition of GST p by Microperoxidases. 
Inhibition of enzyme activity by MP-8, MP-9 and MP-11 was time-dependent and 
displayed pseudo-first order inhibition kinetics, with rate constants of 
7.5 ± 0.7 x 10-4, 7.7 ± 0.8 x 10-4 and 6.1 ± 0.8 x 10-4 s-1, respectively, when 
corrected for spontaneous loss of activity in the absence of rnicroperoxidase 
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Fig. 7.5: Time-dep~dent inhibition of GST p by ~-8 (D), MP-9 (+) and 
MP-11 (0) (2 x 10· 1\1 each). The enzyme (6 x 10· M) was incubated with the 
microperoxidases in 0.11\1 phosphate buffer, pH 7.0, at room temperature 
(24 ± 2 °C) and enzyme activity (CDNB = 1.0 mM; GSH = 1.0 ml\1) measured at 
the relevant time points. 
Curves were fitted to a pseudo first-order decay curve (At = ~ + (Ao -~)e·k1 t). 
Activity(%) was relative to identical zero-time samples in the absence of 
microperoxidase. 
Incubation of GST p with microperoxidases for 30 min before assay of enzyme 
activity indicated that binding of the heme peptide resulted in mixed-type 
inhibition kinetics with respect to CDNB (Fig. 7.6). Inhibition characteristics 
changed as the microperoxidase concentration was increased, as shown in 
double-reciprocal graphs and plots of apparent inhibition constants (Fig. 7.6). At 
MP-9 and MP-11 concentrations below 1 µM there was a straight line relationship 
between Km/V max and microperoxidase concentration. The apparent Ki values 
evaluated increased with microperoxidase size and values of 0.57 ± 0.09, 
1.62 ± 0.16 and 3.15 ± 0.09 µM were obtained for MP-8, MP-9 and MP-11, 
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Fig. 7.6: Inhibition of GST p by MP-8 (A, D), MP-9 (B, E) and MP-11 (C, F) as a 
function of CDNB concentration (GSH = 1.0 mM). GST p and the 
microperoxidases were incubated for 30 min (0.1 M phosphate buffer, pH 7.0, 
24 ± 2 ° C) and enzyme activity measured. Curves were fitted to the 
Michaelis-Menten equation. 
Replots show the relationship between the apparent K /V m x ratios and 
concentration of MP-8 (D), MP-9 (E) and MP-11 (F). i;y.he so,id lines were 
obtained by fitting the data points below 1 µM to a straight line by linear 
regression. 
Microperoxidase concentrations were: 
MP-8 (Fig. 7.6 A): 0 µM (D), 0.4 µM (+), 0.8 µM (0), 2.0 µM (6), 4.0 µM (X), 
MP-9 (Fig. 7.6 B): 0 µM (D), 0.3 µM (+), 0.6 µM (0), 1.0 µM (6), 2.0 µM (X), 
4.0 µM (v'), 
MP-11 (Fig. 7.6 C): 0 µM (D), 0.3 µM (+), 0.6 µ1\1 (0), 1.0 µM (6). 
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7.3 Kinetics of the Binding of Microperoxidases to GST p. 
The kinetics of the interaction of microperoxidases with heme-binding proteins can 
be studied spectrophotometrically (Adams et al, 1989); the same procedure was 
used to investigate microperoxidase binding to GST p by following time course of 
the absorbance decrease observed on mixing at 398 ± 1 run (Fig. 7.7). 
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Fig. 7.7: Absorbance scans of MP-8 binding to GST p showing the time-dependent 
absorbance decrease at :::: 398 nm. The time points are 4 min, 15 min, 25 min and 
60 min. 
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The time-dependent binding of MP-9 to GST p followed pseudo first-order 
kinetics at sub-micromolar microperoxidase concentrations (Fig. 7.8). A plot of 
kobs vs [MP-9] was a straight line (Fig. 7.9), implying a single phase reversible 
binding mechanism as shown in scheme 7.1 (Bernasconi, 1976), with calculated 
values of 4.1 x 1a2 morl.dm3.s-1 and 1.4 x 10-4 s-1 for k1 and k_l, respectively, and 
a calculated apparent dissociation constant (Ko) of 3.4 ± 0.7 x 10-7 M. This value 
agrees well with the value of 4.5 ± 2.0 x 10-7 M calculated from the concentration 
variation of the total absorbance decrease (396 nm) obtained from the first-order 
fit (Fig. 7.10). 
k1 


















0 2 6 
(Thousands) 
Time (sec) 
Fig 7.8: Time-dependent binding of MP-9 (0.6 µM) to GST p (0.03 µM). Binding 
was measured at 398 nm in 0.1 M phosphate buffer, pH 7.0, at 25.0 ± 0.1 °c. 
The curve was fitted to the equationk 
At = ~ + (Ao -~)e· 1 t 
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Fig 7.9: Plot of the pseudo first-order rate constants with respect to MP-9 
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Fig. 7.10: Plot of the calculated absorbance decrease of the binding ofMP-9 to 
GST p. Data was obtained as in Fig. 7.8 and fitted to a hyperbolic equation. 
Incubations of GST p with 1.0 mM GSH for 15 min before the addition of MP-9 
(0.6 µM) had no effect on MP-9 binding (Table 7.1), whereas CDNB (1.0 mM with 
no preincubation) abolished the pseudo first-order binding process although a 
small zero-order change in absorbance was observed. Pre-incubation with 15 µM 
bilirubin (15 min) increased the rate constant approximately 10-fold (Table 7.1), 
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Fig. 7.11: The binding of MP-9 (0.6 µM) to GST p in the presence of bilirubin 
(15 µM). Data was obtained as in Fig. 7.8. 
The line is a linear regression fit of the data at time points greater than 1000 sec. 
The binding of MP-8 and MP-11 to GST p was also found to follow pseudo 
first-order kinetics and rate constants were found to be of the same order of 
magnitude as those observed for MP-9 (Table 7.1). However the total absorbance 
decrease at 398 nm varied with the various microperoxidases (Table 7.1). 
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Table 7.1: Pseudo first-order rate constants of microperoxidase binding to GST p 
and the effects of bilirubin and GSH addition on the rate constants. 
b MP Addition kobs 8 (s-1) AA39g nm 
(0.6 µM) 
MP-9 4.2 ± 0.1 X 10-4 0.017 ± 0.0001 
MP-9 Bilirubinc 2.3 ± 0.6 X 10-3 0.010 ± 0.0006 
MP-9 GSHC 2.4 ± 0.1 X 10-4 0.023 ± 0.0003 
MP-8 3.1 ± 0.1 X 10-4 0.011 ± 0.0002 
MP-11 3.9 ± 0.2 X 10-4 0.006 ± 0.0001 
Microperoxidase binding to GST p (3.0 x 10-6 M) was measured 
spectrophotomerically at 398 nm in 0.1 M potassium phosphate buffer, pH 7.0, at 
25 ± 0.2 °C. 
a Pseudo first-order rate constants ~re determined by fitting the data to 
equation: At = ~ + (Ao - ~)e- 1 t 
b The total absorbance change was calculated using the least squares parameters 
from the best fit. Reactions were measured over 1.5 hours. 
c The enzyme was incubated with bilirubin (15 µM) or GSH (1 mM) for 15 min 
before the reaction was initiated by the addition of MP-9. 
Miscellaneous Results: 
7.4 Concentration-Dependence of MP-8 Absorbance. 
It is well-documented that the microperoxidases aggregate at micromolar 
concentrations (see Adams, 1990). The simplest of these, the dimers, have a lower 
extinction coefficient than the monomers (Aron et al, 1986). Therefore 
absorbance at 398 nm does not obey Beers law with increasing microperoxidase 
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Fig. 8.9: Absorbance of MP-8 as a function of its concentration. 
The indicated line is a linear regression fit to the first three points and is shown to 
indicate the non-linear increase in absorbance with increasing MP-8 levels. 
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Discussion. 
8.1 The Effects of Halothane on GST Activity. 
Halothane, a widely used inhalation anesthetic, is known to rarely elicit acute 
hepatic failure. This usually occurs after multiple exposures and is known as 
halothane hepatitis (Touloukian & Kaplowitz, 1981; Neuberger & Kenna, 1987). 
Halothane also affects various metabolic processes (Mapes, 1977; Biebuyck et al, 
1972; Reilly et al, 1985), including hepatic BSP retention, the latter after multiple 
halothane anesthesia (Biebuyck et al, 1970). Since BSP retention is a function of 
the activity of rat GST subunit 3 (Jakoby et al, 1976; Mannervik & Jensson, 1982), 
we investigated the effect of halothane on rat hepatic GSTs in vivo and in vitro. 
A single exposure of rats to halothane (1.25 MAC for 3 h) did not decrease rat 
hepatic GST activity towards CDNB (Table 3.1); Multiple exposures (1.25 MAC 
for 1 hon 3 alternate days) initially decreased and subsequently increased rat 
cytosolic GST activity (Table 3.2). The effect of halothane was 
isoenzyme-dependent. Activity towards four substrates, ie CDNB, DCNB, 
trans-4-phenyl-3-buten-2-one and cumene hydroperoxide, was affected. The latter 
three substrates are isoenzyme-specific (Boyer & Kenney, 1985; Mannervik, 1985) 
and reflected decreased activity of isoenzymes containing subunits 3 and 4, and 
GSH peroxidase activity (Table 3.2). 
Other workers have shown that under similar conditions multiple, but not single, 
exposures to halothane increased BSP retention in isolated rat liver perfusates 
(Biebuyck et al, 1970). The binding of BSP by rat GST dimers is associated with 
subunit 3 (Jakoby et al, 1976; Mannervik & Jensson, 1982), and intrahepatic 
transport of this compound is facilitated by the GSTs (Boyer, 1989). The report of 
decreased hepatic uptake of BSP (Biebuyck et al, 1970) is consistent with our 
finding of decreased levels of GST isoenzymes containing subunit 3 (Table 3.2). 
Multiple exposures of rats to sub-anesthetic concentrations of halothane 
(0.05 MAC; 6 ha day for 9 days) has also been reported to decrease cytosolic GST 
activity, without affecting body weight, liver to body weight ratios or protein 
concentrations (Dale & Nilsen, 1984). 
The decrease and subsequent increase in GST activity after multiple halothane 
anesthesias (Table 3.2) is similar to the induction phenomenon observed with 
cytochrome P-450 after a single dose of 2-allyl-2-isopropylacetamide (De Matteis, 
1971). Both the microsomal cytochrome P-450 and cytosolic GST enzyme systems 
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are inducible in an isoenzyme-specific manner (Boyer & Kenney, 1985; Eisen, 
1986). Xenobiotics commonly used to induce cytosolic GST activity include 
phenobarbital, 3-methylcholanthrene and trans-stilbene oxide (Boyer & Kenney, 
1985). 
Incubation of a mixture of rat hepatic GSTs with halothane, isoflurane, enflurane, 
methoxyflurane or DBE in vitro decreased activity towards CDNB (Table 3.3). 
Inhibition by halothane exhibited pseudo first-order kinetics (kobs = 2.2 x 10-3 s-1; 
hh z 5 min) (Fig. 3.1), with half maximal inhibition at concentrations of greater 
than 15 mM (Fig. 3.2). This value is significantly greater than blood 
concentrations of halothane (ca 1 mM) (Bull et al, 1959). Inhibition was 
isoenzyme-specific: Activity of GSTs 3-3, 3-4, 4-4, but not 1-1 and 1-2, was 
significantly reduced by halothane (Table 3.4 ). Human placental GST 7£ was not 
inhibited by halothane, isoflurane, enflurane or DBE (Table 3.5), further 
confirming the isoenzyme specificity of GST inhibition. 
Isoenzyme-specific inhibition of GST activity, both in vivo and in vitro, has been 
demonstrated for a wide variety of compounds including 1,1-dichloroethylene 
(Maslen & Reynolds, 1985), carbon tetrachloride (Younes et al, 1980), chloroform, 
bilirubin (Aniya & Anders, 1985a), carbon tetrachloride, bromobenzene (Aniya & 
Anders, 1985b), 1-chloro-2,4-dinitrobenzene (Corrigal et al, 1989) and 
1,2-dibromoethane (Botti et al, 1982; Ivanetich et al, 1984). However, both the 
mechanism and specificity of GST isoenzyme inhibition vary. 
Metabolites of chloroform, as catalyzed by the cytochrome P-450 enzyme system, 
decrease hepatic GST activity (Aniya & Anders, 1985a). In contrast halothane 
per se inhibited GST activity in vitro (Table 3.3). Carbon tetrachloride invoked 
hepatic damage (Younes et al, 1980), and chloroform and bromobenzene 
increased serum, and decreased hepatic, GST concentrations, probably as a result 
of hepatic GST leakage into the serum (Aniya & Anders, 1985a, 1985b ). This 
phenomenon could be responsible for decreased hepatic GST levels in vivo, 
although this point has not been examined here. The elevation of serum GST 
concentrations has been proposed as a criterion of hepatic damage (Mukhtar & 
Bend, 1977; Aniya & Anders, 1985a, 1985b ). 
Inhibition of GST activity by halothane is prevented by cytosol (Table 3.6) or 
albumin (see Section 3.3). The albumin concentrations used in these initial 
experiments increased GST activity in controls . Halothane did not reduce GST 
activity in diluted rat hepatic cytosol (Table 3.6). Neither the in situ perfusion of 
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rat livers before preparation of cytosol nor the dialysis of cytosol reversed the 
protective effect of cytosol (Table 3.7). A low molecular weight compound or a 
component present in the blood does not therefore appear to be responsible for 
the protective effect. It is conceivable that cytosolic proteins protect the GSTs 
against inhibition: Bilirubin inhibition of GSTs is prevented by the presence of 
auxiliary proteins in incubations (Simons & Vander Jagt, 1980; Vander Jagt et al, 
1982, 1983), and isoenzyme 1-1 has been shown to protect other isoenzymes from 
bilirubin inhibition when rat hepatic cytosol was incubated with bilirubin (Fukai 
et al, 1989). 
Attempts to reverse the inhibitory effects of halothane by bubbling with nitrogen 
were unsuccessful (see Section 3.4) suggesting that either halothane binds tightly 
or covalently to the GSTs. Halothane inhibition could take place by a mechanism 
similar to that proposed for CDNB, bromobenzene and paracetamol which form 
covalent bonds with the enzyme (Corrigal et al, 1989; Pabst et al, 1974; Aniya et al, 
1988; Wendel & Cikryt, 1981). An alternative explanation is that active site 
solvation of GST could be facilitated by halothane, as has been proposed for both 
CDNB and MP-8 (Adams et al, 1989; Adams & Sikakana, 1990). 
DBE, but not halothane, was conjugated with GSH upon incubation with rat liver 
cytosol (Fig 3.3). DBE is known to form GSH conjugates (van Bladeren et al, 
1980), whereas GSH is only conjugated with halothane after catalysis of the latter 
by the cytochrome P-450 enzyme system (Cohen et al, 1975). 
The reversible activation of GST by halothane (Fig. 3.4, Fig. 3.5, Fig. 3.6) provides 
evidence for halothane binding. The extent of activation is relatively low ($ 25%) 
and activation is reversible (see Section 3.6). Activation of cytosolic GST 
exhibited uncompetitive and mixed-type kinetics relative to CDNB and GSH, 
respectively (Fig. 3.4). However, only isoenzyme 1-2, but not isoenzymes 1-1 and 
3-3, was significantly activated by halothane (Fig. 3.5, Fig. 3.6). The physiological 
relevance of this process is obscure. 
122 
8.2 Reversible Activation and Inhibition of GST Activity by DBE. 
DBE is a nonessential, reversible activator of the rat hepatic GSTs (Fig. 4.1; 
Fig. 4.2; Fig. 4.3) (Segel, 1975). Cytosolic GST activity was uncompetitively 
activated with respect to GSH (Fig. 4.1), and activated and inhibited in an unusual 
manner with regard to CDNB (Fig. 4.1). The same effect was observed with 
isoenzymes 3-3 and 4-4 (Fig. 4.2): DBE inhibited GST activity at low 
concentrations of CDNB ( < 0.1 mM) and activated the enzyme at high CDNB 
concentrations ( > 0.1 mM) (Fig. 4.1 & Fig. 4.2). Isoenzymes 1-1 and 1-2 were only 
slightly inhibited and not activated by DBE (Fig. 4.3). 
Nonessential activation can be treated kinetically as a partial mixed-type inhibition 
system, although with the opposite effect (Segel, 1975). In a single substrate 
system the pathway shown below applies: 
Ks kp 











where E = free enzyme, S = substrate, A = nonessential activator (Segel, 1975). 
The steady state rate equation for this system is: 
[SJ [AJ [SJ 
Vmax -- + .BVmax 
Ks aKAKs 
V = Equation 8.1 
[SJ [AJ [AJ [SJ 
1 + + -- + 
Ks KA aKAKs 
Mathematical modelling of the above reaction mechanism with hypothetical values 
of a and .B exhibits a spectrum of different modes of activation (Table 8.1). Under 
most conditions a simple, linear type of activation is observed. However, when a 
and .B are greater than unity, and a is greater than .B, a partial mixed-type system is 
encountered: The enzyme is activated at high and inhibited at low substrate 
concentrations (Table 8.1) (Segel, 1975). The same phenomenon being observed 
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with isoenzymes 3-3 and 4-4 in the presence of DBE and CDNB at relatively high 
concentrations of GSH (Fig. 4.2 & Fig. 4.3). 





a>l, /3>1, a</3 
Q>l, /3>1, a>/3 
a<l, /3<1, a</3 






No inhibition or activation 
Activation at all (S]; mixed-type 
Activation at all (S]; mixed-type 
Inhibition at low [SJ, activation 
at high (SJ; partial mixed-type 
Inhibition at high [SJ, activation 
at low [SJ; partial mixed-type 
Activation at all [S]; mixed-type 
Activation at all [SJ; mixed-type 
Activation at all (SJ; mixed-type 
Activation at all [S]; mixed-type 
Activation at all [SJ; competitive 
a Different values of a and /3 were inserted into equation 8.1 (Segel, 1975) with 
hypothetical values of S, A, KA, Ks and V max· The relevant values were then 
plotted and analyzed. 
Under conditions of high GSH and varied CDNB concentrations both a and /3 for 
the GSTs were greater than unity, as assessed from ratios of apparent V max and 
Km values. As a is greater than unity the binding of either the substrate (CDNB) 
or activator (DBE) in a random system was found to decrease the binding affinity 
of the enzyme for the second ligand (ie increasing KA or Ks by the factor a), 
increasing the dissociation of the EAS complex to ES + A and EA + S 
(Scheme 8.1). As the constant /3 is greater than unity the dissociation of EAS to 
EA + P is also enhanced, thus increasing V max by the factor /3. Therefore, at low 
concentrations of CDNB the dissociation of the ESA complex to EA + S and 
ES + A predominates, suppressing activity relative to controls. At higher CDNB 
concentrations dissipation to the product dominates and enzyme activity is 
enhanced (Segel, 1975). 
The GSTs were uncompetitively activated by DBE with respect to GSH (Fig. 4.1 & 
Fig. 4.2). In a single substrate system an uncompetitive inhibitor binds reversibly 
only to the enzyme-substrate complex, not to the free enzyme, forming a inactive 
enzyme-substrate-inhibitor combination (Segel, 1975). However, in the case of an 
uncompetitive activator the enzyme-substrate-activator complex cannot be inactive 
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and presumably dissociates into enzyme, activator and product. It is thus 
hypothesized that the following equilibrium is effective: 
Ks 
E + S ----"' ES ....--
kp 








where E = free enzyme; S = substrate; A = activator; P = product (Segel, 1975). 
Therefore V max is increased as two pathways can form the product, although the 
rate constants for product formation are not identical. The observed decrease in 
Ks (Fig. 4.1 & Fig. 4.2) can be explained by a shift of the E + S = ES equilibrium 
towards the left. The level of free enzyme (E) could be decreased by dissociation 
of the ESA complex to product (P) and an inactive enzyme-activator (EA) 
complex. This is, however, unlikely and the increase in Ks is probably caused by a 
decrease in substrate concentration. 
Since the GSTs are dimeric proteins with two, non-cooperative active sites per 
enzyme molecule (Jakobson et al, 1979b; Mannervik, 1985) the simple equilibrium 
schemes shown above (Scheme 8.1 & Scheme 8.2) are insufficient. A detailed 
equilibrium scheme for a random BiBi rapid equilibrium system is shown below 
(Scheme 8.3). GST 3-3 exhibits a random BiBi steady state mechanism (Ivanetich 
et al, 1990; Jakobson et al, 1977, 1979a, 1979b) and consequently scheme 8.1 does 
not necessarily apply. In addition, DBE metabolism has not been taken into 
account, and a relevant mechanistic model for a partial mixed-type 







EGCA -12.EA + P + Q 
kp 
ECG-+--------t------E+P+Q 
EA t +G 
ECA 
Scheme 8.3: :Model for a nonessential activator A (DBE) for a rapid equilibrium 
bireactant system. It is assumed that the binding of any two ligands has no 
additional effect on the binding of the third ligand. Metabolism of DBE by GST 
has been ignored. 
C = CDNB, G = GSH 
(adapted from Segel, 1975) 
A comparison of the reversible and irreversible interactions of DBE with rat 
hepatic GSTs is shown in table 8.2. Although similar isoenzymes, comprising 
subunits 3 and 4, are affected by DBE, the nature of the two processes is distinct. 
The reversible reaction has a relatively short half-life with both inhibition and 
activation taking place, and the mechanism of the reaction appears to be complex. 
In contrast, the half-life of the irreversible process is approximately 30-fold greater 
than for the reversible reaction and inhibition is a pseudo first-order process. 
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Table 8.2: Interactions of DBE with rat GSTs. 
Effect on CDNB metabolism. 
Reversible Irreversiblea 
Property: 











a (from Ivanetich et al, 1984) 
Inhibition 
300 sec 
3.2 mM DBE 
3-3, 3-4 
1-1, 1-2, 2-2 
8.3 Inhibition of GST Activity by Bilirubin and Protection by Proteins. 
The time-dependent inhibition of GST activity by bilirubin is apparently a complex 
process involving slow conformational changes of the protein (Simons & 
Vander Jagt, 1980; Vander Jagt et al, 1982). However, we hypothesized that the 
complex kinetics could also be the result of inhibition by CDNB or buffer, in 
addition to bilirubin inactivation, and possibly erroneous analysis of the relevant 
data, thus prompting the following investigation. 
Examination of time-dependent inhibition data (Simons & Vander Jagt, 1980; 
Vander Jagt et al, 1982, 1983) indicated that the extent of inhibition at infinite time 
points was ignored. Also, in some instances virtually all the data points are at 
values of greater than 60% inhibition (Vander Jagt et al, 1982). Replots of data at 
values of less than 80% inhibition, ie appreciably different from infinity values, 
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Fig. 8.1: Rep lots of bilirubin inhibition experiments. Data was obtaip.ed from 
(A) Vander Jagt et al, 1983, Fig. 7, and (B) Vander Jagt et al, 1982, Fig. 4A (D) & 
Fig. 4B (0), 
T~ lines are linear regression fit~ to the data. 
(R = 0.98, 0.98 and 0.92, respectively). 
In some cases progress curves were used to determine the time-course of bilirubin 
inhibition (Simons & Vander Jagt, 1980; Vander Jagt et al, 1982). This method of 
evaluating initial velocity patterns should, however, only be performed in special 
cases where the equilibrium constant is high and the products of the reaction are 
not inhibitory. If the product does inhibit the enzyme, as occurs with the 
CDNB/GSH conjugate (Jakobson et al, 1977; Schramm et al, 1984), a number of 
progress curves are required (Cleland, 1970). Also, the inhibition at infinity time 
values were ignored in assessing the kinetics of inhibition. 
In our study, bilirubin reversibly inhibited GST 1-2 in a pseudo-first order process 
(Fig. 5.1) with half-maximal inhibition at approximately 4 µM bilirubin (Table 5.1; 
Table 5.2). Inactivation is thus first-order with respect to enzyme (Fig. 5.1) and 
probably first-order with respect to bilirubin. This deduction and the calculated 
second-order rate constant of approximately 5.2 x 103 M-1.s·1 is, however, based 
on inhibition data at only two bilirubin concentrations (see Section 5.1). 
Inhibition was reversed by dilution or by increasing pH (see Section 5.2), and was 
prevented by the addition of bilirubin-binding proteins (Table 5.2; Table 5.3). 
Inhibition by biliverdin and indocyanine green has been shown to be reversed by 
increased pH, although these ligands were still bound to the respective GSTs at 
the higher pH. Explanations for this phenomenon were that either the ionization 
states of the bile acids affected their ability to act as inhibitors or the 
enzyme-inhibitor conformation was altered (Boyer et al, 1984). Similar processes 
could be responsible for the effect observed with bilirubin. Inactivation of GSTs 
1-1 and 1-2 by bilirubin can be reversed by dilution but not by increased pH 
(Vander Jagt et al, 1982). Reversibility by dilution is consistent with the ligand 
binding and transport function of the GSTs in vivo (Sodeman & Sodeman, 1985; 
Boyer, 1989) and the characterization of bilirubin as a reversible GST inhibitor 
(Bhargava et al, 1978; Kamisaka et al, 1975; Simons & Vander Jagt, 1980; 
Vander Jagt et al, 1982, 1985; Ketley et al, 1975; Sugiyama et al, 1984). 
The order of addition of components to incubations containing GST 1-2, bilirubin 
and albumin had a significant effect on the extent of inhibition: GST 1-2 was not 
significantly inhibited when bilirubin, HSA and CDNB were pre-incubated before 
addition of GST, while pre-incubation of GST 1-2, HSA and CDNB before 
bilirubin addition was found to only partially inhibit enzyme activity (Table 5.2). It 
is known that albumin acts as a scavenger of bilirubin in both serum and aqueous 
solutions (Brodersen, 1980; Simons & Vander Jagt, 1980). Thus, bilirubin 
pre-incubation with sufficient amounts of HSA could decrease free ligand 
concentrations to the extent that GST activity is not affected. In the case of 
bilirubin addition to both HSA and GST bilirubin probably partitions between the 
two proteins (Table 5.2). Thus less bilirubin is bound to the GST than in the 
absence of HSA, and the extent of inhibition is intermediate between that 
obtained in the presence and absence of HSA. 
An alternative explanation is the proposed formation of GST conformations 
stabilized by protein-protein interactions between GST 1-2 and HSA (Simons & 
Vander Jagt, 1980; Vander Jagt et al, 1982, 1983). These protein-protein 
interactions do not involve the formation of stable complexes and conformational 
states are proposed to be kinetically, and not thermodynamically, controlled. This 
influence of proteins on GST activity was proposed to represent "a type of enzyme 
memory" (Vander Jagt et al, 1983). A scavenger effect was rejected as levels of 
proteins were 100- to 1000-fold less than the bilirubin concentrations; These 
proteins also had no apparent effect if the bilirubin-GST complex was allowed to 
go to completion before the addition of protein (Simons & Vander Jagt, 1980; 
Vander Jagt et al, 1982, 1983). 
However, an apparent 1000-fold excess of bilirubin is required for the complete 
inhibition of human ligandin (Vander Jagt et al, 1983). It has also been shown that 
GST 1-1 can protect other isoenzymes from bilirubin inhibition although a 3-fold 
molar excess of GST 1-1 was required to fully prevent inhibition of isoenzymes 2-2 
and 3-4 (Fukai et al, 1989). 
129 
We have shown that albumin, aldolase and hemoglobin can bind bilirubin at high 
ratios, with up to 100 molecules of bilirubin apparently binding per protein 
molecule at concentrations of approximately 0.04 µM protein (Fig. 5.2). This ratio 
is relatively high, but albumin has been shown to bind up to 200 bilirubin 
molecules at neutral pH (Brodersen et al, 1972). Furthermore, bilirubin can also 
form both colloidal aggregates and supersaturated solutions (Brodersen & 
Theilgaard, 1969). Our experiments do not elucidate the mechanism of binding of 
high molar artios of bilirubin. 
GST 1-2 inactivation was prevented at concentrations of RSA, aldolase and 
hemoglobin which decreased levels of bilirubin in solution to below 0.5 µM 
(Fig. 5.2; Table 5.3). In contrast, low concentrations of these proteins, which did 
not significantly decrease levels of free bilirubin, did not prevent inactivation 
(Fig. 5.2; Table 5.3). 
The apparent contradiction observed with ribonuclease, which prevented 
inactivation (Table 5.3) but did not appear to bind bilirubin (Fig. 5.2), can be 
explained by weak binding of bilirubin to ribonuclease. The binding affinity of 
Sephadex for bilirubin could be higher than that of ribonuclease, resulting in the 
release of ribonuclease-bound bilirubin onto the Sephadex resin, thereby giving 
rise to the observed results. In this regard, measurement of bilirubin 
concentrations by Sephadex chromatography has been reported to give anomalous 
results (Kapitulnik et al, 1974) and to overestimate concentrations of free bilirubin 
for weak binding proteins (Kaufmann et al, 1973). The midpoint value of protein 
protection against inhibition of human ligandin by bilirubin has also been shown to 
be significantly higher for ribonuclease (0.5 µM) than for RSA (0.02 µM), aldolase 
(0.01 µM) and hemoglobin (0.003 µM) (Vander Jagt et al, 1983). 
Further evidence cited against the role of proteins as bilirubin scavengers is the 
apparent inability of proteins to reverse the inhibitory process (Vander Jagt et al, 
1983). This anomaly can be resolved by a very slow rate of bilirubin release from 
proteins as a result of the hydrophobic nature of the bilirubin molecule. 
A similar phenomenon has been observed with the binding of the heme peptide 
MP-11 to RSA in aqueous solutions as a model for heme/protein interactions*. 
The forward rate constant for MP-11 binding to RSA (k1) was not altered 
significantly by increasing the hydrophobicity of the solution with methanol 
(20% v /v), whereas the off rate constant (k_ 1) was increased approximately 
400-fold. We hypothesize that MP-11 binds to a sterically hindered hydrophobic 
* Adams & Thumser, in preparation. 
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site on HSA and therefore the forward rate constant (k1) is not affected by the 
hydrophobicity of the solution. Methanol, postulated as being of higher dielectric 
constant than the environment of the binding site, is hydrophobic enough to enter 
the hydrophobic binding domain and increase the effective dielectric constant 
(thus decreasing the hydrophobicity) of the binding site. This results in 
destabilization of the MP-ll··HSA complex, increasing the reverse rate constant 
(k-1). A similar process could take place with bilirubin binding to GST: A stable 
GST .. bilirubin complex is formed and dissociation is not affected by addition of 
proteins as these have no direct access to the bilirubin binding site. The proteins 
only decrease bilirubin concentrations in solution, resulting in a constant, but slow, 
leaching process of bilirubin from the GST. 
We propose that the protective effect of proteins is the result of a "scavenger" 
system which decreases the effective concentration of bilirubin in solution. More 
complicated explanations such as "enzyme memory" are not required to rationalize 
this phenomenon. 
8.4 The Kinetic Mechanism of GST p (rho). 
The human placental 7r and erythrocyte p GST isoenzymes are similar in terms of 
amino acid composition, apparent kinetic constants, substrate specificities, 
molecular weight and immunological cross-reactivity, and it has therefore been 
speculated that these two isoenzymes are either very closely related or identical 
(Guthenberg & Mannervik, 1981). The kinetic mechanism of the placental n 
isoenzyme has been demonstrated as being random sequential BiBi rapid 
equilibrium with dead-end enzyme-CDNB-product complex formation (Ivanetich 
& Goold, 1989). However, the kinetic mechanism of the human erythrocyte p 
isoenzyme has yet to be elucidated. 
The kinetic mechanism of GST p was analyzed by determining initial rates of 
conjugation at various concentrations of the substrates CDNB and GSH (Segel, 
1975; Cleland, 1970). Preliminary analysis of the data fitted to the 
Michaelis-Menten equation indicated a random sequential BiBi rapid equilibrium 
mechanism (Fig. 6.1; Table 6.1), Michaelis constants (Km) for both substrates lies 
in the sub-millimolar range and the binding of one substrate decreases affinity for 
the other (Fig. 6.1) (Segel, 1975). The data was fitted to various bimolecular 
kinetic mechanisms, the rate equation for a random steady state mechanism was 
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found to display the lowest residual sums squared value (Table 6.2). However, 
further analysis of the relevant [substrate]/velocity plots exhibited non-random 
distribution of the experimental versus predicted rates, especially at low substrate 
concentrations (Fig. 6.2). Thus there existed a possibility that the random steady 
state mechanism was either an overfit of the data, or the low residual sums squared 
was an anomaly emanating from the limited substrate concentration range utilized. 
Biphasic Lineweaver-Burke plots and non-Michaelis-Menten kinetics would be 
predicted over a wide range of substrate concentrations for a random steady state 
mechanism (Segel, 1975; Cleland, 1970). Initial rate plots for supplementary 
experiments over a wider range of GSH concentrations were hyperbolic (Fig. 6.3), 
the data thus fitting the Michaelis-Menten mechanism and a random steady state 
mechanism was rejected (Segel, 1975; Cleland, 1970). 
Examination of initial rate plots and non-linear regression (Fig. 6.2; Table 6.2) 
provided evidence for either a random rapid equilibrium or an ordered steady 
state mechanism. It is not possible to discriminate between these two mechanisms 
by initial rate studies alone as the relevant rate equations are mathematically 
equivalent, product inhibition studies were thus required to determine the true 
exact kinetic mechanism (Segel, 1975). 
The CDNB/GSH conjugation product was prepared and its effect on initial rates 
at different substrate concentrations elucidated. The conjugate inhibited the 
enzyme in a competitive and mixed-type manner with respect to GSH and CDNB 
(Fig. 6.5), the Ki being of the order of approximately 16 IM (Fig. 6.6; Table 6.3). 
Further replots of the data showed that the value of Ki(slope) was not independent 
of substrate concentration, ie the data points were not parallel to the x-axis (Fig 
6.6), pointing to a random mechanism (Segel, 1975). 
In a random sequential system the substrates are bound and products released in a 
arbitrary manner, but both the substrates must bind before any products are 
released. Binding of the first substrate affects the dissociation constant of the 
second substrate by a constant a, the complete process described by the following 
scheme: 
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E + B 
KB 




KA j[ aKA 
EAB 
kp 
E + p EB+ A 
aKB 
where E = free enzyme; A, B = substrates of the enzyme; 
enzyme-catalyzed reaction (Segel, 1975). 
P = product of the 
In a general random BiBi rapid equilibrium mechanism the binding of one product 
(P) * excludes both substrates, preventing EAP or EBP complex formation, as 
shown below (Scheme 8.5). The second product of the reaction (Q) can establish a 
EQ complex which does not exclude binding of the substrate B, generating a 
catalytically inactive EBQ complex. The product Q excludes A and therefore 
competes with the latter substrate. Increasing the concentration of B does not 
prevent the binding of Q and inhibition will be mixed-type or non-competitive with 
respect to B (Segel, 1975). 
Thus, in the presence of P: 




E + B EB 
+ + 
A A 
J[ KA j[ OKA 
EB+ A EAB 
kp 
E + p + Q 
aKB 
* Footnote: The notation of A and B as the two substrates, and P and Q as the 
two products, of the reaction is arbitrary and does not refer to any particular 
substrate or product of the GSTs at this point. 
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In the presence of Q: 
KQ KA 
EQ Q + E + A EA Scheme 8.6 
+ + + 
B B B 
j[ KB j[ KB j[ aKB 
EBQ Q + EB+ A EAB E + p + Q 
KQ aKA kp 
where E = free enzyme; A, B = substrates of the enzyme; 
enzyme-catalyzed reaction (Segel, 1975). 
P, Q = products of the 
The conjugation reaction of GSH with CDNB yields two products, viz a 
GSH/CDNB conjugate and a chloride ion (Pabst et al, 1974). The chloride ion 
does not inhibit the enzyme under the conditions used in the inhibition 
experiments (Fig. 6.7), and inactivation at higher chloride concentrations is the 
result of ionic strength effects (Jakobson et al, 1977). As the conjugate is a 
competitive and mixed-type inhibitor relative to GSH and CDNB (Fig. 6.5) the 
terms A, B, P and Q pertain to GSH, CDNB, chloride and the conjugate, 
respectively, in the above equilibria (Scheme 8.5 & Scheme 8.6). The EP (E00Cr) 
complex does not inactivate the enzyme and scheme 8.5 can be eliminated. The 
mode of inhibition by the conjugate provides confirmation of an EBQ 
(enzyme-CDNB-conjugate) dead-end complex (Segel, 1975). This is verified by 
non-linear regression analysis of the kinetic results (Table 6.3). 
A comparison of the kinetic constants obtained for GST p and GST ,r, which have 
been proposed to be similar or identical (Guthenberg & Mannervik, 1981), 
discloses that these two isoenzymes are comparable at the primary kinetic level 
(Table 8.3). 
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Table 8.3: Kinetic constants obtained for GST p and GST 7£ with a random 
sequential BiBi rapid equilibrium mechanism and dead-end complex formation. 
p (rho) 
Parameters: b,c 
KcoNB (rnM) 0.70 ± 0.11 
KGSH (rnM) 0.12 ± 0.02 
Kp (rnM) 0.016 ± 0.004 
a 2.0 ± 0.4 
"( 3.1 ± 1. 5 
Isoenzyrne 
7£ (pi)a 
0.87 ± 0.07 
0.13 ± 0.01 
0.018 ± 0.003 
2.9 ± 0.27 
8.1 ± 3.3 
a Values for GST 71' were obtained from Ivanetich & Goold, 1989. 
b Values for GST p are shown in Tables 6.2 and 6.3. 
c Keo.NJ~, KasH and a were obtained by fitting the data to the random rapid 
equihbnum rate equation in the absence of product inhibition; Kn and "f were 
obtained from fits of the inhibition data to the random rapid equilibrium 
mechanism with dead-end enzyme-CDNB-conjugate complex formation. 
Other GSTs demonstrating a random rapid equilibrium mechanism are the major 
bovine brain isoenzyme (Young & Briedis, 1989) and isoenzyme 1-1 (Schramm 
et al, 1984). In contrast, isoenzyme 3-3 displays a random sequential steady state 
mechanism (Jakobson et al, 1977; Ivanetich et al, 1990). 
8.5 GST p and the Microperoxidases. 
Published methods for the preparation and purification of the microperoxidases, a 
group of heme peptides derived from cytochrome c, are tedious and time 
consuming, requiring at least 24 hours preparative time (Peterson et al, 1980, 1983; 
Baba et al, 1969; Plattner et al, 1977). No detailed studies of the kinetics of the 
proteolysis reaction have been published. 
The microperoxidases can be separated and identified by reverse-phase HPLC 
chromatography (Fig. 7.1). As MP-11 is commercially available and no known 
heme intermediates are produced by the tryptic digestion of MP-11 to form MP-8, 
investigation of the proteolytic process is relatively simple. 
Analysis of the kinetics and temperature-dependence of MP-11 digestion by 
trypsin indicated a pseudo first-order process, with an apparent Arrhenius 
activation energy of 16.2 kcal.mor1 (Fig. 7.2; Fig. 7.3). At 40 °C the digestion was 
essentially complete within two hours (Fig. 7.2). Purification of the peptide by 
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HPLC required less than four hours (less than 20 min per chromatography), 
depending on the yield of the purification, the complete process usually requiring 
less than six hours. 
MP-8 and MP-11 were obtained at high purity(~ 98%) by reverse-phase HPLC 
chromatography (Fig. 7.1), but MP-9 preparations, produced by the tryptic 
digestion of cytochrome c, were contaminated with non-heme peptides (Fig. 7.1). 
Nagarse digestion of cytochrome c yielded three heme peptides (Fig. 7.1), MP-6 
could be obtained high purity by HPLC chromatography. 
Microperoxidases 8, 9 and 11 inhibited GST p in a time-dependent process with 
pseudo first-order rate constants of approximately 7.5, 7.7 and 6.1 x 10-4 s-1, 
respectively, corresponding to an estimated half-life of 900 seconds (Fig. 7.5). 
These pseudo first-order rate constants lie within the range of values obtained for 
the inactivation of a number of GSTs (Adams et al, 1989), although approximately 
3-fold lower than the rate constant obtained for the reaction of 0.4 µM MP-8 with 
placental GST 7f (2.2 x 10-3 s-1) (Adams et al, 1989). 
Inhibition of GST p by the microperoxidases was mixed-type with respect to 
CDNB (Fig. 7.6). Values of Ki appeared to be related to microperoxidase size in 
the sub-micromolar range, the apparent Ki increasing from 0.57 µM (MP-8) to 
1.62 µM (MP-9) and 3.15 µM (MP-11) (Fig. 7.6). Replots of Km/Vmax against 
MP concentration deviated from a straight line above concentrations of 1 µM for 
MP-9 and MP-11 (Fig. 7.6). This observation can almost certainly be rationalized 
by the dimerization characteristics of the microperoxidases as MP-9 and MP-11 
are known to dimerize more extensively and in a different manner to MP-8 (Urry 
& Pettegrew, 1967; Urry, 1967; Peterson et al, 1980, 1983; Wilson et al, 1977). We 
assume that the microperoxidase dimers bind at the same site as the monomers 
with inhibition by the aggregates being proportionately greater than for the 
corresponding monomers, increasing ratios of Km/V max· As MP-8 dimerization 
is negligible at the sub-micromolar level (Baldwin et al, 1987), this effect was not 
apparent for MP-9 (Fig. 7.6). 
The kinetics of microperoxidase binding to GST p can be followed 
spectrophotometrically at 398 nm (Fig. 7.7). Binding of MP-9 to GST p was 
monoexponential at sub-micromolar concentrations of the peptide (Fig. 7.8), thus 
the binding reaction appears to involve a reversible single step mechanism 
(Bernasconi, 1976), as shown below: 
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GST + MP-9 -- GST··MP-9 
The calculated dissociation constant for MP-9 and GST p was approximately 
4.0 x 10-7 M (Fig. 7.9, Fig. 7.10). Incubation of GST p with GSH did not 
measurably affect MP-9 binding; However, CONB abolished MP-9 binding and 
bilirubin increased the rate constant for MP-9 binding approximately 10-fold 
(Table 7.1; Fig. 7.12). 
Both CONB and bilirubin also decreased absorbance at 398 nm in a slow 
zero-order process (Fig. 7.12). Zero-order kinetics are characteristic of surface 
reactions at substrate concentrations in excess of those required for saturation; 
Limiting factors being the rates of diffusion or the availability of surface sites (Bull, 
1964; Capellos & Bielski, 1972). Both CONB and bilirubin are GST inhibitors 
(Vander Jagt & Simons, 1980; Pabst et al, 1974), bilirubin having been proposed to 
alter the conformation of these proteins (Vander Jagt et al, 1982). It is plausible 
therefore that binding of either bilirubin or CONB to the enzyme initiates a slow 
conformational change, thereby exposing more potential binding sites for MP-9, 
and in the case of bilirubin, intensifying the rate of binding in the second-order 
reaction (Fig. 7.12; Table 7.1). 
Binding of MP-8 and MP-11 to GST p was also monoexponential, rate constants 
being of the same order of magnitude as for MP-9, although the total decrease in 
absorbance differed (Table 7.1). It can be speculated that the mechanism of 
binding is similar for the three microperoxidases. Inhibition would, however, also 
be related to the size of the peptides and their positions relative to the active site, 
the latter factor perhaps influencing the observed absorbance change. 
The dissociation constant (Ko) of MP-9 binding to GST pis of the same order of 
magnitude as that calculated for binding of MP-8 to a kinetically slow binding site 
on placental GST ,r (Adams & Goold, 1990). MP-8 was found to be bound at two 
sites on GST n, ie a kinetically fast (Ko = 7.2 x 10-8 M; ty2 z 220 s) and a slow site 
(Ko = 5.9 x 10-7 M; ty2 z 1200 s). Binding to the fast and slow sites was 
eliminated by CONB and bilirubin, respectively (Adams & Goold, 1990). 
Binding of MP-8 to GST p is a monoexponential process with a Ko of 4.0 x 10-7 M 
(Fig. 7.9; Fig. 7.10), the same order of magnitude as the slow site for MP-8 binding 
to GST n (Adams & Goold, 1990). However, MP-8 binding at the slow site was 
abolish by bilirubin (Adams & Goold, 1990), while the opposite effect was 
observed with GST p. GST ,r has two microperoxidase binding sites per subunit, in 
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contrast to the single site per subunit on GST p, bilirubin and CDNB appearing to 
have disparate effects on these isoenzymes. Therefore it can be concluded that the 
binding site and/or binding mechanism are not the same for isoenzymes 7r and p 
and these proteins are probably distinct. 
8.6 Conclusions. 
It has been shown that halothane, an inhalational anesthetic, inactivates rat 
hepatic GSTs in an isoenzyme-dependent manner both in vivo and in vitro. Rats 
exposed to multiple doses of halothane showed a selective decrease and 
subsequent increase in GST activity. GST isoenzymes containing subunits 3 and 4, 
viz isoenzymes 3-3, 3-4, 4-4, were inhibited in vitro, and probably in vivo, as 
assessed by the substrate-specificity of GST inhibition and activation in vivo. 
Inhibition in vitro was a a relatively slow process with a pseudo first-order rate 
constant of 2.2 x 10-3 s-1 (ty2 z 5 min) and an apparent Ki of 15 mM. The latter 
value is substantially higher than halothane concentrations in human blood during 
anesthesia. Inhibition was prevented by a high molecular weight cytosolic factor, 
but the exact nature of the protective component was not established. In contrast 
to DBE, halothane was not metabolized by the GSTs, as determined by GSH 
conjugation. Halothane reversibly activated rat GST activity, but the physiological 
relevance of this observation is unknown. 
DBE was a reversible, nonessential activator of rat cytosolic GSTs. The effect of 
DBE was unusual, activity of isoenzymes 3-3 and 4-4 inhibited or activated 
depending on the concentration of CDNB. These isoenzymes were 
uncompetitively activated with respect to GSH. DBE had no significant effect on 
GSTs 1-1 and 1-2. A hypothesis effects has been proposed, although a detailed 
analysis is not possible. 
Bilirubin inhibition of GST 1-2 was concentration- (Ki=:: 4 µM) and 
time-dependent, and could be reversed by dilution or increased pH. GST 
inactivation by bilirubin was prevented by the addition of proteins, the degree of 
protection dependent on both bilirubin and protein concentrations and the order 
of addition of constituents to incubations. We postulate that added proteins are 
protective as a result of "scavenging" bilirubin from solution and consider the 
concept of "enzyme-memory" unnecessary. 
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Human erythrocyte GST p demonstrates a random sequential BiBi kinetic 
mechanism with the formation of enzyme-substrate-product 
(enzyme-CDNB-conjugate) dead-end complex. The kinetic constants for GST p 
are similar to values published for GST 71", and these two enzymes appear to be 
kinetically closely related at the primary kinetic level. 
The procedure for preparation of the microperoxidases has been substantially 
improved by the use of reverse-phase HPLC. Inhibition of GST p by MP-8, MP-9 
and MP-11 was time-dependent and pseudo first-order (kobs = 7 x 10-4 s-1; 
ti;2 = 900 s), the mechanism of inhibition being mixed-type with respect to CDNB. 
The inhibition constant (Ki) increased with the size of the microperoxidases and 
also appeared to be related to dimerization characteristics of the peptides. The 
microperoxidases bound to GST p in a single-step process with a Ko for MP-9 of 
approximately 4 x 10-7 M. GSH had no influence on MP-9 binding, although 
binding was abolished by CDNB and enhanced by bilirubin. The mode of MP-9 
binding to GST p differed from that of MP-8 to GST 71". We propose that 
isoenzymes p and 71", although kinetically similar, appear to show small differences 
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